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Abstract 
Small molecules are of interest both as metabolites in tumor cell biology and as potential 
therapeutics in the fight against cancer.  In this work, small molecules in both roles have 
been examined.  Modulation of tumor cell metabolism holds promise as a strategy to 
combat cancer, and both glucose and glutamine have been identified as critical fuels for 
tumor cell growth and proliferation.  However, the reason for glutamine addiction is 
poorly understood.  The differential metabolism of glutamine and glucose was therefore 
examined using 
13
C labeling and NMR-based metabolomics in the VM-M3 tumor cell 
line, which requires both glucose and glutamine for survival and proliferation.  In the 
course of this study, a novel mammalian metabolite itaconic acid was identified.  Itaconic 
acid was detected in extracts and tissue culture media from the murine macrophage-
derived tumor cell lines VM-M3 and RAW 264.7 as well as in primary macrophages.  
Production and secretion of itaconic acid was increased upon stimulation.  LC-MS and 
NMR based metabolomics studies show that this metabolite is synthesized by the 
decarboxylation of cis-aconitate from the TCA cycle, and provided evidence for a novel 
mammalian homologue of the enzyme cis-aconitic decarboxylase. 
 D-3-deoxy diC8PI is a small molecule of interest as a potential cancer therapeutic.  This 
compound was designed to induce apoptosis in tumor cells by competitively binding to 
the Akt PH domain and preventing Akt translocation.  However, high resolution 
31
P field-
cycling studies show that both D-3-deoxy diC8PI and an inactive analogue L-3,5-dideoxy 
diC8PI bind to the same site on the PH domain, which is distinct from the binding site of 
the ligand diC8PI(3,4,5)P3.  This makes the aforementioned mechanism of cytotoxicity 
unlikely.  Aggregation of the PH domain in the presence of soluble headgroup IP6 was 
also observed, which may be related to a physiological function of this protein and 
invalidates at least one other binding assay. 
Investigation into alterations in signaling pathways in the MCF-7 breast cancer cell line 
showed that D-3-deoxy diC8PI activates the p38MAPK pathway which results in CREB 
hyperphosphorylation.  However, activation of this pathway appears to be compensatory 
and unrelated to the mechanism of action.  D-3-deoxy diC8PI also decreases levels of 
cyclin D1 and cyclin D3, which regulate the progression of the cell cycle.  These 
decreases appear to be occurring at the transcriptional level rather than due to increased 
proteasomal degradation.  The loss of these two proteins does not cause apoptosis in 
MCF-7 cells, but siRNA knockdown of specifically cyclin D1 inhibits proliferation.  This 
is consistent with the cell cycle arrest observed upon D-3-deoxy diC8PI treatment in these 
cells.  These findings do not conclusively elucidate the mechanism of cytotoxicity of D-
3-deoxy diC8PI, but provide a characterization of some of its effects in the MCF-7 cell 
line which may be useful for further studies. 
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Chapter 1: 
Introduction  
2 
1.1 Tumor Cell Lines as Models for In Vivo Cancer Biology 
Between 2003 and 2007, approximately 1 out of every 212 Americans has been 
diagnosed with some type of cancer; cancer affects both sexes and a wide range of races 
(Kohler et al., 2011).  While cancer has been diligently investigated by the academic and 
industrial scientific communities, it is a complex disease that is still not completely 
understood by the scientific community.  Fortunately, tumor cell lines are readily 
available to facilitate research on individual types of cancer.  Established tumor cell lines 
provide convenient access to the large numbers of cells required for many experiments 
without requiring invasive surgery (Fogh, 1975).  They can divide indefinitely and grow 
rapidly and are, therefore, relatively easy to maintain, in vitro models of many types of 
cancer.  However, it is important to recognize that there is significant “sameness” in 
growth characteristics between tumor cell lines stemming from a number of different 
tissues (due to the poor level of cell differentiation)
 
(Eagle and Foley, 1958; Hsu and 
Kellogg, 1960; Leibovitz, 1975).  Therefore these cultured cells, while extremely useful, 
are imperfect models of in vivo tumorigenesis.  Many of these lines are commercially 
available from sources such as the American Type Culture Collection; specific examples 
include the MCF-7 and RAW 264.7 cells with which I have worked (www.ATCC.org), 
while others, such as the VM-M3 line, are derived from solid tumors by researchers at 
industrial or academic institutions (Huysentruyt et al., 2008). 
 
 
3 
1.2 Breast Cancer 
Breast cancer is currently the most frequently diagnosed cancer in women, affecting 
approximately 1 in 8 American women (Kohler et al., 2011).   It is the second most 
common cause of cancer death, only being surpassed by lung cancer
 
(Kohler et al., 2011).  
It is therefore not surprising that significant resources have been devoted specifically to 
breast cancer research – in 1999, an average 27.4 publications on breast cancer genetics 
were added to the Breast Cancer Gene Database daily (Baasiri et al., 1999).  Two genes, 
BRCA1 and BRCA2 have been identified as genetic markers for an increased breast 
cancer risk of 60 to 80% (Miki et al., 1994; Wooster et al., 1994; Martin et al., 2000).  
Unfortunately, mutations in these genes have been linked to less that 10% of all breast 
cancers (Claus et al., 1996) so BRCA screening alone is not sufficient to determine a 
patient‟s breast cancer risk.  A number of other risk factors including environmental 
exposures, alcohol consumption, past medical history and diet have also been shown to 
be correlated with breast cancer incidence (Brinton et al., 2002).   
1.2.1 The Role of Estrogen in Breast Cancer 
In order to gain mechanistic insight into the biology of breast cancer, there has been a 
significant research towards the genetics, protein expression and cell signaling pathways 
involved in normal and malignant mammary cells (Miller, 2002).  Estrogen is a critical 
hormone for both normal breast growth as well as the progression of breast cancer – 
many risk factors are linked to changes in estrogen levels, and two thirds of primary 
breast tumors express the estrogen receptor (ER) (Miller, 2002; Allegra et al., 1979).  In 
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cells expressing the ER, estrogen drives cell cycle progression through the early G1 phase 
(Osborne et al., 1983).  Drugs that target the ER block cell cycle progression and 
subsequently proliferation by decreasing levels of G1 cyclins, particularly cyclins D1 and 
E which are frequently overexpressed in breast cancer (Hall and Peters, 1996; Christov et 
al., 2003).  Estrogen may also contribute to survival in breast cancer cells by increasing 
the levels of Bcl-2, an antiapoptotic protein (Teixera et al., 1995; Wang and Basson, 
2008). 
1.2.2 EGF Signaling in Breast Cancer 
The EGF signaling pathway is involved in normal mammary cell development, survival 
and proliferation (Earp et al., 1995).  However, alterations in the signaling pathway are a 
characteristic of multiple diseases, including breast cancer (Lo et al., 2006).  Growth 
factors like EGF and heregulin bind to the family of tyrosine kinase receptors HER-1,-2,-
3,-4, and upregulation of this pathway encourages growth, proliferation and migration of 
tumor cells by stimulating the PI3K, Jak/Stat and ERK pathways (Berclaz et al., 2008; 
Liang et al., 2009; Kruger and Reddy, 2003).  Growth factors bind to the HER receptors 
and ultimately induce cell cycle progression through G1 phase via the cyclins, cdk 
activity and the phosphorylation of Rb (Miller, 2002).  Of particular interest is HER-2, 
which is very similar to the EGFR and is the human homolog of the neu oncogene 
identified in rat neuroglioblastomas (Slamon et al., 1987).  HER2/neu expression is 
linked to breast cancer, as gene amplification has been found in several mammary 
carcinoma cell lines as well as primary tumors.  This increase in copy number was 
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correlated with worsened clinical outcome when compared to patients without HER-
2/neu gene amplification.  Mutations of HER-2 can also cause tumorigenesis (Guy et al., 
1996).   HER-2 amplification or overexpression results in resistance to apoptosis induced 
by tamoxifen, an estrogen receptor antagonist commonly used in breast cancer 
chemotherapy (Shou et al., 2004).  Alternatively, trastuzumab, a therapeutic monoclonal 
antibody, is directed against the extracellular domain of HER-2 and is a successful 
treatment for breast cancers that significantly overexpress HER-2 (Goldenberg, 1999).  
The exact mechanism of action of trastuzumab is unknown, but may involve clearance of 
the tumor cells by antibody-dependent immune cell-mediated toxicity, inhibiting 
signaling pathways or preventing HER-2 cleavage (Hall and Cameron, 2009). 
1.2.3 Cyclins and Breast Cancer 
Increased proliferation is a major characteristic of cancer cells.  In breast and other 
cancers, this frequently involves deregulation of the cell cycle, a progression of phases 
that must be completed in sequential order (Fernandez et al., 1998).  A family of proteins 
known as the cyclins plays a critical role in allowing the cell to pass through checkpoints 
separating the phases of the cell cycle by binding to cyclin dependent kinases (CDKs) 
(Hunter and Pines, 1994).  These now activated CDKs phosphorylate targets such as the 
retinoblastoma protein (pRb) and allow the cell to progress through a checkpoint to the 
next phase of the cycle.  In breast cancer, cyclin D1 and cyclin E have been particularly 
well studied (Landberg and Roos, 1997).   
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Cyclin D1 is an oncogene that, when overexpressed, leads to neoplasia (for review see 
Arnold and Papanikolauo, 2005).  The CCND1 gene that codes for cyclin D1 is amplified 
at least ten-fold in 13 to 20% of breast cancers (Courjal et al., 1997; Schuuring, 1995) 
and overexpression of cyclin D1 without gene amplification (often due to alterations in 
degradation and translation) is found in up to 50% of breast cancers (Courjal et al., 1997).  
The primary function of overexpressed cyclin D1 in tumorigenesis is to act as a 
regulatory subunit of cdk4 and/or cdk6, which results in phosphorylation of pRb and 
subsequent progression through the G1/S checkpoint (Sherr, 1996; Alao, 2007).  While 
this increased progression confers an advantage to cultured cells, in many tumors there 
are redundancies in this pathway that make a single alteration unlikely to result in 
complete cell cycle deregulation (Arnold and Papanikolauo, 2005).  However, recent 
evidence indicates that cyclin D1 may contribute to tumorigenicity through other cdk-
independent mechanisms including binding to and inactivating transcription factors like 
DMP1 (Inouye and Sherr, 1998) and B-Myb (Horstmann et al., 2000).  So while cyclin 
D1 is a designated breast cancer oncogene, the mechanism(s) by which it exerts its 
effects are not completely understood.   
Similarly to cyclin D1, cyclin E regulates the G1-S cell cycle transition by binding to 
cdk2 and causing the phosphorylation of Rb (Nielsen et al., 1997; Gray-Bablin et al., 
1996).  One study shows that the knock-in of cyclin E (under the control of the cyclin D1 
promoter) to cyclin D1-null mice (which are resistant to breast cancer formation by the 
neu or ras oncogenes) rescues the ability of neu and ras to cause breast cancers in mice 
and demonstrates the redundancy of cyclins D1 and E (Yu et al., 2001; Geng et al., 
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1999).  Cyclin E overexpression does not drive tumorigenicity as dramatically as cyclin 
D1; only 10% of mice developed mammary carcinomas (Bortner and Rosenberg, 1999), 
and cyclin E is not classified as an oncogene (Arnold and Papanikolauo, 2005).  Although 
the evidence implicating a role for cyclin E in tumor development is weak, it has been 
proposed that targeting both cyclin D1 and cyclin E may be a useful therapeutic strategy 
against breast cancer (Yu et al., 2001). 
1.2.4 The MCF-7 Breast Cancer Cell Line 
The MCF-7 human breast cancer cell line was obtained from the pleural effusion of a 69 
year old woman suffering from malignant mammary adenocarcinoma (Soule et al., 1973).  
This epithelial cell line is a useful in vitro model for breast cancer, as the cells have 
retained many characteristics of the mammary epithelium, including the ability to process 
estrogen via estrogen receptors and the ability to form domes similar to mouse mammary 
epithelium (Brooks et al, 1973; Soule et al., 1973).  The MCF-7 cell line is HER-2
-
, 
meaning it is sensitive to treatment with tamoxifen (Benz et al., 1993).   MCF-7 cells 
express the c-myc oncogene (Dubik and Shui, 1988) but the wild type p53 tumor 
suppressor (Alkahaf and El-Mohafy, 2001).  I chose to use these cells for my studies 
because they are adherent and have a relatively small nucleus compared to the area of the 
cytosol.  This makes them ideal for imaging the translocation of GFP tagged proteins to 
different organelles.  Also, prior studies by the Roberts lab indicated that expression of 
Akt1 as the major Akt isoform was critical to the activity of D-3-deoxy-PI, and this is the 
major isoform expressed in this cell line (Wang and Basson, 2008; Zinda et al., 2001).   
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1.3 Glioblastoma Multiforme 
Glioblastoma multiforme (GBM), a grade IV glioma, is aggressive and the most common 
form of brain tumor in the U. S. (Hess et al., 2004).  It affects both children and adults 
and is incurable. Patients live only 9 to 15 months after diagnosis when treated, and only 
3 months without treatment (Souhami et al., 2004; Stupp et al., 2009; Wen et al., 2008).  
GBM tumors are particularly invasive, and demonstrate rapid proliferation and 
angiogenesis (Nakada et al., 2011).  Currently, the therapy of choice for GBM patients is 
surgical removal of the tumor followed by radiotherapy and treatment with a DNA 
alkylating agent like temozolomide; however this is insufficient for significant 
prolongation of life (Cimini and Ippoliti, 2011; Wick et al., 2011).  A major obstacle in 
GBM treatment is the development of multi-drug resistance due to the hypoxic tumor 
environment and expression of Multi-Drug Resistance Protein 1 (Garrido et al., 2011; 
Zhou et al., 2011).   
This lack of success has led to increased interest in molecular targeting of glioblastoma 
pathology, including signaling pathways (Cloughesy and Mishel, 2011; Wick et al., 2011; 
Cimini and Ippoliti, 2011) and metabolism (Colen et al., 2011; Seltzer et al., 2010).  
Biomarkers that show promise for therapeutic use are mutations of the isocitrate 
dehydrogenase -1 and -2 genes (IDH1 and IDH2) that occur frequently in gliomas and 
glioblastomas (Yan et al., 2009).  Isocitrate dehydrogenase canonically catalyzes the 
conversion of isocitrate and NADP
+
 to α-ketoglutarate and NADPH; however mutations 
in the active site result in a new catalytic activity wherein α-ketoglutarate and NADPH 
9 
react to form D-2-hydroxyglutarate and NADP
+
 (Dang et al., 2009).  While this is a 
relatively recent finding and bears further investigation, early evidence indicates the 2-
hydroxyglutarate may contribute to tumor formation by increasing oxidative stress and 
interfering with the mitochondrial electron transport chain and driving cells towards 
dependency on glycolysis (Bleeker et al., 2010; Latini et al., 2005; Seltzer et al., 2010).  
However the role of this mutation and suspected oncometabolite in tumorigenesis may be 
far more complex, as patients with IDH1/2 mutations were found to live longer than 
those with the wild type genes (Weller et al., 2009).  One potential way this mutant 
enzymatic activity can be targeted is by inhibition of glutaminase, an enzyme that 
converts glutamine to glutamate and ultimately α-ketoglutarate (Seltzer et al., 2010).  
Inhibition of glutaminase slowed the growth of glioblastoma cells engineered to express 
mutant IDH1, and this enzyme and its modulation hold promise as a biomarker and 
potential therapeutic (Seltzer et al., 2010).   
A characteristic of GBM is an extremely hypoxic microenvironment that causes 
upregulated glycolysis compared to surrounding normal tissue, so attempting to inhibit 
glucose metabolism is another current target in cancer research (Jin et al., 2007; Zhu et 
al., 2005).  Compounds like 2-deoxyglucose, a glucose analog that is converted to 
phosphorylated 2-deoxyglucose and subsequently inhibits glycolysis (Liu et al., 1999; 
Nelston et al., 1996), have shown promise as therapeutics in breast and GBM cancer 
models especially in combination with other drugs (Zhu et al., 2005; Pistollato et al., 
2010).  A clinical trial of 2-deoxyglucose in combination with radiotherapy as treatment 
for malignant tumors is currently in advanced stages; patients have shown increased 
10 
tumor necrosis but minimal damage to the surrounding brain tissue (Prasanna et al., 
2009).  Colen and coworkers have also had success in targeting glucose metabolism by 
inhibiting the monocarboxylate transporters responsible for lactic acid efflux with α-
cyano-4-hydroxy-cinnamic acid (Colen et al., 2011).  Α-cyano-4-hydroxy-cinnamic acid 
treatment minimized tumor invasiveness in mice and caused tumor necrosis when 
delivered directly to the tumor.  These compounds are excellent examples of how 
understanding the complex metabolism in tumor cells can lead to novel therapeutic 
strategies. 
1.3.1 The VM-M3 Tumor Cell Line 
The VM-M3 tumor cell line was isolated from a brain tumor that spontaneously arose in 
a mouse of the VM/Dk strain (Huysenstruyt et al., 2008).  VM-M3 cells form highly 
metastatic tumors when injected subcutaneously or intravenously into mice, spreading to 
multiple organ systems including the lung, liver, spleen, kidney and brain; this metastatic 
capability can be inhibited by cisplatin (Huysenstruyt et al., 2010).  This cell line has 
been identified as deriving from macrophage origin due to its in vitro morphology, 
expression of the microglial Iba1 gene, phagocytic capability, and similarities in lipid 
profile to the RAW 264.7 macrophage-derived cell line (Huysenstruyt et al., 2008).  It 
has also been noted that the tumor from which the VM-M3 line was isolated is similar to 
those found in GBM, and that these macrophage-like cells could be part of the population 
of the most invasive GBM tumor cells (Huysenstruyt et al., 2008).  However, these cells 
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are not commercially available and have been used in a very small number of studies, so 
much further investigation is required in order to confirm this hypothesis. 
1.4 Macrophages 
Macrophages are important effector cells of the immune system.  Macrophages are 
differentiated monocytes, and can be capable of moving freely throughout the organism 
or localized to specific tissues (Goldsby et al., 2003).  They are phagocytic, clearing 
erythrocytes, cellular debris, and apoptotic cells even without prior stimulation (Mosser 
and Edwards, 2008; Mackaness, 1977).  Macrophages can be activated by endogenous 
and exogenous stimuli including cytokines secreted by immune cells like interferon 
gamma (IFN-γ) and tumor necrosis factor (O‟Shea and Murray, 2008), components of 
pathogens like lipopolysaccharide (LPS) that bind to Toll-like receptors (TLRs) (Goldsby 
et al., 2003), phagocytosed antigens and even particulate matter (Santini et al., 2004).  A 
macrophage that is activated by exposure to IFN-γ and through antigen binding to Toll-
like receptors is classified as a classically activated macrophage (Mosser and Zhang, 
2008).  IFN-γ acts as a primer that activates transcription factors STAT 1/2; these 
promote the transcription of genes involved in the immune response (Mosser and Zhang, 
2008).  For complete classical activation, the macrophage is treated with a TLR ligand 
like LPS, which results in the production of tumor necrosis factor (TNF) and stimulates 
the macrophage (Mosser and Edwards, 2008; Mosser and Zhang, 2008). 
 Activated macrophages are able to kill invading microorganisms by producing large 
quantities of reactive oxygen species like nitric oxide in a respiratory burst, which are 
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toxic to pathogens like bacteria and fungi (Goldsby et al., 2003).  Another way that 
activated macrophages can help defend an organism from pathogens is by secreting 
cytokines like interleukin 1, 6 and 23 that aid in the inflammatory response and the 
proliferation and development of certain T cells (Langrish et al., 2005; Veldhoen et al., 
2006).   Classically activated macrophages also upregulate MHC Class II, enabling them 
to act as professional antigen presenting cells that activate T cells (Mosser and Zhang, 
2008).   
1.4.1 The RAW 264.7 Tumor Cell Line 
The RAW 264.7 tumor cell line was isolated from a murine lymphocytic lymphoma 
induced by the Abelson leukemia virus (Raschke et al., 1978).  The RAW 264.7 line is 
characterized as being from macrophage origin based on phagocytic capability, secretion 
of lysozyme, and the ability to lyse red blood cells (Rashke et al., 1978).  These cells are 
commercially available (www.atcc.org) and have been used in a wide range of studies 
including metabolism (Stuckey et al., 2005), macrophage activation (Santini et al., 2004) 
and lipid synthesis (Singh et al., 1994).  These cells have also been shown to be activated 
by lipopolysaccharide and produce NOS and TNF (Rimbach et al., 2000; Aybay and 
Imir, 1998) similar to non-transformed macrophages, making these an easy to maintain 
and immortal source of cells for many in vitro studies of macrophages. 
1.5 The PI3K-Akt pathway 
One of the most frequently deregulated signaling pathways in cancer is the 
phosphatidylinositol 3-kinase - AKT pathway (Hennessey et al., 2005; Vivanco and 
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Sawyers, 2002).  Exogenous growth factors such as insulin, EGF, heregulin and PDGF 
bind to receptor tyrosine kinases, which phosphorylate (and activate) PI3K (see reviews 
Leevers et al., 1999; Vanhaesbroeck et al., 1997).  PI3K then phosphorylates the 3‟ 
hydroxyl group on phosphatidylinositols, including PI(4,5)P2 PI(4)P, PI(5)P and PI to 
form lipid second messengers (Whitman et al., 1998; Carpenter and Cantley, 1990).  
These PIPs bind to cellular proteins with specific lipid binding domains, causing 
membrane recruitment and/or conformational chances that affect enzymatic activity 
(Leonard and Hurley, 2011).  Activation of the PI3K pathway starts a signaling cascade 
that regulates a number of critical cellular functions including cell survival, 
differentiation, transcription and glucose uptake (Yao and Cooper, 1995; Faber et al., 
2006; Datta et al., 1999).  In tumor cells, upregulation of the PI3K pathway results in 
uncontrolled growth of tumor cells and resistance to apoptosis (Datta et al., 1997; 
Cardone et al., 1998).  It is for this reason that small molecule inhibitors of the PI3K 
pathway are currently a major area of interest in oncology research (Dimpy et al., 2010; 
Noguchi et al., 2008; Fruman and Rommel, 2011). 
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Figure 1.1.  A brief summary of the PI3K-Akt pathway, which regulates a number of cellular processes 
including apoptosis, proliferation, the cell cycle, glycogen synthesis, translation initiation and cell growth. 
 
1.5.1 Akt and its Isoforms 
The major effector kinase of the PI3K signaling cascade is Akt.  Akt, or protein kinase B, 
is a 56 kDa serine – threonine kinase that is a member of the AGC kinase family, and it is 
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the mammalian homolog of the transforming oncogene of the AKT8 retrovirus (Staal 
1987, 1977; Bellacosa, 1991).  There are three isoforms: Akt-1, Akt-2 and Akt-3 (or PKB 
//) that are differentially localized within a given cell (Gonzalez and McGraw, 2009).  
Most normal tissues and tumor cell lines express some level of each isoform (Zinda et al., 
2001; Fillmore et al., 2005).  The differing roles of the Akt isoforms were investigated 
using transgenic knockout mice (Yang et al., 2004).  Akt-1 was found to play a role in 
placental development, animal growth and adipogenesis, and knockout animals were 
unusually small and displayed higher rates of spontaneous apoptosis in thymic cells and 
perinatal mortality.  Akt-2 knockout mice developed diabetes, and Akt-2 was found to be 
critical for glucose metabolism in addition to animal growth and adipogenesis.  Knockout 
of Akt-3 in mice resulted in animals with significantly smaller brain size and weight as 
compared to control mice, and therefore this isoform is involved in the regulation of 
postnatal brain growth.  Overexpression or increased activation of one or more isoforms 
of Akt is common in many cancers including Akt-2 in malignant glioma, pancreatic 
cancer and ovarian and breast carcinomas  (Mure et al., 2010; Miwa et al., 1996; 
Bellacosa, 1995) and Akt-3 in ER- breast cancers and in prostate cancer cell lines that are 
androgen-independent (Nakatani et al., 1999).  The distribution of isoforms, particularly a 
decrease in Akt-1, is also linked to metastasis induced by pressure-stimulated cancer cell 
adhesion (Wang and Basson, 2007). 
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Table 1.1. Sequence similarities between the three Akt isoforms (expressed in percent 
sequence identity).  Modified from Kumar and Madison, 2005.   
Comparison PH Domain Linker Catalytic 
Domain 
C-term 
extension 
AKT1/AKT2 80 46 90 66 
AKT1/AKT3 84 40 88 76 
AKT2/AKT3 76 17 87 70 
 
1.5.2 The Structure of Akt 
The structure of Akt consists of three domains – the pleckstrin homology (PH) domain, 
the catalytic kinase domain (CAT), and a C-terminal extension (EXT) containing a 
hydrophobic motif (Kumar and Madison, 2005).  The N-terminal PH domain is attached 
to the CAT domain by a flexible linker region (LINK) which is poorly conserved (17-
46% identical) between Akt isoforms.  In contrast, the PH, CAT and EXT are well 
conserved between isoforms, showing ~80%, 90%, and 70% homology, respectively 
(Table 1.1) (Kumar and Madison, 2005).  Unfortunately, the flexibility of LINK has 
made it impossible to obtain a crystal structure of full length Akt.  However, multiple 
crystal structures of the PH Domain (Thomas et al., 2002; Millburn et al., 2003) and 
CAT/EXT domains (Lippa et al., 2008; Yang et al., 2002) with substrate mimics and/or 
inhibitors have been solved separately allowing insight into the structures of these 
domains.  The Akt CAT domain catalyzes the transfer of a phosphate group from ATP to 
the serine or threonine of a protein with the consensus sequence RXRXXS/T-bulky 
hydrophobic (Alessi et al., 1996).  The CAT domain, which spans approximately 150 
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amino acids, contains the ATP and peptide binding sites, as well as a threonine residue 
(Thr308, Akt-1; Thr309, Akt-2; Thr305, Akt-3) in the activation T-loop that must be 
phosphorylated for maximum activity.  When phosphorylated, this activation loop allows 
ATP and the peptide substrate to access the peptide site; in the unphosphorylated state, 
this loop blocks kinase activity (Scheid and Woodgett, 2001).  The EXT contains a 
hydrophobic motif (HM), containing a serine residue (Ser473, Akt-1; Ser474, Akt-2; 
Ser472, Akt-3) which, when phosphorylated, causes the HM to insert into a hydrophobic 
groove and become an allosteric effector of the active PKB conformation (Yang et al., 
2002). 
The PH domain is a lipid binding domain that is specific for PI(3,4,5)P3 and PI(3,4)P2 
(Frech et al., 1997; James et al., 1996).  It is so named for its sequence homology to 
pleckstrin, the protein kinase C substrate in platelets (Haslam et al., 2003; Tyers et al., 
1989).  Binding these phospholipids results in minimal increase of catalytic activity in 
vitro; instead, the primary function of the PH domain is to mediate the translocation of 
Akt from the cytosol to the membrane by binding these membrane localized PIPs 
(Downward, 1998).  The structure of the PH domain consists of 7 ß-sheets arranged in a 
ß-barrel, with a C-terminal α-helix closing one end of the barrel and a cationic lipid 
binding pocket  consisting of three variable loops at the other end (Thomas et al, 2002). 
[Figure 1.2] This positively charged site binds specifically PI(3,4)P2 and PI(3,4,5)P3 and 
causes the translocation of Akt to the plasma membrane in response to PI3K activation 
(Andjelkovic et al., 1997; Bellacosa et al., 1998).   
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Figure 1.2.  (A) Crystal structure of the Akt1 PH domain (green) (PDB 1UNQ) bound to inositol (1,3,4,5) 
tetrakis-phosphate (cyan and orange).  Residues in the cationic binding site that make contacts with the IP4 
phosphates are highlighted (blue). (B) The Akt2 CAT (purple), EXT and HM domains (red) (PDB 106K) 
crystallized with ANP (yellow) and a peptide from GSK-3β that includes the Akt phosphorylation motif.  
Phosphorylation of Thr308 in the activation loop (cyan) and Ser473 in the hydrophobic motif (blue) are 
required for full Akt activation. 
 
Lipid binding induces significant structural changes, as evidenced by comparing the 
crystals structures of the apo-PH domain from Akt1 to the PH domain bound to inositol 
(1,3,4,5)P4 (IP4) , a PI(3,4,5)P3 analog (Milburn et al., 2003; Thomas et al., 2002).  This 
structural change includes the formation of a small α-helix, movement of the variable 
loop regions and changes in the amino acids present in the phosphatidylinositol binding 
site.  The variable loops (VL1-3) at the open end of the β-barrel of the Akt-1 PH domain 
bind the inositol (1,3,4,5)P4 head group by interactions between the basic amino acid 
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residues and the IP4 phosphate groups.  Specifically, Arg-86 forms hydrogen bonds with 
the 4-phosphate, Lys14 and Asn52 interact with both the 3- and 4-phosphates and Arg23 
makes contact with the 1- and 3- phosphates (Milburn et al., 2003).  The authors of this 
study postulated that the conformational change induced by lipid binding might result in 
the exposure of the activation loop in the CAT domain, permitting the phosphorylation of 
Thr308.  
Interestingly, the 5-phosphate does not make contact with any residue in the PH domain, 
which may explain the dual specificity of the Akt PH domain for PI(3,4)P2 and 
PI(3,4,5)P3 (Milburn et al., 2003).  In the apo structure, Glu17 blocks the ligand binding 
pocket but rotates outward upon headgroup binding.  This makes room for the 5-
phosphate, which otherwise would be prevented due to steric hindrance.  It has been 
shown that the mutation of this glutamate residue to lysine causes Akt to be constitutively 
located at the plasma membrane (Landgraf et al., 2008).  This mutation has been 
identified in multiple human cancers (Carpten et al., 2007; Malanga et al., 2008).  
Landgraf and colleagues suggest that this increased membrane localization (and resulting 
activation) of Akt is due to the E17K charge reversal causing an increased affinity for 
PI(4,5)P2, which is continuously present at much higher levels in the plasma membrane 
than PI(3,4,5)P3 or PI(3,4)P2.   
1.5.3 Activation of Akt 
The phosphorylation of both Thr308 and Ser473 are required for complete Akt activation, 
but it has been difficult to elucidate the order of and kinases responsible for these 
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phosphorylation events.  It is well accepted that the Thr308 site in the catalytic domain is 
phosphorylated by 3-phosphoinositide dependent kinase 1 (PDK1) after Akt has 
translocated to the plasma membrane (Alessi et al., 1997).  Identifying the kinase 
responsible for the phosphorylation of Ser473 in the hydrophobic motif has created more 
controversy – evidence implicating PDK1, ILK and even autophosphorylation by Akt has 
been presented (see Leslie et al., 2001 for a review).  However, it is currently accepted 
that Ser473 is phosphorylated by the rictor-mTOR complex (Sarbassov et al., 2005).  The 
order and timing of these events further contributes to the complexity of activation. 
Reports suggested that phosphorylation of Ser473 by the rictor-mTOR complex greatly 
increased phosphorylation of Thr308 by PDK1 (Sarbassov et al., 2005) which 
corresponds to other studies that have shown phosphorylation at Ser473 is a prerequisite 
for Thr308 phosphorylation and full activity (Scheid et al., 2002; Yang et al., 2002).  
However, this is not always the case as Toker and Newton found the Thr308 
phosphorylation event to happen prior to that of Ser473 (2000).  Despite these continuing 
discrepancies, the one thing that is well agreed upon is that phosphorylation at both these 
sites is required in order for Akt to be fully active (Alessi et al., 1996). 
Calleja and colleagues have proposed a link between an intramolecular interaction 
between the PH and CAT domains and of Akt activation (Calleja et al., 2007).  Using 
intramolecular FRET and molecular modeling, they have determined that the PH domain 
can adopt two configurations.  When Akt is inactive, it adopts the PH-IN configuration 
where the PH domain hydrophobically interacts with the CAT domain and obscures 
Thr308 and the ATP binding pocket.  This prevents phosphorylation of Thr308 by PDK1.  
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The binding of the PH domain to PIPs causes a shift to the PH-OUT conformer where the 
PH domain no longer blocks the activation loop and PDK1 can phosphorylate Thr308.  
This mechanism illustrates the necessity of plasma membrane translocation in order for 
Akt activation, and the complexities involved in the upstream activation of this protein.  
1.5.4 Akt Substrates and Downstream Effectors 
Akt phosphorylates a broad range of targets that control critical cellular functions like 
glucose uptake, transcription, proliferation and survival.   One mechanism by which Akt 
promotes cell survival is by phosphorylating and deactivating pro-death signals like BAD 
at Ser136 (Datta et al., 1997; Del Peso et al., 1997).  Phosphorylation of BAD prevents 
the release of cytochrome C from the mitochondria and the subsequent formation of the 
apoptosome and ultimately apoptosis (see review by Tsujimoto, 1998).  Even after 
cytochrome C is released, Akt can prevent cell death by phosphorylating and inactivating 
the catalytic activity of caspase 9 (Cardone et al., 1998).  This prevents active caspase 9 
from initiating a caspase cascade that culminates in apoptosis (Solary et al., 1998).  Akt 
can also block apoptosis at the transcriptional level by phosphorylating the Forkhead 
family of transcription factors, which keeps them localized in the cytoplasm and prevents 
them from entering the nucleus where they would be active (Biggs et al., 1999; Brunet et 
al., 1999).  These transcriptional activators have been implicated in the induction of 
apoptosis by stimulating the transcription of death genes such as the Fas ligand (Brunet et 
al., 1999).   
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The range of cellular functions that Akt regulates is not limited to apoptosis.  The first 
Akt direct substrate found was glycogen synthase kinase 3 (GSK3) (Shaw et al., 1997), 
which is involved in glycogen synthesis, as well as control over transcription factors and 
mediation of ubiquitin-dependent proteasomal degradation by phosphorylating proteins 
such as cyclin D1 (Welsh et al., 1996; Diehl et al., 1998).  Akt can also phosphorylate the 
insulin-responsible glucose transporter GLUT4 and stimulate its translocation from the 
cytosol to the plasma membrane, enhancing glucose uptake (Kohn et al., 1996).   Akt can 
also phosphorylate and activate mTOR and thus regulate an extensive signaling cascade 
that controls the phosphorylation of downstream proteins such as p70S6K (Proud, 1996) 
and 4EBP1 (Graves et al., 1995) and mediates translation and autophagy (Scott et al., 
1998; Fu et al., 2009).  These are limited examples, but they illustrate the diverse effects 
of Akt activity on cell survival, transcriptional regulation and metabolism.   
1.5.5 Aberrant Akt Activation and Cancer 
Uncontrolled growth is a characteristic of tumor cells, and one of the ways this occurs is 
through increased activation of the pro-survival Akt pathway (Noguchi et al., 2008).  
Overexpression of Akt is a characteristic of many cancers including breast, pancreatic 
and ovarian cancers (Bellacosa et al., 1995; Cheng et al., 1996).  As previously 
mentioned, the E17K mutation is commonly found in multiple cancers, and imparts less 
specificity and greater activity to Akt.   However, there are ways this pathway can be 
hyperactivated in tumorigenesis that do not involve alterations or overexpression of Akt 
itself.  The PI3K-AKT pathway can be upregulated in cancer by mutation or deletion of 
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critical proteins required to negatively regulate Akt.  An important example is PTEN 
(phosphatase and tensin homologue deleted on chromosome ten), a lipid phosphatase that 
dephosphorylates PI(3,4,5)P3 and PI(3,4)P2 at the 3‟ position and consequently decreases 
the concentration of phospholipids that can bind to the Akt PH domain and cause 
membrane translocation (Li et al., 1997; Maehama and Dixon, 1998).  PTEN is a 
common oncogene that is deleted or mutated in a number of cancers including 
glioblastoma, prostate cancer and breast cancers (Li et al., 1997; Georgescu, 2010).  
These mutations are so frequent that it is considered the second most commonly mutated 
tumor suppressor gene after p53 (Noguchi et al., 2008).  Loss of PTEN activity is also 
found in Cowden‟s and Bannayan-Zonana diseases (Marsh, 1998).  This deletion or loss 
of activity results in upregulation of the Akt pathway, as dephosphorylation of PIPs 
required for activation is impaired (Cantley and Neel, 1999; Alimonte et al., 2010).  
SHIP (SH2 containing inositol 5‟ phosphatase 1), a 5‟ phosphoinositide phosphatase, 
converts PI(3,4,5)P3 to PI(3,4)P2 (Damen et al, 1996 and Kavanaugh et al, 1996).  SHIP-1 
downregulation, similar to PTEN, confers a proliferation advantage to tumor cells, and 
decreased SHIP-1 expression is common in chronic myelogenous leukemia patients 
(Sattler et al., 1997) and in adult T-cell leukemia/lymphoma (Fukuda et al., 2005).   
Protein phosphatases such as PHLPP (PH domain leucine-rich repeat protein 
phosphatase) and protein phosphatase 2A are also important downstream regulators of 
Akt.  Both can dephosphorylate Akt at the Ser473 site, causing inactivation (Gao et al, 
2005; Chen et al., 1999).  PHLPP is endogenously expressed at moderate levels in most 
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cell types, and overexpression in H157 cells results in an increase in the number of 
apoptotic tumor cells (Gao et al., 2005).  Loss of PHLPP expression has been observed in 
colorectal cancer tissue, resulting in increased Akt activity (Liu et al., 2009).  These lipid 
and protein phosphatases are critical to maintaining control over Akt activity in the cell 
and are therefore potential therapeutic targets for modulation of this pathway in cancer 
(Ching and Hansel, 2010; Ciuffreda et al., 2009). 
1.5.6 Akt as a Therapeutic Target – Phosphatidylinositol Analogs 
Since Akt is a critical player in deregulated PI3K signaling, it is a prime target for 
inhibition by small molecules.  A variety of small molecules have been discovered that 
mediate activity by binding to the PH domain and the active site in the catalytic domain 
(Yang et al., 2004; Kondapaka et al.; Plu et al., 2000).  Of particular relevance to this 
work are the phosphatidylinositol analogs (PIAs).  This class of inhibitors are designed to 
mimic PI(3,4,5)P3 or PI(3,4)P2 and competitively bind to the cationic binding pocket of 
the PH domain, preventing membrane translocation and Akt activation (Gills and Dennis, 
2004; Cheng et al., 2005).  This type of inhibitor has advantages over a small molecule 
that inhibits kinase catalytic activity, as most kinase inhibitors target the active site, 
which is highly similar among the over 500 kinases found in the cell (Gills and Dennis, 
2004).  This strategy was first adopted after the observation that D-3-deoxy myo-inositols 
could halt the proliferation of tumor cells (Powis et al., 1991).  To improve potency and 
eliminate transport issues (the synthetic myo-inositols competed with endogenous myo-
inositol for import into the cell), Kozikowski and coworkers synthesized 1-D-3-
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deoxyphosphatidylinositol (DPI) (1995).  This lipid lacks a 3‟ hydroxyl group and cannot 
be phosphorylated by PI3K, and was considered to serve as a mimic of PIP3.  DPI was 
effective at inhibiting cancer colony formation, and spurred an interest in modifications 
to further improve potency (Qiao et al., 1998).   By replacing the diacylglycerol linkages 
with ether linkages to prevent degradation by phospholipases, Qiao and colleages 
synthesized a novel PIA called DPIEL that showed an increase in potency (Qiao et al., 
1998).  The activity and PH domain binding capability of DPIEL and analogs has been 
further studied, and it was concluded that these PIAs can bind to the Akt PH domain, and 
molecular modeling confirmed that the myo-inositol ring of DPIEL could bind 
specifically to the cationic lipid binding pocket with relatively high energy (Meuillet et 
al., 2003).  The Dennis group has investigated a number of further modifications to this 
structure including substitutions and deoxygenation of the inositol ring, shortening of the 
sn-2 position acyl chain, varying the linkage between the ether lipids and the inositol 
ring, and the substituents on the inositol ring (Kozikowski et al., 2003; Castillo et al., 
2004).  Effective compounds inhibited the phosphorylation of Akt at Ser473 and 
downstream Akt targets such as AFX and GSK 3-β, induced apoptosis in H157, H1155, 
MB468 and H1703 tumor cell lines, and did not affect signaling in closely related 
pathways like MAPK1/2.  Castillo and colleagues reported that the most potent PIAs 
induced more apoptosis after 24 hours than did commonly used chemotherapeutics like 
paclitaxel, cisplatin and trastuzamab at comparable concentrations (Castillo et al., 2004; 
Brognard et al., 2001).   
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To further attempt to optimize the PIA, the Miller group in collaboration with the Roberts 
lab synthesized a series of stereospecific deoxygenated PIP analogs with octanoyl chains 
(Xu et al., 2006; Wang et al., 2008).  The series included D- and L-3-deoxy diC8PI, and 
D- and L-3,5 dideoxy diC8PI.  The elimination of the hydroxyl group at the C3 position 
will prevent phosphorylation by PI3K and was intended to produce PIA activity (Wang et 
al., 2008).  The removal of the C5 hydroxyl group as well was included in the series to 
investigate whether this site could affect efficacy despite the fact the C5 phosphate of 
PIP3 has been reported not to make any contacts with the cationic binding pocket as 
evidenced by the crystal structure (Millburn et al., 2003).  Additional compounds, D- and 
L-3-deoxy diC8PI(5)P, were tested as potential dual therapeutics; the C5 phosphate group 
has been shown to kinetically activate PTEN in addition to the intended PIA activity that 
could result from the removal of the C3 hydroxyl group (Campbell et al., 2003; Wang et 
al., 2008).  These molecules were synthesized with shorter acyl chain lengths as 
compared to DPIEL in the hope that a higher monomeric concentration in the cytosol due 
to increased CMCs would result in increased efficacy. 
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Figure 1.3. Structures of relevant phosphatidylinositol analogs (PIAs). 
 
The Roberts laboratory extensively characterized this series of PIAs using biophysical 
methods in order to gain insight into the relationship between structure and potency 
(Wang et al., 2008).  In collaboration with the Chiles laboratory, the cytotoxicity of all 
compounds were tested in the U937 human lymphoma line and only D-3-deoxy diC8PI 
was found to be cytotoxic with an IC50=40 µM.  The fact that this compound was 
cytotoxic but D-3,5-dideoxy diC8PI was not is particularly intriguing since the 5- 
phosphate is not supposed to be involved in the binding of phospholipids to the PH 
domain, and suggests that the deoxy PIAs may bind differently to the PH domain than  
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PIP3, or possibly the PH domain is not the primary target (Wang et al., 2008; Meiullet et 
al., 2003).  The stereoselectivity of cytotoxicity is also interesting and suggests a very 
specific interaction between with D-3-deoxy diC8PI and its target.  D-3-deoxy diC8PI was 
found to inhibit PTEN, the phospholipase PI-PLC and PI3K, but at concentrations 
comparable to that used for diC8PI(3)P, not the best substrate for PTEN, or diC8PI, again 
not a good substrate for PI-PLC or PI3K. The Ki for the D-3-deoxy diC8PI inhibition of 
PTEN is estimated as 0.1-0.2 mM, a value higher than the IC50 of 40 µM in U937 cells, 
suggesting it is unlikely to inhibit this critical phosphatase in cells. Several of the non-
cytotoxic compounds were also as good or better inhibitors of these enzymes, which 
further supports that the cytotoxic activity of D-3-deoxy diC8PI is not due to inhibition of 
PTEN, PI-PLC or PI3K.  While evidence was presented that the Akt pathway was 
inhibited by D-3-deoxy diC8PI, there was no investigation into the ability of this 
compound to directly bind the PH domain of Akt.  The immunoblotting data presented 
showed a decrease in Ser473 phosphorylation and the phosphorylation of downstream 
(although importantly, not direct) substrates. However, this is not enough information to 
definitively conclude that D-3-deoxy diC8PI exerts its cytotoxic effects by binding to the 
PH domain and preventing membrane translocation of Akt. 
1.5.7 Cytotoxic Alkylphospholipids – Perifosine and Miltefosine 
Perifosine is an alkylphospholipid originally suspected to cause cytotoxicity in cancer 
cells by preventing the translocation of Akt to the plasma membrane, similar to a PIA 
(Kondapaka et al., 2003).  It has been shown to decrease phosphorylation of Akt at 
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Thr308 and Ser473 and but not directly affect Akt activity, PI3K activity, or 
phosphorylation of PDK-1 in multiple tumor cell lines and human multiple myeloma 
cells (Kondapaka et al., 2003; Hennessey et al., 2007; Hideshima et al., 2006).  Perifosine 
is currently in phase II clinical trials for a number of different cancers (Gills and Dennis, 
2009).  Although fluorescence microscopy has been utilized to demonstrate that 
perifosine prevents the Akt membrane translocation (Hennessey et al., 2007), there has 
been no direct evidence that perifosine can directly bind to the Akt PH domain and 
subsequently cause this inhibition.  The signaling effects of perifosine consistently 
involve the Akt pathway, but also can variably affect related pathways such as JNK and 
MEK/ERK depending on the cancer cell line (Fu et al., 2009; Hideshima et al., 2006).  
Miltefosine (hexadecylphosphocholine) is another cytotoxic alkylphospholipid that is 
effective in a number of tumor cell lines and primary tumors (Eibl and Unger, 1990; 
Mushiol et al., 1987).  Like perifosine, miltefosine has been used in clinical studies 
(Verweij et al., 1992; Terwogt et al., 1999).  The mechanism of action seems to be 
complex, and it has been shown to include inhibition of phospholipase C δ (Pawelczyk 
and Lowenstein, 1993), inhibition of protein kinase C (Berkovik et al., 1994) and 
inhibition of the Akt-PI3K pathway (Ruiter et al., 2003).  It is also useful in the treatment 
of leishmaniasis (Thakur, 2003). 
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Figure 1.4. Structures of cytotoxic alkylphospholipids. 
 
1.6 The p38MAPK Pathway 
The p38MAPK signaling pathway is involved in a number of cellular functions including 
apoptosis, growth inhibition and differentiation (Hui et al., 2007).  This pathway can be 
activated primarily in response to stress, (UV, heat and osmotic shock) and inflammatory 
cytokines, but also by growth factors (Hui et al., 2007; Raingeaud et al., 1995; Neve et 
al., 2002).  p38MAPK, the major mediating kinase of this pathway, is activated by 
phosphorylation by MKKs (MAPK Kinases) in response to these stimuli and 
phosphorylates downstream targets like MAPK-APK2 to mediate its cellular effects (for 
review see Cuenda and Rousseau, 2007).  Overall, activated p38MAPK is considered to 
be a tumor suppressor rather than an oncogene due to its role in regulating cell cycle 
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progression and proliferation (Cuenda and Rousseau, 2007).  Part of the mechanism of 
tumor suppression by this pathway is by promoting apoptosis and growth arrest in 
response to reactive oxygen species produced by oncogenes (Dolado et al., 2007).  
p38MAPK has also been shown to regulate the cell cycle by phosphorylating cyclin D1 
on Thr386 and targeting it for proteasomal degradation (Thoms et al., 2007), as well as 
negatively regulating cyclin D1 promoter transcription (Page et al., 2001).  However, 
there are limited examples where activated p38MAPK can contribute to tumorigenesis.  
In breast cancer, elevated phospho-p38MAPK levels are linked to cultured cell 
invasiveness and the overproduction of urokinase-type plasminogen activator (uPA), a 
pro-invasion protein (Huang et al., 2000; Whyte et al., 2009).  And in T47D breast cancer 
cells, activation of the p38MAPK pathway in combination with the PI3K and MAPK 
pathways is required for proliferation and entry into the cell cycle in response to growth 
factor stimulation (Neve et al., 2002).    
1.7 High-Resolution Field Cycling 
31
P NMR Spectroscopy to Monitor Protein-Lipid 
Interactions 
Valuable information about phospholipid dynamics can be obtained by NMR from T1 
relaxation experiments (Smith and Ekiel, 1984; Rommel et al., 1988).  The spin-lattice 
relaxation rate R1 of a particular phosphorus atom in a phospholipid is calculated from 
the relaxation time T1 (R1=1/T1), and will be affected by relaxation mechanisms 
including chemical shift anisotropy (CSA) and dipolar interactions with nearby 
1
H nuclei 
in the same or in neighboring molecules (for example protein residues in a binding site 
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around the 
31
P).  Thus, changes in the relaxation rate of 
31
P atoms can be used to 
determine whether or not a given phospholipid binds to a protein, as well as the size of 
the protein-lipid complex (Pu et al., 2010).  If a phospholipid is bound to a protein, the 
1
H 
nuclei in the protein residues involved in binding will increase the relaxation due to 
dipole-dipole interactions.  However, at the high fields necessary for good chemical shift 
resolution (i.e., a 11.7 or 14.0 T spectrometer with 
1
H resonances at 500 or 600 MHz  ), 
the relaxation rates of 
31
P in small molecules as well as in larger molecules or aggregates 
are dominated by chemical shift anisotropy (Roberts and Redfield (a), 2004).  At much 
lower fields (< 2 T), the relaxation rates are far more dependent on dipolar interactions 
between a 
31
P and nearby intra- and intermolecular protons.  The intermolecular dipole-
dipole relaxation resulting from nearby 
1
H nuclei in a protein interacting with the 
31
P of 
the phospholipid is very small. Monitoring the R1 as a function of magnetic field, 
provides information on time-scales for different molecular motions and allows one to 
estimate the averaged distance between the 
31
P and 
1
H that relax it with greater accuracy. 
However, isolating the contribution due specifically to the protein is still difficult. The 
relaxation effect can be greatly enhanced (and the analysis simplified) by spin labeling 
the protein to introduce an unpaired electron close to the phospholipid binding site.  An 
unpaired electron is about 1000-fold more effective at relaxing a given nucleus (
1
H, 
31
P, 
13
C) than another nucleus. This dipolar interaction dominates relaxation of 
31
P in the case 
of phospholipids; interpretation of the enhanced relaxation is easier and if the effect is 
observed at low fields, some idea of the complex lifetime can be made. The key to these 
experiments is the ability to monitor R1 as a function of magnetic field strength but still 
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maintaining any chemical shift differences if a given molecule (e.g., PIP3) contains more 
than one 
31
P. 
The technique to access low field relaxation behavior for 
31
P in diverse molecules is high 
resolution field cycling. In this methodology, the fringe field of a high resolution 
superconducting magnet supplies the low field with the sweet spot occupied by the probe 
providing the high field for resolution of different 
31
P resonances.  The sample is first 
excited at a high field within the magnet, then mechanically shuttled to a position in the 
fringe field (and in some cases out of the magnet) where relaxation at a lower field occurs 
(Roberts and Redfield, 2004).  Finally, the sample is returned to the high field, where the 
final readout is obtained. T1 is measured with a 180
o
-pulse at 11.7 T, followed by 
relaxation at a low field (from 10 T down to 0.003 T) for a variable amount of time, then 
readout of remaining relaxation at 11.7 T with a 90
o
-pulse.  The relaxation rate, R1, is 
obtained over a wide range of fields. If the phospholipid in question is bound to a protein, 
an increase in relaxation rates due to intermolecular dipolar interaction between the 
31
P 
and unpaired electron in the spin label (compared to control samples) should be visible at 
very low fields (Pu et al., 2010).  This information is also used to calculate the correlation 
time τ for the 31P-spin-labeled protein complex.  is a measure of the rotational diffusion 
of the lipid-protein complex, and r, the distance between the unpaired electron of the spin 
label and the phosphorus atom (Pu et al., 2009). 
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1.8 Metabolomics  
The “omics” family of technologies has garnered a significant amount of attention over 
the past several years.  Genomics, or the study of global collection of genes in a cell and 
their expression, was the first of the “omics” to be embraced by the scientific community, 
and was soon followed by its relatives proteomics, transcriptomics, and more recently 
metabolomics (Castrillo and Oliver, 2005).  Metabolomics is the analysis of all (or a 
defined subset of) the metabolites in a cell (Nielsen).  Metabolomic analyses can provide 
important information about alterations in metabolic pathways in the cell, but working 
with the metabolome creates significant challenges.  An effective metabolomics study 
requires a combination of sophisticated bioanalytical chemistry coupled with a solid 
understanding of cellular metabolism.   
1.8.1 Metabolism and the Metabolome  
The word „metabolism‟ is derived from the Greek word for change or transformation, and 
describes the network of chemical reactions that, appropriately, change and transform 
small molecules in the cell (Roessner).  These enzyme-catalyzed reactions provide the 
cell with methods to convert carbon and energy sources into usable metabolites necessary 
for cell growth, amino acid and nucleotide biosynthesis, and energy production.  These 
reactions can be divided into two groups; anabolic reactions are energy intensive and 
involve the synthesis of more complex, energy storing molecules from simple precursors, 
while catabolic reactions break down larger, often macromolecules in order to release 
energy (Nelson and Cox, 2005).  The metabolites that act as the cellular energy currency 
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include ATP, a source of a high energy phosphate group, and NADH, NADPH, and 
FADH2 which contain reducing equivalents necessary to fuel the electron transport chain 
and for other biological reactions.  Metabolic reactions in the cell are highly organized 
and enzyme activities are regulated by level of expression and control of activity by other 
proteins (i.e. phosphorylation) or endogenous metabolites that can act as allosteric or 
competitive inhibitors (Roessner, 2007).  These reactions can also be modulated by 
compartmentalization of enzymes or substrate metabolites (Nelson and Cox, 2005).   
By definition, a metabolite must be a molecule that serves a useful function in the 
growth, survival or maintenance of a cell, or is a precursor to a molecule that will play 
such a role (Roessner, 2007).  The metabolites that act as the substrates and products of 
the metabolic reactions encompass a wide variety of chemical compounds.  The major 
classes of these include but are not limited to amino acids and amines, mono- and 
polysaccharides, organic acids, hormones, fatty acids and lipids, sterols and vitamins 
(Nelson and Cox, 2005).  These metabolites are present at varying levels in the cell, 
which can fluctuate depending on the extracellular environment, availability and uptake 
of precursor molecules, turn-over rate, and the activity and number of pathways in which 
a specific metabolite is involved (Wagner and Fell, 2001; Jeong et al., 2000; Tweeddale 
et al., 1998).   There is a wide range in intracellular concentration between different 
metabolites – for example, in yeast cells, total glutathione has been reported to be present 
at 1883 ± 318 µM whereas homocysteine is present at less than 4 µM (Lafaye et al., 
2005).  
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1.8.2 Relevant Metabolic Pathways in Cancer Cells 
Metabolomics has been used to investigate a number of metabolic pathways in the cell, 
but my studies have been confined to the metabolism of glucose and glutamine in tumor 
cells.  Glycolysis, the pathway of glucose catabolism, has been well established.  The end 
product of glycolysis, pyruvate, can feed into the TCA cycle via the PDH complex or, 
less frequently, through PC, and produce reducing equivalents necessary for oxidative 
phosphorylation and produce ATP.  Otto Warburg noted that despite the presence of 
sufficient oxygen for oxidative phosphorylation, tumor cells displayed upregulated 
glycolysis and preferentially converted pyruvate to lactate rather than acetyl CoA 
(Warburg et al., 1924; Warburg, 1956).  By this strategy, tumor cells derive the bulk of 
their energy via glycolytic substrate level phosphorylation rather than oxidative 
phosphorylation.  As a result of this observation, glycolysis in cancer cells has been 
heavily investigated as a therapeutic target (for a review see Dang et al., 2011).   
More recently, the reliance of many tumor cell lines on glutamine in addition to glucose 
has been established (Reitzer, 1979 and Meng, 2010).  “Glutaminolysis” involves 
catabolism of glutamine via conversion to glutamate and α-ketoglutarate, at which point 
it enters the TCA cycle and is further metabolized.  There are multiple theories on why 
glutaminolysis is so important in tumor cells.  It is well known that glutamine is an 
important nitrogen source, and that its metabolism can produce energy via substrate level 
phosphorylation in the TCA cycle and for replenishing the TCA cycle intermediates via 
anaplerotic reactions (Dang, 2010 and Meng, 2010).  One study suggests that the driving 
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force behind glutaminolysis is the generation of NADPH for lipid and nucleotide 
biosynthesis (DeBerardinis, 2007).  The c-Myc oncogene has been shown to positively 
regulate glutaminolysis by upregulating genes required for glutamine uptake and 
metabolism (Wise et al., 2008).  This indicates that cell lines that display c-Myc 
amplification are more likely to show this dependence on glutaminolysis for proliferation 
and survival.   Additionally, activation of the β-catenin pathway in hepatocarcinoma cells 
has been shown to upregulate the transcription and expression of the GLT-1 glutamate 
transporter as well as glutamine synthetase, which catalyzes the reaction of glutamate and 
ammonia to produce glutamine (Cadoret et al., 2002).  Activation of this pathway can 
free the cell from dependence on extracellular glutamine, but still provide itself with 
sufficient glutamine to meet its metabolic needs.   
1.8.3 Techniques of Metabolomic Extraction and Analysis 
Because of the diversity of chemical structures in metabolites, it can be challenging to 
develop extraction protocols and instrumental techniques that allow for identification and 
accurate quantitation of all the classes of metabolites in a given metabolome.  The 
extraction solvent must solubilize the vast majority of metabolites while precipitating 
proteins that can interfere with downstream analytical techniques, and the procedure will 
vary depending on the tissue, cell type or fluid that contains the metabolites of interest 
(Sellick et al., 2011; Fiehn 2002; Allen et al., 2003).  In order to prevent decomposition 
of thermally unstable metabolites, it is preferable to use ice-cold extraction solvents such 
as 80% methanol that solubilize a broad range of small, polar molecules (Olzewski et al., 
38 
2010; Lu et al., 2008).  If studying a particular class of molecules, it is advantageous to 
optimize the extraction solvent to produce the greatest yield of the metabolites of interest.  
Extractions should be performed quickly and at low temperatures in order to maintain the 
integrity of the metabolome.  
Currently, the most commonly used analytical techniques for metabolomics are NMR 
spectroscopy and mass spectrometry (MS) coupled with gas or liquid chromatography 
(Zhang et al., 2012).  Both have advantages and disadvantages and are complementary to 
one another.  With NMR, a number of different experiments can be performed that 
provide chemical shift information about metabolites.  This is helpful in identification of 
both known molecules, as multiple databases with chemical shift information of cellular 
metabolites are available (Cui et al., 2008; Lundberg et al., 2005; Wishart et al., 2009), as 
well as unknown molecules for which knowledge about the type of proton or carbon that 
gives rise to a characteristic signal can be critical in determining a metabolite‟s identity.  
The simplest NMR experiment, yielding a 
1
H spectrum in one dimension, can be 
acquired in a relatively short period of time and can be accurately quantified with respect 
to an internal standard.  However, the 
1
H chemical shift range is small and most samples 
show significant spectral overlap between peaks (Ludwig and Viant, 2010).  This makes 
accurate quantitation much more difficult.  It is possible to spread the signals out by 
performing experiments in two or more dimensions; however, these experiments take an 
impractically long time to run and currently cannot be absolutely quantified in a 
straightforward manner (Ludwig and Viant, 2010).  The sensitivity of NMR is lower than 
that of other techniques such as MS by a factor of 100 to 1000 (Baxan et al., 2008), 
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therefore NMR metabolomics experiments require larger numbers of cells and reagents, 
which can be expensive.  However a sample is not destroyed during the course of an 
NMR experiment, which under some circumstances can be a relevant experimental 
consideration. 
MS is a much more sensitive instrumental technique than NMR spectrometry 
(Smedsgaard, 2009).  When coupled with liquid or gas chromatography to separate 
metabolites based on polarity, exact mass information for a very broad range of 
metabolites present at very low concentrations can be obtained.  After careful 
optimization of liquid chromatography column, choice of mobile phase and gradient, data 
with excellent separation can be obtained in less than 40 minutes (Bajad et al., 2006).  
However, it is critical to optimize these parameters based on the metabolites of interest 
since the structure of the metabolites will cause them to behave drastically differently 
depending on the type of column and polarity of the mobile phase.  The data obtained 
from an LC-MS experiment consists of two parts: the retention time of the metabolite on 
the column, and exact mass of the metabolite.  While the retention time will change 
depending on the type of column used and the composition of the mobile phase, the mass 
peaks (provided the same ionization source is used) will not change.  This is used to 
putatively identify the metabolite, which is then verified by comparing the experimental 
retention time and mass of a standard to that of the unknown metabolite.  In the case of 
isomers, which have the same mass, tandem MS (MS/MS) can be helpful in metabolite 
identification, as each isomer may give rise to unique fragmentation patterns 
(Smedsgaard, 2009).   
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To quantitate metabolites as accurately as possible using MS methods, it is necessary to 
use an internal standard of the metabolite of interest.  When available, this standard 
should be isotopically labeled to easily distinguish between the standard (with an 
increased exact mass due to the isotope(s)) and the metabolite present in the sample 
(Olszewski et al., 2010).  This ensures that the standard and the metabolite of interest 
pass through the column and are ionized as similarly as possible, yielding the most 
accurate quantitation.  Since different compounds will ionize with differing efficiencies, 
whenever possible and practical this method should be applied if absolute concentrations 
are required.    
1.8.4 Isotopic Labeling Analysis 
In some cases, it is desirable to determine the metabolic fates of a particular small 
molecule.  Isotopic labeling followed by metabolomic analysis makes this possible.  
Molecules labeled with tracers like 
2
H, 
13
C and 
15
N can be introduced into a biological 
system, and their metabolic products will be easily identifiable as they will incorporate 
the tracer(s) (Henderson et al., 1967).  These tracer studies can be performed in real-time 
or analyzed post-metabolite extraction following a tracer incubation period (DeBeradinis 
et al., 2007; Doughty et al., 2006).  Isotopic labeling is ideal because it is non-invasive to 
the cell or tissue yet yields critical information about the pathways by which a particular 
molecule is metabolized, and a significant number of isotopically labeled biomolecules 
are commercially available.  Isotopic information can also be used to calculate fluxes 
through different pathways (Yoo et al., 2008; Teixeira et al., 2008).  Both NMR and MS 
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methods can be used for isotopic tracer analysis (Doughty et al., 2006; Neese et al., 
2001).  If using LC-MS, it is possible to differentiate between isotopologues (compounds 
that differ only in the composition and number of isotopes) as there will be a distribution 
of mass peaks with a difference of 1 amu corresponding to the different masses of 
isotopologues.  However, isotopomers (compounds that differ in the structural location of 
a set number of isotopes) will have an identical increase in mass compared to the natural 
abundance metabolite but actually have the isotopes located at different structural 
positions.  To differentiate between isotopomers using MS, tandem MS must be 
employed in the hope that the fragmentation patterns will elucidate which isotopomers 
contribute to a single mass peak (Choi and Antoniewicz, 2011).  Unfortunately this is not 
always the case, and many times with MS it is difficult to determine the exact location of 
isotopic enrichment. 
In contrast, NMR can provide structural information about the specific site of isotopic 
enrichment in a given metabolite.  For example, to analyze an experiment tracing the 
metabolism of a 
13
C labeled compound, one could compare control and isotopically 
labeled samples by looking at a 
13
C 1D spectrum.  The 
13
C enrichment at a particular 
position in a metabolite will be very clear, as the natural abundance of 
13
C is only 1.07%.  
Therefore, when a particular metabolite is labeled with 
13
C, the signals of the labeled 
carbons can increase by nearly 100-fold.  Commonly, investigators use uniformly labeled 
tracers in order to identify the broadest scope of labeled downstream metabolites.  
However, sometimes to answer a specific biological question, it is more practical to use 
non-uniformly labeled tracers.  For example, DeBerardinis and colleagues used [1,6-
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13
C2]glucose to compare the flux of glucose-derived [3-
13
C] pyruvate into the TCA cycle 
via either PDH or PC (DeBerardinis et al., 2007).  They examined the steady state ratio of 
[4-
13
C1]glutamate (arising from the flux of [3-
13
C]pyruvate through the PDH complex) to 
[2-
13
C]glutamate, which arises from the entry of [3-
13
C] pyruvate into the TCA cycle via 
PC using 1-D 
13
C NMR spectroscopy.  This experimental design simplifies the spectrum 
by minimizing the splitting of signals due to J coupling from adjacent 
13
C neighbors, as 
well as decreasing the number of overall resonances labeled by the tracer molecule. 
13
C 1-D NMR spectroscopy is a straightforward method of isotopic analysis, but its use is 
limited by long acquisition times and poor sensitivity as compared to a 
1
H experiment.   
A 1D-gHSQC experiment, which detects the magnitude of the 
13
C signal but in the 
proton dimension, increases the sensitivity and speed of the experiment, which is 
advantageous given the low concentrations of most metabolites in a cell lysate.  While 
the 1D-gHSQC experiment is useful, this type of experiment does not readily distinguish 
between 2 or more isotopologues that may have 
13
C labels at the same position, which 
contributes to a single signal.  These issues can partially be resolved using a battery of 
more sophisticated 2-D editing experiments and J coupling analysis.  Fan and Lane have 
developed an elegant but labor-intensive method to quantify isotopologues using a 
combination of these methods including TOCSY cross-peak pattern analysis, 2D-gHSQC 
experiments to determine 
1
H-
13
C connectivities and 
13
C-
13
C couplings, HACACO 
experiments to directly detect 
13
C labeled carbonyls and 
1
H-
1
H HCCH-TOCSY 
experiments to reveal the number of adjacent 
13
C atoms in a given isotopomer (Fan and 
Lane, 2011).   However, this method requires rigorous data analysis. The experiments 
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take a significantly long time to run, and the data that can be obtained are still limited by 
the relatively poor sensitivity of NMR.  It is for these reasons that a combination of NMR 
and MS methods is currently the most efficient comprehensive strategy to interpret data 
obtained from isotopic tracers. 
1.8.5 Metabolite Identification from Complex Mixtures 
The development of several metabolite databases has played a significant role in the 
increasingly widespread application of metabolomics to basic research.  Major databases 
include the Madison-Qingdao Metabolomics Consortium Database (Cui et al., 2008), the 
NMR Metabolomics Database of Linkoping, Sweden (Lundberg et al., 2005) and the 
Human Metabolome Database (Wishart et al., 2009).  These databases are freely 
accessible and provide experimental and theoretical NMR chemical shift information 
and/or MS mass information on over 7900 metabolites (Wishart et al., 2009).  Depending 
on the database, users can search by metabolite name, NMR chemical shifts or by mass.  
It is infrequent that the user-entered information will exactly match that stored in the 
database – many 1H chemical shifts are pH dependent, and the numerical values can vary 
slightly depending on the reference standard used, while the exact mass of a metabolite 
can vary slightly between mass spectrometers depending on how they have been 
calibrated.  These databases correct for this by allowing the user to enter a tolerance, or 
range, for the chemical shift or molecular weight information they input.  By carefully 
tuning this tolerance, the user can obtain a reasonable number of candidate metabolites 
that could potentially give rise to a specific chemical shift or mass peak.  This pool of 
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candidates can be narrowed by comparing other chemical shifts arising from the same 
metabolite (obtained by NMR TOCSY or HSQC-TOCSY experiments), or analyzing 
fragmentation patterns from tandem MS experiments to determine whether a potential 
parent molecule would likely give rise to such fragments.  To unequivocally determine a 
metabolite‟s identify, a sample must be doped with a pure standard of the candidate 
metabolite.  If the identification is correct, a significant increase in peak intensity in either 
the mass spectrum or NMR spectrum should be observed. 
1.8.6 Applications of Metabolomics 
Metabolomics is a relatively young field, but it has already been applied to a broad range 
of disciplines.  In particular, the environmental community has embraced metabolomics – 
the National Institute of Standards and Technology has investigated the impacts of 
environmental stressors on marine life such as the Atlantic blue crab using NMR-based 
metabolomics at its Hollings Marine Laboratory (Schock et al., 2010).  Metabolomics has 
also been utilized in environmental risk assessment and determination of mechanism of 
chemical toxicity (Van Aggelen, et al., 2010).  A significant portion of the metabolomics 
community is interested in plant based research. The NSF has funded the Arabadopsis 
Metabolomics Consortium, which has been investigating the Arabadopsis metabolome 
and probing for the function and products of unidentified genes using functional 
metabolomics, as well as developing multiple platforms for plant metabolomic analysis 
(Bais et al., 2010).  The pharmaceutical industry has also to a lesser extent recognized the 
value in a metabolomics-based approach to toxicity studies.  Five major pharmaceutical 
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companies formed the Consortium for Metabonomic Toxicology (COMET) in 
conjunction with Imperial College with the aim of building a database of metabolomic 
data from rats that were treated with a variety of toxic compounds. Ideally that data could 
be used to predict whether early drug candidates might result in similar toxicity (Lenz, 
2005).  This is an example of a global metabolomics approach, as opposed to the more 
targeted approach that can be used in specific mechanism of toxicity studies like the 
investigation into the toxicity of PF 376304, a PI3K inhibitor (Robertson et al., 2007).  
This is a limited list, but it is clear that metabolomics techniques are already applicable 
across many scientific fields, and likely will be increasingly utilized as standardized 
platforms with improved accessibility become available. 
1.9 Summary and Aims of Study 
My research has involved two very different subject areas: the first involves the 
differential metabolism of glucose and glutamine in tumor cells, and the second, the 
investigation of the mechanism of cytotoxicity of the phosphatidylinositol analog D-3-
deoxy diC8PI.  For my metabolic studies, previous work by the Seyfried lab at Boston 
College with the VM-M3 macrophage derived tumor cell had indicated that both 
glutamine and glucose were required for cell proliferation.  These researchers were 
particularly interested in glutamine metabolism. I decided to use 
13
C labeled glucose or 
glutamine in order to get a better overall perspective on how those two fuels contribute to 
the metabolism of the VM-M3 cells.  I examined both intracellular extracts for 
incubations with both [
13
C5]glutamine and [
13
C6]glucose, but tissue culture media only 
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for the [
13
C5]glutamine samples, as the signal from the high concentration of labeled 
glucose overwhelmed those from all the other metabolites.  I found a number of 
interesting trends that are outlined in Chapter 3, and that bear further investigation.  Both 
glutaminolysis and glycolysis are active, but glycolysis is the predominant source of 
lactic acid production.  Both glucose and glutamine are precursors for glutamate which is 
then incorporated into glutathione, which may be particularly important because of the 
VM-M3 cell line‟s macrophage characteristics.  High concentrations of both citrate and 
glutamate are secreted into the tissue culture media, which may be linked to an 
excitotoxic and NMDA receptor modulating mechanism of glioma cell invasion.  These 
results are intriguing, but my results are merely a starting point for further experiments 
due to the limitations of NMR-based metabolomics and 
13
C labeling.  Ideally, a 
complementary set of LC-MS experiments will be completed in order to gain critical 
information about the mixtures of isotopologues present and allow for accurate 
quantitation of metabolite concentrations. 
In the process of my metabolic studies, I discovered an unusual compound previously 
reported to be only a fungal metabolite.  The VM-M3 cells synthesize this metabolite, 
itaconic acid, from both glucose and glutamine, and biosynthesis and cell-type specificity 
is discussed in Chapter 4.  Collaboration with the Rabinowitz group at Princeton 
University provided information on the distribution of isotopologues of itaconic acid and 
suspected precursor molecules.  This was used to determine that in mammalian cells, 
itaconic acid is synthesized via the site-specific decarboxylation of cis-aconitic acid 
derived from the TCA cycle.  This decarboxylation requires a novel mammalian enzyme, 
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cis-aconitic decarboxylase (cADC), for which I developed an activity assay.  With 
assistance from the Chiles lab, I was able to determine that itaconic acid production is not 
a characteristic of all mammalian cells, but specifically macrophages. 
My final project was an extension of work done by the Roberts and Chiles labs to 
characterize a series of deoxy-modified phosphatidylinositols using biophysical and 
biological methods.  These compounds, synthesized by the Miller laboratory (previously 
at B.C. but now at Yale University), were tested for potential as a PIA and one, D-3-
deoxy diC8PI, was found to be cytotoxic to the U937 tumor cell line (Wang et al., 2009).  
The mechanism of PIA cytotoxicity is generally thought to be by binding to the PH 
domain and inhibiting the translocation of Akt to the plasma membrane (Gills and 
Dennis, 2004; Cheng et al., 2005). However, preliminary immunoblotting data indicated 
that this might not be the case with D-3-deoxy diC8PI.  I decided to delve deeper into the 
mechanism of cytotoxicity, investigating whether or not D-3-deoxy diC8PI could bind to 
the Akt PH domain and better determine which signaling pathways were contributing to 
its cytotoxicity.  Using high-resolution field cycling 
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P NMR spectroscopy, we were able 
to determine that D-3-deoxy diC8PI and an inactive analog, L-3,5-deoxy diC8PI both bind 
to the same site on the PH domain, making the canonical mechanism of cytotoxicity 
unlikely.  These compounds also appear to bind to a different site than a short-chain of 
the natural ligand, diC8PI(3,4,5)P3.  My studies of the PH domain and its interactions 
with lipids and soluble lipid head groups are discussed in Chapter 5.  
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Chapter 6 details my investigation into the effects of D-3-deoxy diC8PI and in parallel, 
perifosine (an alkylphospholipid), on cell signaling in the MCF-7 breast cancer cell line.  
D-3-deoxy diC8PI is cytotoxic to this cell line with an IC50=90 µM, and induces 
apoptosis.  The p38MAPK pathway was found to upregulated in response to D-3-deoxy 
diC8PI, resulting in hyperphosphorylation of the transcription factor CREB.  Inhibition of 
p38MAPK, however, does not prevent apoptosis and therefore activation of this pathway 
is likely to be compensatory and not the cause of cytotoxicity.  Cyclin D1, cyclin D3 and 
to a lesser extent, cyclin E levels are decreased by D-3-deoxy diC8PI treatment, and these 
changes are not related to the activation of the p38MAPK pathway.  The decrease in 
these levels appears to be controlled at the transcriptional level rather than increased 
degradation by the proteasome.  While these studies are incomplete, it does not appear 
that inhibition of Akt translocation to the plasma membrane is responsible for the 
apoptosis induced by D-3-deoxy diC8PI.   
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Chapter 2: 
Materials and Methods  
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2.1 Chemicals and Cell Culture Reagents 
Itaconic acid, cis-aconitic acid, L-glutamine, D-glucose, lysozyme, Tris base, kanamycin 
sulfate, chloramphenicol, ampicillin, HEPES, inositol hexakisphosphate (IP6), leupeptin, 
aprotinin, benzamidine, LPS (0111:B4), miltefosine, 0.1% poly L-lysine solution, and 
D2O were obtained from Sigma-Aldrich (St. Louis, MO).  4-(2-
Aminoethyl)benzenesulfonyl fluoride HCL (AEBSF) was purchased from Gold 
Biotechnology (St. Louis, MO).  D-3‟-deoxy diC8PI was a gift from Scott Miller and 
Peter Jordan (Yale University).  DNAse I was purchased from Roche (Indianapolis, IN).  
The GoTaq PCR kit was obtained from Promega (Madison, WI).  (1-Oxyl-2,2,5,5-
tetramethyl-Δ3-pyrroline-3-methyl) methanethiosulfonate (MTSL) spin label reagent was 
obtained from Toronto Research Chemicals, Inc. (Toronto, Canada).  PI(3,4,5)P3 (1,2-
diC8) and PI(3,4,5)P3 (1,2-diC6) were purchased from Cayman Chemical (Ann Arbor, 
Michigan).  Inositol (1,3,4,5)-tetrakisphosphate was purchased from Echelon (Salt Lake 
City, UT). L-glutamine ([
13
C5]), [
13
C1]sodium formate and D-glucose ([
13
C6]) were 
obtained from Cambridge Isotope Laboratories (Cambridge, MA).  
The detergent compatible (DC) BCA Protein Assay, molecular weight markers, agarose 
and 30% acrylamide/bisacrylamide solution were obtained from Bio-Rad (Hercules, CA).  
The FITC-BRDU flow cytometry assay kit was purchased from BD Pharmingen (San 
Diego, CA).  Ni-NTA Resin, Qproteome Mitochondria Isolation kit and DNA extraction 
kits (Miniprep, PCR Purification and Gel Extraction) were obtained from Qiagen 
(Valencia, CA).  LB broth and LB-agar were obtained from Fisher Scientific (San Jose, 
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CA). Restriction enzymes and Taq polymerase were supplied by New England Biolabs 
(Ipswich, MA). BL-21 Star (DE3) competent cells were a gift from the Kantrowitz lab 
(Boston College, Chestnut Hill, MA).  Novablue Gigasingles competent cells and the 
pET 28a vector were purchased from EMD Biosciences (Gibbstown, NJ). Q-sepharose 
fast flow resin was purchased from GE Healthcare (Piscataway, NJ). 
The RAW 246.7, MCF-7 and U937 cell lines were purchased from the ATCC (Manasses, 
VA).  The VM-M3 cell line was a generous gift from Dr. Thomas Seyfried (Boston 
College, Chestnut Hill, MA).The media DMEM, MEM (without L-glutamine, with or 
without phenol red) and RPMI were purchased from Mediatech (Manasses, VA).  Base 
DMEM without glucose or glutamine was purchased from Sigma-Aldrich (St. Louis, 
MO). Murine recombinant interferon-γ was purchased from Pierce (Rockford, IL).  Heat 
inactivated, characterized bovine fetal calf serum (FCS) was purchased from Hyclone 
(Rockford, IL).  Bovine insulin was obtained from Gemini Bio-products (West 
Sacramento, CA).  Mycozap CL and Nucleofector Solution V were purchased from 
Lonza (Basel, Switzerland).    Perifosine was purchased from Selleck (Houston, TX). All 
primary antibodies were acquired from Cell Signaling (Danvers, MA) except for Cyclin 
D1 (Fisher Scientific, San Jose, CA).  Secondary goat anti-mouse and anti-rabbit 
antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).  ECL 
reagents were purchased from KPL (Gaithersburg, MD). 
Ontarget plus SMARTpool CREB1 siRNA, SMARTpool cyclin D1 siRNA, SMARTpool 
cyclin E siRNA, siGENOME cyclin D3 siRNA (GAUCGAAGCUGCACUCAGG) and 
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siGENOME Control siRNA #3 were purchased from Dharmacon (San Jose, CA).  
SB203580 was obtained from EMD Biosciences (Gibbstown, NJ).  Lipofectamine 
RNAimax was acquired from Invitrogen (Carlsbad, CA).  Human Heregulin β-1 was 
obtained from Biovision (Mountain View, CA).  CD11b
+ 
 microbeads were purchased 
from Miltenyi Biotec (Auburn, CA).  Alamar Blue solution was purchased from AbD 
Serotec (Raleigh, NC).  Propidium iodide was purchased from Sigma-Aldrich (St. Louis, 
MO).   
2.2 Molecular Biology 
2.2.1 Cloning of Akt1 PH domain into pET28a vector 
Human Akt1 cDNA was obtained from Origene.  PCR primers were designed to 
introduce restriction sites into the beginning (NdeI) and end, including a stop codon 
(SalI-HF) of the PCR product.  The forward primer was 5‟ 
AGCCTCGGCCCATATGAGCGACGT 3‟ and the reverse primer was 5‟ 
CAGGGACACCTGTCGACCTCAAGCCCCTGA 3‟.  This results in a PCR product that 
codes for residues 1-131 (the PH domain) of Akt1.  The PCR reaction was performed as 
described in 2.2.3.  The PCR product and the pET28a vector (Novagen) were doubly 
digested with SalI-HF and NdeI-HF (New England Biolabs) at 37°C for 1 h.  Ligation of 
the PCR product into the pET28a vector resulted in a gene that codes for the Akt1 PH 
domain with an N-terminal HIS-tag that aids in purification of the recombinant protein. 
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2.2.2 Cloning of Mouse Akt1 into AcGFP Vector 
Wild type mouse Akt1 cDNA was obtained from Upstate (Lake Placid, NY).   Primers 
for PCR amplification were 5‟ GAGCTGCTAGCCATGAACGACGTAGCCATTGTG 
3‟ (forward, to insert an NheI restriction site immediately 5‟ to the gene start codon) and 
5‟ ATTTACCCGGGAGGCTGTGCCACTGGCTGA 3‟ (reverse, to insert a XmaI 
restriction site 3‟ to the gene).  The resulting PCR product codes for full-length Akt1.  
The PCR product and vector were doubly digested with 10 units XmaI and NheI-HF in 
NEB Buffer 4 with 100 µg/mL BSA. The digested PCR product was ligated into the 
multiple coding site of the pAcGFP1-N1 vector (Clontech) to create a construct gene that, 
when expressed in mammalian cells, codes for full length Akt1 (480 amino acid residues) 
with a C-terminal eGFP tag. 
2.2.3 Polymerase Chain Reaction 
PCR was used to introduce new restriction sites and amplify gene sequences for cloning.  
Standard PCR techniques were employed.  Primers to flank both ends of the target gene 
and introduce new restriction sites (when necessary) were designed to be between 20 and 
30 nucleotides, and ordered from Integrated DNA Technologies.  The PCR reaction was 
performed in a 50 μL volume as directed using the Promega GoTaq Core System.  Each 
reaction contained 1X Green GoTaq Flexi Buffer, 200 μM nucleotide mix, 1.25 units 
GoTaq polymerase, 2 mM MgCl2, 1.4 μM upstream and downstream primers, and 0.1 μg 
template DNA.  The thermocycler was initially held at 94°C for 5 minutes, followed by 
30 cycles of denaturation (94°C for 30 seconds), annealing (55°C for 45 seconds), and 
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elongation (74°C for 1 min).  The sample was then held at 72°C for 7 minutes, followed 
by termination at 4°C.  During this program, the double stranded template DNA is 
denatured into single strands.  During annealing, the primers bind to their target 
sequences, and during the elongation period the Taq polymerase adds nucleotides to the 
3‟ end of each primer to synthesize the desired PCR product.  The PCR product was 
purified using the Qiagen PCR Purification Kit, in which nucleic acids bind to the 
Qiaquick spin column silica membrane.  The pure nucleotides were subsequently washed 
and eluted in 30 μl ultrapure water. 
2.2.4 Digests and Ligation 
1 µg DNA was subjected to double digestion by 10 units of the desired restriction 
enzymes (New England Biolabs) in a total volume of 50 µL appropriate 1X NEBuffer.  
When required for enzyme activity, 100 µg/mL BSA was included in the reaction 
mixture.  The digests were incubated for 1-3 h at 37°C, except for that with XmaI which 
required an extended overnight digestion.  Restriction enzymes were heat inactivated at 
65°C or 80°C as directed, and the digested DNA was purified using the Qiagen PCR 
purification kit (Akt1-eGFP) or run on a 1% agarose gel and extracted using the Qiagen 
Gel Extraction kit (HIS-PH).  Ligations were carried out in a 20 µL volume by 800 units 
T4 DNA ligase in T4 ligase buffer.  Molar ratios of 1:3 to 1:5 vector:insert were tested, 
holding the total DNA concentration constant at 5 ng/µL.  Successful ligations were 
achieved using two methods.  The first, utilized in the cloning of the Akt1-eGFP 
construct, involved placing the reaction tube in a beaker containing room temperature 
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water, enclosing the beaker in a Styrofoam cooler, and placing the entire cooler at 4°C 
overnight.  This allowed the T4 ligase to be subjected to a range of temperatures in which 
it might be active rather than simply holding the reaction at 16°C, the temperature at 
which T4 ligase is reported to show the highest activity.  The second ligation was 
performed in a thermocycler programmed to hold the sample at 16°C for 5 min, and then 
perform 99 cycles of 45 s at 10°C, 16°C, and 20°C, followed by 7 min at 16°C.  This 
technique also varies the reaction temperature in order to maximize T4 ligase activity.  
The ligations were heat inactivated at 65°C for 20 min.  5 μL of the ligation was used to 
transform competent cells, which were plated on medium with selective antibiotics.  
Resulting colonies were grown as minicultures, and purified DNA was sequenced in 
order to determine whether or not the cloning was successful. 
2.2.5 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was used to visualize DNA including PCR products, vectors, 
and ligation products.  A 1% w/v solution of agarose in TAE buffer was heated in order 
to dissolve the agarose.  After brief cooling, ethidium bromide was added to bind the 
DNA as it moved through the gel, causing it to fluoresce under UV light.  The liquid gel 
was poured into a horizontal mold and allowed to harden.  Samples (around 20 to 40 ng 
DNA) were loaded and run in 1X TAE buffer with 1 mg/mL ethidium bromide at 80V.  
DNA bands were visualized using a UV light box. 
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2.2.6  Transformation 
Competent cells (Novablue Gigasingles,  BL-21 STAR) were transformed according to 
manufacturer‟s directions.  A tube of cells was thawed on ice, and 1 μL plasmid DNA or 
5 μL ligation mixture was added and mixed by gentle flicking.  The cells were incubated 
on ice, heat shocked for exactly 30 s in a 42°C water bath and returned to the ice for 
another 2 min.  250 μL room temperature SOC medium (provided with the kit) was 
added, and cells were allowed a 1 h outgrowth at 37°C rotating at 200 rpm.  50-200 μL 
cells were plated on agar plates with appropriate antibiotics, and plates were incubated at 
37°C overnight for no longer than 16 h. 
2.2.7 DNA Isolation and Purification 
A 6 mL miniculture grown overnight was used to prepare plasmid DNA.  The Qiagen 
Miniprep kit was used to lyse cells, and the cleared lysate was applied to the Qiaprep 
module that selectively binds plasmid DNA.  The Qiaprep module was then washed as 
per manufacturer‟s instructions, and plasmid DNA was eluted in 30 μL ultrapure water.  
The concentration of DNA was determined using its absorbance at 260 nm, where an 
absorbance of 1 OD260=50 ng/μL. 
2.2.8 Bacterial Plates and Media 
All bacteria were grown in LB Media, which was made by suspending 25 g of LB media 
mix (containing 10 g Tryptone, 5 g yeast extract, 10 g NaCl) in 1 L of ultra pure water 
and autoclaving.  LB agar plates were prepared by autoclaving 40 g LB-agar suspended 
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in 1 L ultrapure water, and then supplementing the mixture with appropriate antibiotics 
(100 μg/mL ampicillin, 30 μg/mL kanamycin and/or 34 μg/mL chloramphenicol).  The 
agar solution was poured in sterile plates and allowed to set at 37°C for 2 h before storage 
at 4°C. 
2.3  Overexpression and Purification of Proteins and Protein Biochemistry 
2.3.1  Akt1 HIS6-PH Domain 
A single colony from the BL-21 STAR cells transformed with the PH-HIS plasmid was 
grown overnight in 6 mL LB media supplemented with 30 μg/mL kanamycin.  The 
following morning, the miniculture was evenly distributed between 4 x 1 L flasks of 
autoclaved LB media supplemented with 30 μg/mL kanamycin; cultures were grown at 
37°C, with shaking at 250 rpm, to O.D.600 = 0.6-0.8.  The PH domain overexpression was 
then induced with the addition of 0.1 mM IPTG and incubation at 24°C for 4 h.  Cells 
were collected by centrifugation for 10 min at 5,000 rpm; the pellet was stored at -20°C 
until needed. 
Cells were thawed and resuspended in 42 mL of ice cold lysis buffer (1X PBS, 1% Triton 
X-100, 10 μg/mL leupeptin, 0.2 mM AEBSF, 1 μM aprotinin).  A fresh 10 mg/mL 
lysozyme stock was added to the cell suspensions for a final working concentration of 1 
mg/mL lysozyme. The mixture was incubated with shaking for 30 min at room 
temperature.  DNAseI and MgCl2 were added to final working concentrations of 40 
units/mL and 10 mM, respectively, and the mixture incubated for 15 min with shaking at 
room temperature.  The lysates were centrifuged at 14,000 rpm at 4°C for 20 min, and the 
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solution further clarified by passing it through a syringe fitted with a 0.45 μm filter.  A 
3M  imidazole stock solution was added to a final concentration of 20 mM. 
A 7 mL slurry of Ni-NTA was washed three times with 20 mM imidazole in PBS.  The 
washed resin was added to the cleared lysate and incubated for 20 minutes at 4°C with 
gentle shaking.  The resin-lysate slurry was then decanted into a narrow column, and 
packed at a 1.5 mL/min flow rate.  The column was then washed with 50 mM imidazole 
in PBS at 1.5 mL/min for 1 h to remove contaminating protein.  The PH domain was then 
eluted with 100 mM imidazole in PBS at a flow rate of 1 mL/min.  The fractions 
containing protein were then dialyzed against 25 mM HEPES, pH 7.4, containing 75 mM 
NaCl and 1 mM EDTA, for 3 h at room temperature, followed by another dialysis into 25 
mM HEPES, pH 7.4, with 20 mM NaCl and 1 mM EDTA, at 4°C overnight.  Purity of 
collected fractions was analyzed by SDS-PAGE.  
The next morning, 15 mL of QFF slurry was packed in a wide column at a flow rate of 
2.5 mL/min and washed with 25 mM HEPES, pH 7.4, 1 mM EDTA.  The dialyzed 
protein preparations were applied to the column at 1.5 mL/min, and the column was 
washed with 25 mM HEPES, pH 7.4, 1 mM EDTA.  The PH domain was eluted using a 
salt gradient supplied by a gradient mixer with 25 mM HEPES, pH 7.4, 1mM EDTA as 
Buffer “A” and 25 mM HEPES, pH 7.4, 600 mM NaCl, 1 mM EDTA as Buffer “B”.  
The PH domain eluted approximately 20 minutes after gradient initiation using a flow 
rate of 1.5 mL/min.  Collected fractions were concentrated at 5000 rpm at 4°C using a 15 
mL 10 kDa cutoff centrifugal concentrator, and buffer exchanged into 25 mM HEPES, 
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125 mM NaCl, 1 mM EDTA, pH 7.4.  Purity was assessed by SDS-PAGE; anything 
greater than 80% pure was deemed acceptable for further experiments. 
  
Figure 2.1 SDS-PAGE of Akt1 HIS-PH fusion protein after purification by Ni-NTA and QFF columns.  
Lane 1: molecular weight markers.  Lane 2: Purified HIS-PH. 
 
2.3.2 Akt1 PH-GST 
The plasmid for the GST-tagged Akt PH domain was obtained from Boguslaw Stec 
(Sanford-Burnham Medical Research Institute, La Jolla, California).  The plasmid was 
transformed into BL-21 CodonPlus (DE3-RIL) competent cells and plated on LB-agar 
plates containing 34 μg/mL chloramphenicol and 100 μg/mL ampicillin.  Colonies were 
selected and grown in 6-mL minicultures overnight.  The miniculture was split evenly 
between 2 x 2 L flasks of autoclaved LB media with 34 μg/mL chloramphenicol and 100 
μg/mL ampicillin and incubated until the solution reached O.D.600 = 0.6-0.8.  Protein 
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overexpression was induced with the addition of 1 mM IPTG followed by incubation at 
16°C for 16 h.  Cells were collected by centrifugation at 5,000 rpm for 10 min. The cell 
pellet was stored at -20°C until needed for protein purification.   
Cells were thawed and resuspended in 60 mL of ice cold lysis buffer (1X PBS, 10 μg/mL 
leupeptin, 0.2 mM AEBSF, 1 μM aprotinin).  The cell suspension was mixed with 180 
mg lysozyme and 2400 units DNAseI, and gently rocked for 25 min at 4°C.  The lysates 
were then subjected to three freeze thaw cycles. The debris from this treatment was 
removed by centrifugation at 14,000 rpm, 4°C.  The lysate was then further clarified by 
passage through a 0.45 μm filter.   
A glutathione Sepharose B slurry (3 mL) was washed three times with 10 mL PBS.  The 
cleared lysate was added to the resin, and gently agitated at room temperature for 1 h.  
The resin was washed twice with 10 mL PBS with 0.1% Triton X-100, followed by two 
washes with thrombin cleavage buffer (50 mM Tris, 0.15 M NaCl, 25 mM CaCl2, pH 
8.0). Thrombin cleavage buffer (3 mL) was added to the resin along with 80 units 
thrombin. The slurry was rocked at room temperature for 2 h, then resin was separated 
from the supernatant, which contained cleaved PH domain. The protein solution was 
stored overnight at 4°C. 
Further purification used a QFF column. 10 mL of QFF resin was packed in a 1” 
diameter column and equilibrated with thrombin cleavage buffer.  The sample was 
applied, and the column was washed with 3 bed heights of thrombin cleavage buffer.  A 
linear salt gradient,  formed using a gradient mixer and 50 mM Tris, 1 mM EDTA, pH 8 
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(Buffer “A”) and 50 mM Tris, 600 mM NaCl, 1 mM EDTA, pH 8 (Buffer “B”).  The pH 
domain eluted after approximately 160 min using a flow rate of 1.5 mL/min.  Fractions 
containing the PH domain we concentrated using a centrifugal protein concentrator and 
buffer exchanged three times into fluorescence binding buffer. 
2.3.3 SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used for 
western blots and to analyze protein purity.  Acrylamide and bis-acrylamide were 
polymerized using ammonium persulfate and N,N,N‟,N‟-tetramethylethylenediamide 
(TEMED) to form the gel.  A 5% stacking gel (5% acrylamide) was used to ensure that 
all the loaded protein simultaneously entered the separating gel (9 or 12% acrylamide). 
Protein, 20 to 40 μg protein per well, was loaded into wells.   For western blots of whole 
cell lysates, samples in loading buffer were boiled for 5 minutes prior to loading.  Gels 
were run at 70V until samples passed through the stacking gel, then the voltage increased 
to 100V (9% acrylamide) or 150V (12% acrylamide).  Gels to analyze protein purity 
were briefly stained with Coomassie Blue (0.0125%) and then destained overnight with 
acetic acid (10%).   
2.3.4 Protein Concentration Determination 
The concentrations of protein samples (purified PH domain, cell lysates, etc.) were 
determined using the Detergent Compatible Protein Assay (Bio-Rad) with bovine γ-
globulin as the protein standard.  This is a modified Lowry protein assay, which is 
colorimetric and solubilizes detergents so that they do not interfere with the measurement 
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of protein concentration.  The reaction involves two steps:  the protein first reacts with an 
alkaline copper tartrate solution, and then Folin reagent is added and reduced by the 
copper treated protein.  This reduction is primarily dependent on the tyrosine and 
tryptophan residues in the protein.  The reduced Folin reagent is blue, and its absorbance 
at 750 nm (measured in a Beckman DU640 spectrophotometer) is proportional to the 
concentration of protein as determined from the bovine γ-globulin standard curve. 
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Figure 2.2 Representative standard curve of bovine gamma globulin concentrations used for detergent 
compatible protein assays. 
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2.3.5 Spin Labeling of the Akt1 PH Domain  
This PH domain has two cysteine residues that can be modified to introduce probes. In 
this case we added a nitroxide spin-label to the protein. For each sample, 0.24 mg His-PH 
domain in 20 mM Hepes, 125 mM NaCl, pH 7.4, was reduced by adding a 10-fold molar 
excess of DTT in 2 increments, followed by a 45 min incubation at room temperature.  
Buffer was then added to increase the volume to ~ 50 μL.  The sample was applied to a 
spin columns equilibrated with 20 mM Hepes, 125 mM NaCl, pH 7.4, to remove excess 
DTT.  An aliquot of a 20 mg/mL stock solution of MTSL in acetone was then diluted in 
50 μL 20 mM Hepes, 125 mM NaCl, pH 7.4 and added to the reduced protein solution to 
produce a 10-fold molar excess of MSTL with respect to cysteine residues.  The solution 
was mixed by gentle flicking intermittently for ~ 3 h.  Excess spin label was removed by 
an additional passage through a spin column.  The final protein concentration was 
checked by A280 of a 1:100 dilution of the protein solution.   
For preparation of the final sample, the spin-labeled PH domain was diluted into a 400 
μL volume containing 20 mM Hepes, 125 mM NaCl, 1 mM EDTA, pH 7.4, with 30% 
D2O and various concentrations of potential ligands. The sample was sealed in a home-
made Shigemi tube (a 3.5” long 5 mm diameter NMR tube with an epoxy plug in the 
bottom) and kept at 4
o
C until placed in the NMR spectrometer.   
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2.4  Cell Culture 
2.4.1  Mammalian Cell Culture 
The MCF-7 human breast cancer cell line (ATCC), U937 human lymphoma line 
(ATCC), RAW 264.7 murine macrophage line (ATCC), and VM-M3 murine macrophage 
line (Boston College) were incubated at 37°C in a 5% CO2 atmosphere at 95% humidity.  
Cells were maintained below 90% confluence, and media was changed 2-3 times per 
week.  Cells were sub-cultured at a ratio of 1:4.  Adherent cells were passaged either by 
scraping with a cell scraper (VM-M3 and RAW 264.7) or using 0.25% trypsin-EDTA 
(MCF-7).  U937 cells were cultured in RPMI 1640 supplemented with 2 mM glutamine , 
10% heat inactivated fetal bovine serum (FBS), 100 U/mL penicillin and 100 μg/mL 
streptomycin .  MCF-7 cells were cultured in Eagle‟s MEM supplemented with 10% 
FBS, 2 mM glutamine, 0.01 mg/mL bovine insulin and 1 μl/mL Mycozap CL.  For 
imaging experiments, MCF-7 cells were cultured in serum/insulin free media without 
phenol red.  The VM-M3 and RAW 246.7 cell lines were cultured in DMEM 
supplemented with 25 mM glucose, 4 mM L-glutamine, 10% FCS, and 1 μL/mL 
Mycozap CL. For labeling experiments, cells were grown for 12 h in DMEM without L-
glutamine or glucose, and then supplemented with unlabeled or [
13
C6]glucose or 
[
13
C5]glutamine, respectively (Cambridge Isotope Laboratories, Cambridge MA) and 
Mycozap CL.   
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2.4.2  Isolation and Culture of Murine Peritoneal Macrophages 
BALB/cByj mice were obtained from Jackson laboratories (Bar Harbor, ME) and housed 
in the Boston College Animal Facility.  Cells were obtained by peritoneal washouts as 
described (Zhang et al., 2008) and subjected to positive separation by MACS CD11b+ 
selection (Miltenyi Biotec, Auburn, CA).  Approximately 4 x 10
6
 cells were cultured in 
DMEM supplemented with 10% FCS, 25 mM glucose, 10 mM glutamine and 100 
units/mL penicillin and 100 µg/mL streptomycin. Macrophages were activated by culture 
with 150 U/mL murine recombinant IFNγ for 6 h, followed by incubation with 10 ng/ml 
LPS 0111:B4 for 24 h.  For labeling experiments, macrophages were incubated for 12 h 
in DMEM supplemented with 10 mM glutamine and 25 mM glucose or [
13
C6]glucose . 
2.5  Cytotoxicity Assays 
2.5.1  Basic Alamar Blue Protocol 
About 30,000 cells were plated in each well of a 96-well plate and allowed to adhere 
overnight.  The following day, the medium was replaced with 180 μL of fresh complete 
or serum free medium containing various concentrations of test compounds.  At least 5 
different concentrations of each test compound were tested with 4 replicates for each 
concentration.  The cells were incubated for 20 h prior to adding 20 μL Alamar Blue to 
each well and incubating for an additional 4 h.  The fluorescence of the reduced Alamar 
Blue, which is proportional to the number of living cells, was read by excitation at 560 
nm and emission at 590 nm on a Molecular Devices Spectromax M5 Plate Reader 
66 
(Sunnydale, CA).  Data were normalized to the control fluorescence and plotted as a 
viability curve in KaleidaGraph in order to determine the EG50 of each compound. 
2.5.2 Pretreatment with SB203580 – Alamar Blue Protocol 
When determining if pretreatment with an additional inhibitor affected viability, the same 
basic protocol was followed.  However, the inhibitor was added in fresh serum free media 
for 1 to 6 h prior to the addition of the test compound.  The test compound was always 
added in a 3 μL volume into the 180 μL microplate volume and mixed by pipetting.  
Wells incubated for 1-6 h with the inhibitor vehicle in serum free media were used as 
controls with the test compound to ensure identical conditions.  After the addition of the 
test compound, the cells were incubated for 20 h prior to adding 20 μL Alamar Blue to 
each well and incubating for an additional 4 h before the plates were read. 
2.5.3  Cytotoxicity Assays with siRNA Knockdowns 
MCF-7 cells, 10,000 per well, were reverse transfected with targeted siRNA or control 
non-targeting siRNA and plated in a 96-well plate.  After 48 h, the media was changed 
and if used, the test compound was added in 180 μL serum free media per well.  After 20 
h, 20 μL Alamar Blue was added to each well and the plates were incubated for 4 h 
before reading. 
2.6  Western Blots 
Cells were rinsed with PBS and lysed in ice cold 20 mM Tris, pH 7.4, with 100 mM 
NaCl and 0.1% Triton X-100 complete with protease and phosphatase inhibitors (10 
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μl/mL protease inhibitor cocktail, 10 mM β-glycerophosphate, 1 mM PMSF, 1 mM NaF, 
1 mM Na3VO4, 100 nM okadaic acid, 1 mM DTT) were kept on ice for 10 min, then 
freeze-thawed with dry ice to ensure complete lysis.  Lysates were cleared by 
centrifugation at 16000xg, 4°C.  Proteins in the lysate sample (20 μg) were separated by 
SDS-PAGE.  The gel was then transferred onto a 0.2 μm PVDF membrane at 200 mA for 
75 min.  5% w/v skim milk powder in TBS-T was used to block the membrane, which 
was then washed with TBS-T and incubated overnight at 4°C with 1:1000 diluted 
primary antibody.  The following morning, the membrane was washed repeatedly and 
incubated with anti-rabbit or –mouse HRP-conjugated antibody (1:2500 dilution) for 1 h.  
The blots were developed using chemiluminescence (ECL).   
2.7  Transfections 
2.7.1  Nucleofection –Akt1-GFP 
MCF-7 cells were transferred into complete media free from antibiotics 24 h prior to 
nucleofection.  Cells (1-2 x10
6
) were trypsinized and centrifuged at 640xg for 10 min at 
room temperature.  The cell pellet was suspended in 100 μL Nucleofector Solution V, 
and added to 2 μg Akt-GFP DNA.  The reaction mixture was transferred to a 
Nucleofector cuvette, and transfected on setting E-014.  Cells were gently transferred to 
poly-L-lysine coated 35 mm glass bottomed dishes (~250,000 cells/dish) containing 
complete medium and allowed to adhere overnight. 
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2.7.2 Transfection of siRNA 
For siRNA transfections in a 12-well plate, 12 pmol siRNA (appropriate concentration 
was determined by western blot) was mixed with 190 μL Optimem in each well of the 
plate.  1.9 μL of Lipofectamine RNAiMAX at room temperature was added to each well 
and mixed by pipetting. The complexes were incubated at room temperature for 20 min.  
MCF-7 cells were trypsinized and transferred into media free from antibiotics.  The cells 
were diluted to a density of 100,000 cells/mL, and 95,000 cells were plated in each well.  
After 48 h, the cells were transferred into fresh media containing antibiotics.  Changes in 
protein expression between cells transfected with control RNA and targeting RNA were 
assayed 24-72 h post transfection by western blot.  For transfections in a 96-well plate, 
the same protocol was used, but with 10,000 cells, 1.2 pmol siRNA, 20 μL OptiMem and 
0.2 μL RNAiMAX per well.  siRNA-RNAiMAX complexes were pooled then plated due 
to the low volumes required.  All siRNAs were obtained from DHARMACON and the 
sequences are as follows: 
siGENOME CCND3 siRNA (GAUCGAAGCUGCACUCAGG) 
SMARTpool ON-TARGET plus CCND1 siRNA (ACAACUUCCUGUCCUACUA, 
GUUCGUGGCCUCUAAGAUG, GCAUGUAGUCACUUUAUAA, 
GCGUGUAGCUAUGGAAGUU 
SMARTpool ON-TARGET plus CREB1 siRNA (GAGAGAGGUCCGUCUAAUG, 
UAGUACAGCUGCCCAAUGG, CAACUCCAAUUUACCAAAC, 
GCCCAGCCAUCAGUUAUUC) 
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2.8 Metabolomics Analysis by LC-MS 
2.8.1 Preparation of Cell Extracts 
Confluent flasks of adherent cells were washed with ice cold PBS, and cells were 
immediately harvested with a 7 mm cell scraper into ice cold 80:20 methanol:water or 
70:30 ethanol:water. The lysates were incubated on ice for 10 min, sonicated in an ice 
water bath for 10 min, and then centrifuged at 14,000 rpm at 4°C for 10 min. The pellet 
was extracted two additional times, and the supernatants were pooled.  The supernatant 
was dried under N2 gas and lyophilized overnight. Extracts were stored at -20°. 
2.8.2 Preparation of Tissue Culture Media Extracts for LC-MS and NMR Analysis 
Approximately 1.5 mL of tissue culture supernatant was collected from VM-M3 and 
RAW 264.7 cells labeled with [
13
C6]glucose for 12 h, lyophilized and stored at -20°C. To 
remove excess glucose, which saturated the NMR spectrum, the samples were dissolved 
in water and adjusted to pH 6.5. Weak acids, including itaconic acid (ITA), were then 
extracted using 100 mg sorbent mass Strata-X-A solid phase extraction cartridges 
(Phenomenex, Torrance CA). The columns were conditioned with methanol, equilibrated 
with deionized water, and then loaded with sample. The columns were washed with 25 
mM ammonium acetate, methanol and then the material eluted with 5% formic acid in 
methanol; the eluent was dried under N2 gas and lyophilized. The samples were dissolved 
in 250 µL D2O and adjusted to pH 7.4. For peritoneal macrophages, 1 mL of tissue 
culture supernatant was collected, lyophilized, and stored at -20°C. The samples were 
then dissolved in 200 µL HPLC-grade water and analyzed by LC-MS. 
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For NMR analysis of media samples containing [
13
C5]glutamine, 2 mL of tissue culture 
supernatant was collected from VM-M3 cells labeled with [
13
C5]glutamine for 12 h, 
lyophilized and stored at -20°C.  The samples were dissolved in 500 µL D2O and 
adjusted to pH 7.4;  250 μL was used for NMR experiments.  
2.8.3 LC-MS and Isotopologue Analysis 
The dried cell extracts were re-dissolved in 200 μL HPLC-grade water, and analyzed via 
reverse-phase ion-pairing chromatography coupled to an Exactive orbitrap mass 
spectrometer (ThermoFisher Scientific, San Jose, CA). The mass spectrometer was 
operated in negative ion mode with a scan rate of 1 Hz and resolving power of 100,000, 
scanning range being m/z 85-1000. The LC method, described previously (Lu et al., 
2010), used a Synergy Hydro-RP column (100 mm × 2 mm, 2.5 μm particle size, 
Phenomenex, Torrance CA) with a flow rate of 200 μL/min. The LC gradient was 0 min, 
0% B; 2.5 min, 0% B; 5 min, 20% B; 7.5 min, 20% B; 13 min, 55% B; 15.5 min, 95% B; 
18.5 min, 95% B; 19 min, 0% B; 25 min, 0% B. Solvent A is 97:3 water−methanol with 
10 mM tributylamine and 15 mM acetic acid; solvent B is methanol. Other LC 
parameters were autosampler temperature 5°C, injection volume 10 μL, and column 
temperature 25 °C.  
Authentic metabolite standards including ITA were used to determine their retention 
time. The metabolites were detected using the accurate mass with a 5 ppm m/z window; 
the signal of 
13
C-labeled forms were corrected for the natural isotope abundance of the 
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unlabeled glucose. Retention times, in minutes, for selected metabolites included 11.75 
(succinate), 12.70 (ITA), 12.85 (malate), 13.20 (α-ketoglutarate), and 13.65 (citrate).  
2.8.4 Quantitation of Intracellular ITA Concentration 
Approximately 2x10
6
 VM-M3 cells cultured in [
13
C6]glucose for 12 h were extracted 
with ice cold methanol/water (80:20) doped with 1 μg/mL authentic ITA. Extracts were 
analyzed by LC-MS, and using the previously determined isotopomer percentages, the 
number of ion counts corresponding to the ITA internal standard were calculated and 
subtracted from the parent C12 ion counts. The ion counts of each isotopomer were then 
converted to concentration using the ion counts corresponding to the concentration of the 
internal standard. The average volume of the VM-M3 cells, 2.913x10
-3
 nL , measured 
using the Sceptor 2.0 cell counter (Millipore, Billerica, MA), was used to calculate the 
intracellular concentration of ITA. 
2.9 NMR Spectroscopy 
2.9.1 NMR Spectroscopy for Metabolomic Analysis and cADC Activity Assays 
Extracts were resuspended in 250 μL D2O with a 2 μM (cell extracts) or 4 μM (media 
samples) 
13
C formate standard and adjusted to pH 7.4 with DCl. The 
1
H- 
13
C formate 
resonance was referenced to 
1
H-
13
C (8.45 ppm, 173.9 ppm) for all experiments.  Samples 
were run in Shigemi tubes on a Varian 600 MHz VNMRS equipped with a triple 
resonance probe. Analyses included 1D-
1
H, and 1- and 2-D gHSQC and gHSQC-TOCSY 
experiments. For 2D gHSQC and gHSQC-TOCSY experiments, total transients per time 
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interval were typically 128 scans per 128 increments. For 1D gHSQC experiments, 
typically 6400 scans were collected for each experiment. Data were analyzed using 
VNMRJ software. For comparison of peak areas and volumes, the labeled peaks from the 
99% 
13
C-formate (Cambridge Isotope Laboratories) standard were integrated and used as 
a standard comparison for changes in ITA concentration.   All standard 
1
H and 
13
C 
chemical shifts were obtained from the Madison-Qingdao Metabolomics Consortium 
Database (Cui et al., 2008), and confirmed by doping extracts with standard compounds.  
For 
1
H spectra used for cADC assays, 1200 transients were used to compare spectra from 
lysates incubated with and without cis-aconitic acid. 
2.9.2 High Resolution 
31
P Field-Cycling NMR 
Shuttle Apparatus  
 Automated movement of the sample from the probe, into the fringe field for a 
defined time, and then bring it back into the probe for readout has been described 
previously (Roberts et al., 2004). However, more recently it has been modified so that it 
is now powered by a composite carbon tube push rod attached at its lower end to the 
sample shuttle. It extends 30 cm above the top of the magnet, where it is fastened to a 
horizontal cross piece assembly that clamps onto two timing belts. These belts run over 
upper pulleys that are nearly two meters above the magnet top, and lower pulleys (HTD5, 
40 teeth) on a common horizontal shaft connected directly to a powerful stepping motor 
(Pacific Scientific, (Milford OH) holding torque 10.8 Nm, 1.4 mH phase inductance) 
mounted about 20 cm above the magnet top. The components just mentioned (other than 
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the easily disconnected push rod) are connected together by a rigid frame as a linear 
motor assembly that we can manually slide and clamp on the horizontal top of a rigid 
frame on top of the magnet for installation. The shuttle comes to rest at the lower end on 
a shoulder exactly as previously described for completely pneumatic drive. But the upper 
end of the shuttle is coupled to the lower end of the push rod via a linkage that allows it 
to move loosely vertically by about 7 mm relative to the push rod. The lower end of the 
push rod, like the shuttle, is constrained radially by precision-machined plastic rings that 
fit the inside of the precision glass tube. The stepper motor is programmed to stop the 
push rod about 3 mm below the point where the shuttle is stopped by the shoulder 
mentioned above, and the connecting linkage is made so that the upper part of the 
linkage, connected to the push rod, does not directly touch the lower part, connected to 
the upper end of the shuttle. Thus, major vertical motion of the linear motor and push rod, 
inevitable for any kind of linear motor that moves as sample rapidly by about one meter, 
is largely isolated from the sample. Continuous air pressure of about 0.1 bar is applied to 
keep the sample in the lower position and at the bottom of the linkage, during the relax 
time. The highest point that is reached by the sample‟s center is 63 mm above the top of 
the magnet, where the fringe magnetic field of 0.040 T can be further reduced by an 
opposing magnetic field from a set of Helmholtz coils (Roberts and Redfield (b), 2004), 
to get to zero field. 
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Basic 
31
P-fc-NMR experiment  
 The 
31
P field-cycling spin-lattice relaxation rate (R1) experiments were made at 
20
o
C on a Varian Unity
plus
 500 spectrometer using a standard 10-mm Varian probe in a 
custom-built device that moves the sample, sealed in a 10 mm tube, from the sample 
probe location to a higher position within, or just above, the magnet, where the magnetic 
field is between 0.04 and 11.7 T (lower fields are accessed by shuttling to the middle of a 
permanent magnet mounted on the magnet top that can be tuned down to 0.002 T) 
(Redfield, 2003). Spin lattice relaxation rates at each field strength were measured using 
6-8 programmed delay times and analysis of the data with an exponential function to 
extract R1 = 1/T1. We use a pulse sequence in which, after the usual pulse preparation to 
dis-equilibrate the spins, we mechanically move the sample up to some specific point in 
the fringe field with the desired lower value. The sample stays at the low field during the 
relax-time tr, and then is moved back down vertically to the center of the magnet, and is 
pulsed to observe the spin magnetization. The time tr is stepwise increased from zero to a 
time of the order of the expected T1 in a series of experiments that comprise the R1 
measurement reported. Thus, the experiment is a conventional R1 experiment at the low 
field, but with preparation and readout at the high field, thereby gaining much sensitivity 
and versatility. In this study, the 
31
P resonances of the various lipids (diC8PI(3,4,5)P3, D-
3-deoxy diC8PI, L-3,5-dideoxy diC8PI, miltefosine, perifosine) in micelles or monomeric 
compounds (IP6, IP4)  could easily be resolved and assigned if the compound contained 
multiple 
31
P, and the R1‟s of each determined in the same run. At magnetic fields above 
about 2 T the chemical shift anisotropy (CSA) interaction is dominant – this provides 
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little useful information and is analyzed only to improve extracting dipolar parameters 
from the low field dispersion. 
The monomeric molecules and anionic micelles formed by the charged lipids exhibited 
fast motions and little dipolar relaxation. To enhance binding to the PH domain, the 
protein was spin-labeled on its two cysteine residues. This provides a much larger dipole 
(the unpaired electron) that can relax 
31
P fast-exchanging into and out of a discrete 
binding site over a much larger distance (up to 25 Å) (Pu et al., 2010). 
To isolate the relaxation due to the spin-label when the 
31
P-molecule is bound, we obtain 
a field dependence for the lipid with unlabeled protein and subtract it from the R1 profile 
for the same ligand using spin-labeled protein. The specific contribution of the spin-
labeled protein to 
31
P relaxation, the residual R1 (noted ΔR1) is then fit to the expression: 
ΔR1 = RP-e(0)/(1 + 
2P-e
2
)) + c 
where RP-e(0) is the maximum relaxation enhancement for that fraction of ligand bound 
to the spin-labeled protein, and P-e is the correlation time for the bound ligand/spin-label 
interaction; for micelle systems this usually reflects the overall aggregate correlation time 
of the system. A constant residual R1 at higher fields that is likely to reflect the CSA 
contribution associated with this P-e.  
For a single spin-label on the protein, the parameters RP-e(0) and P-e along with the  total 
enzyme E-SL and ligand concentration, Lo, are related to rP-e, the averaged distance 
between the 
31
P and nitroxide when the ligand is bound. 
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RP-e(0) = ([E-SLL]/[L]o) x ( S
2 P-e rP-e
-6
) (0.3  2(h/2)2 P
2 e
2
 
Here ([E-SLL]/[L]o) is the fraction of ligand bound to the enzyme relative to the 
total ligand. The next term contains S
2
, the order parameter of the electron spin-
31
P 
dipolar interaction which we take as unity because of the long distance rP-e between the 
phosphorus of cIP and the electron spin compared to the size of local picosecond 
motions. The last term contains standard constants of relaxation theory defined elsewhere 
(Roberts et al., 2004; Roberts and Redfield, 2004).  
Since the PH domain has two Cys, we cannot obtain accurate distances – but we can 
compare ligands and see if they binding to the same place. Future work would have us 
prepare the protein with a single Cys residue for mapping out binding sites. 
2.10  cis-Aconitic Decarboxylase Characterization 
2.10.1  cADC Activity Assays  
Confluent flasks of RAW 264.7 and VM-M3 cells were washed with PBS and scraped 
into ice-cold hypotonic lysis buffer (20 mM Hepes, 3 mM MgCl2, 1 mM PMSF and 10 
μL/mL protease inhibitor cocktail, pH 7.6) and incubated on ice for 10 minutes in order 
to obtain a crude lysate.  Cells were fully lysed by several strokes of a Dounce 
homogenizer until >90% were visible by Trypan Blue staining.  To perform the assays, 
an aliquot of a 100 mM cis-aconitic acid (Sigma) solution freshly prepared in lysis buffer 
and adjusted to neutral pH was added to a final concentration of 4 mM. Lysates were then 
incubated at 37°C with shaking at 100 rpm for 3 h. For metabolite extraction, a 4-fold 
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volume of ice cold methanol was added and samples were incubated on ice for 10 min 
before centrifugation at 14,000 rpm, 4°C.  The supernatant was dried under N2 gas, 
lyophilized, and dissolved in D2O for NMR analysis. 
2.10.2  Subcellular Localization of cADC Activity 
In order to determine the subcellular localization of cADC, a variety of subcellular 
fractionation kits and unpublished methods were employed.  All centrifugation steps were 
at 4°C. 
Differential Centrifugation – The first protocol involved separation of the crude lysate 
(3.16) by centrifugation at 14,000 rpm (4°C) to pellet nuclei and heavy mitochondria.  
The second involved a spin at 850xg to pellet nuclei, followed by a spin at 14,000 rpm to 
pellet mitochondria.  All pelleted fractions were resuspended in volumes of lysis buffer 
with protease inhibitors equal to the volume of the cytosolic fraction and all fractions 
were tested for cADC activity.    
Detergent Method – Pure nuclear fractions were prepared by adding 0.1% NP-40 to the 
crude lysate and vortexing in order to solubilize the plasma membrane and remove it 
from the intact nucleus.  The nuclei were then collected by centrifugation at 850xg. 
Kit Method – The Qproteome Mitochondrial Isolation Kit (Qiagen) was used to separate 
a crude mitochondrial fraction from nuclear, membrane and cytosolic fractions.  
Approximately 10
7
 cells were rinsed with ice cold 0.9% NaCl solution and scraped into 
the kit lysis buffer.  The broken cells were pelleted at 1000xg, the supernatant being the 
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cytosolic fraction.  The broken cells were resuspended in disruption buffer and fully 
disrupted by passage through a 25.5 gauge needle until the nuclei appeared to be 
separated from the cell membranes when viewed under a light microscope.  The nuclei 
were pelleted by centrifugation at 1000xg.  The supernatant, containing membranes and 
mitochondria, was centrifuged at 6000xg to pellet mitochondria.  The pelleted fractions 
were resuspended in the same volume of hypotonic lysis buffer used for the initial lysis 
step. All fractions were tested for cADC activity. 
2.11  Fluorescence  
2.11.1  Intrinsic Fluorescence Binding Assay 
In order to monitor protein binding to ligands by changes in intrinsic fluorescence of 
tryptophan residues, 0.5 μM purified PH domain in a total volume of 1.00 mL binding 
buffer was used.  The original binding buffer (25 mM HEPES-KOH, pH 7.4, 140 mM 
KCl, and 15 mM NaCl) (Landgraf et al., 2008) was adjusted in order to optimize binding 
conditions.  This included altering the pH, adding 0.5-5 mM MgCl2, adding 0.5 mM 
EDTA, adding 1 mM CHAPS detergent, eliminating salt, and adding 10 mM 
dithiothreitol (DTT).  All experiments were carried out at 25°C.  IP6, perifosine and 
miltefosine, and vehicle controls were titrated into the cuvette, which was inverted to mix 
the contents. The fluorescence was measured at 345 nm after excitation at 284 nm.  Data 
were corrected for a decrease in signal due to photobleaching, and volume 
dilution/background fluorescence of test compound, and then normalized to relative 
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fluorescence.  Relative fluorescence was plotted versus substrate concentration in 
attempts to establish a quantitative binding curve.   
2.11.2  Confocal Fluorescence Microscopy 
Cells nucleofected with Akt1-GFP were serum starved in Phenol Red-free media for 16 h 
prior to treatment with 100 μM D-3-deoxy-diC8PI, 17 μM perifosine, or vehicle control 
for 1-4 h.  Cells were imaged on a Leica SP-5 confocal microscope using an Argon laser, 
equipped with a 63X H2O objective and a heated stage maintained at 37°C.  After 
stimulation with 100 ng/mL human heregulin β-1 or 10% FCS and 0.1 mg/mL bovine 
insulin, Z-stack images were taken every 2 min for a total of 20 min in order to capture 
the translocation of Akt1-GFP to the plasma membrane.  Z-stacks for each time point 
were combined as a maximum projection image.  Leica LAS imaging software was used 
to capture and process images. 
2.12  BRDU Incorporation Assay 
MCF-7 cells plated 2 days in advance were incubated without serum and with or without 
D-3-deoxy diC8PI for 24 h in a 6 well plate.  After 24 h, adequate BRDU to give a final 
concentration of 10 µM was added to each well and incubated for an additional 8 h.  The 
media and one PBS wash from each well was saved, and added to the cells which were 
trypsinized and quenched with ice-cold complete media.  The cells were pelleted by 
centrifugation and washed once with ice-cold PBS, and stored a minimum of overnight 
and for up to one week in BD  Cytofix/Cytoperm buffer at 4°C.  Cells were then washed 
with BD Perm/Wash buffer and fixed with BD Cytoperm Permeabilization Buffer Plus.  
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The cells were washed and fixed again in Cytofix/Cytoperm buffer.  The fixed and 
permeabilized cells were then incubated with 30 µg DNAse in Dulbecco‟s PBS for 1h at 
37°C to expose the incorporated BRDU. After washing, the cells were stained with FITC 
conjugated anti-BRDU antibody, washed, and resuspended in PBS for analysis by flow 
cytometry using a FACSCanto Flow Cytometer. 
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Chapter 3:  
Glutamine and Glucose Metabolism in the  
VM-M3 Tumor Cell Line  
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3.1  Introduction 
Upregulated glucose metabolism is widely regarded as one of the hallmarks of cancer.  
As first noted by Otto Warburg in 1924, cancer cells display a much greater reliance on 
aerobic glycolysis than the oxidative phosphorylation that drives the metabolism of most 
differentiated cells, despite the fact that there is ample oxygen present and mitochondrial 
function is generally not impaired (Warburg et al., 1924; Warburg, 1956; Moreno-
Sanchez et al., 2007).  This “fermentation” of glucose generates 2 ATPs from each 
molecule of glucose and results in the production of large quantities of lactate, compared 
to the 36 ATPs that a cell can obtain from the complete oxidation of a single glucose 
molecule. Several theories have been proposed as to why cancer cells preferentially 
utilize this less efficient method of ATP production.  It has been suggested that 
insufficient ATP production from glycolysis is only a problem when the cell has 
inadequate resources, which is not an issue for proliferating mammalian cells (Vander 
Heiden et al., 2009).  Since the tumor microenvironment is extremely hypoxic, reliance 
on anaerobic glycolysis for ATP production rather than oxidative phosphorylation may 
confer a survival advantage on the tumor cell (Koukourakis et al., 2006).  However no 
single explanation for the Warburg effect is universally accepted.   
It has also been established that a number of tumors and cancer cells show a requirement 
for high concentrations of glutamine in culture media (Kovacevic, 1971; DeBerardinis 
and Cheng, 2009).  This may be a result of its necessity as a nitrogen donor for nucleotide 
or non-essential amino acid synthesis, or as a precursory substrate for anaplerotic 
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reactions (Wise and Thompson, 2010).  This so called “glutamine addiction” is intriguing 
since glutamine can be synthesized from glucose and is therefore not an essential amino 
acid (Wise and Thompson, 2010; Eagle, 1955).  I was curious about the interplay 
between these two fuels in cancer cells, so I chose to investigate glucose and glutamine 
metabolism using 
13
C labeling and NMR-based metabolomics in the VM-M3 tumor cell 
line. 
The VM-M3 tumor cell line initially appeared to be unique, as its survival was reported 
to depend predominantly on glutamine rather than glucose (Laura Shelton, unpublished 
data).  These data later proved to be suspect due to mycoplasma contamination of the 
cells and questionable experimental design. However, it does not change the fact that 
glutamine addiction is a characteristic of many tumor cell lines.  I therefore chose to 
incubate the cleaned VM-M3 cells (continuously maintained in anti-mycoplasma 
antibiotic) with 4 mM
 
[
13
C5]glutamine without glucose, 4 mM [
13
C5]glutamine and 25 
mM unlabeled glucose, 25 mM [
13
C6]glucose without glutamine, or 25 mM [
13
C6]glucose 
with 4 mM unlabeled glutamine.  This allowed us to use 1- and 2-D 
1
H-
13
C gHSQC 
NMR spectroscopy to determine the major products of each fuel‟s catabolism, as well as 
how these products changed depending on whether or not the alternative fuel source was 
available.  I chose to incubate without serum in order to eliminate any uncontrolled 
sources of glutamine or glucose, and for a 12 hour window because at longer time points, 
cells deficient for either nutrient were much less viable.  I examined both intracellular 
extracts (made by extraction with 70% ethanol) and samples from the tissue culture 
media.  
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While using 1D-gHSQCs to identify 
13
C-labeled metabolites is an efficient method of 
analysis, the fact that the resulting spectrum is in the crowded 
1
H dimension can result in 
significant spectral overlap.  Therefore, I could not effectively integrate the signals 
arising from each 
13
C-
1
H in a given metabolite.  Instead I chose a signal(s) for each 
metabolite that had minimal overlap with neighboring peaks.  This method is imperfect, 
as there may be different isotopologues of each metabolite present resulting from 
multiple turns of the TCA cycle or different biosyntheses.  Also, major changes in 
metabolite labeling patterns may also not directly relate to increases or decreases in 
concentration, but instead shifts in biosynthetic pathways or pools of precursor 
metabolites.  It is also impossible to obtain quantitative information from these data sets 
due to the nature of the 1- and 2D gHSQC experiments.  These results are therefore best 
used as a starting point for more focused experiments.     
     
3.2  Metabolites Identified in Extracts from VM-M3 Cells Incubated With 
[
13
C5]Glutamine   
To analyze the dependence of the VM-M3 cell line on glutamine, we incubated 80% 
confluent T-75 flasks of cells in serum-free DMEM with 4 mM [
13
C5]glutamine or both 4 
mM [
13
C5]glutamine and 25 mM unlabeled glucose for 12 hours.  After the incubation 
time, cells were washed with ice cold PBS and scraped into ice cold 70% ethanol.  The 
lysates were cleared by centrifugation and ethanol extracted three additional times (see 
Materials and Methods).  The lyophilized pooled supernatants were resuspended in D2O 
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with a 2 μM 13C formate standard and adjusted to pH 7.4.  Metabolites were identified 
using 2D-gHSQC and 2D-gHSQCTOCSY experiments and using the Madison-Qingdao 
Metabolomics Database (Cui et al., 2008).  In the cases of nucleotide phosphates, it was 
not possible to discern either the number of phosphate groups or between the bases 
adenosine and inosine, so in figures and the text this ambiguity exists. Peaks that did not 
significantly overlap with neighboring peaks were integrated with respect to the formate 
peak.  Values were normalized to the protein concentration in mg/mL in order to 
accurately make comparisons between sample sets and conditions.  For each condition, 2 
sample sets with 3 lysates each were obtained.   
The overall composition of metabolites labeled by [
13
C5]glutamine remained largely 
consistent regardless of whether or not the cells had also been incubated with glucose 
(Figures 3.1, 3.2).  A notable exception is UnP, where the uracil moiety is labeled only 
when glucose is available.  The numerical relative peak intensities are somewhat 
inconsistent between sample sets. However, in many cases a general trend between 
conditions (glutamine alone vs. glucose and glutamine) could be identified. 
The errors (influenced not only by sample preparation, but by the accuracy of protein 
concentration used for normalization, and inaccuracy in integration) were often too large 
to detect potentially subtle differences in metabolite concentration between conditions.  
This is true for the signals detected arising from glutamate (δH = 2.35 ppm), glutamine 
(δH
 
= 2.45 ppm) and succinate (δH
  
= 2.40 ppm).  There is certainly some overlap between 
these signals, which will also contribute to the large errors (Figure 3.1).   
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Figure 3.1 Sample 1D-gHSQC spectrum of ethanol cell extracts from 10
7
 VM-M3 cells incubated for 12 h 
with 4 mM [
13
C5]glutamine and 25 mM glucose.  Peaks labeled with multiple metabolites 
(GSSG/GSH/Gln/Glu) are made up of contributions from multiple metabolites and that could not be 
integrated individually at that position due to spectral overlap.  Spectra were obtained on a Varian 600 
MHz VNMRS equipped with a triple resonance probe with nt=6400. 
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Figure 3.2 Relative levels of [
13
C]-labeled metabolites in VM-M3 ethanol extracts after 12 h incubation 
with 4 mM [
13
C5]glutamine and 25 mM unlabeled glucose (blue) or 4 mM [
13
C5]glutamine (pink).  Each 
color consists of 2 discrete data sets (indicated by shading) made up of three replicates each.    
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Despite this, there are examples of statistically significant changes (Figure 3.2).  Levels 
of [
13
C]alanine, [
13
C]glutathione (glutamate moiety), and [
13
C]aspartate are increased in 
extracts from cells incubated without glucose as compared to cells treated with both 
[
13
C5]glutamine and glucose.  In contrast, the concentration of [
13
C]ITA was higher when 
the cells were incubated with both [
13
C5]glutamine and glucose, and the uracil moiety of 
UnP was only labeled under these conditions.  It is under these conditions that we first 
observed itaconic acid in the VM-M3 cells (see Chapter 4 for more detail). 
The [
13
C]lactate (δH
  
= 1.32 ppm) methyl resonance also increases when the cells were 
incubated with glucose. However, the 
13
C-
1
H lactate peak is incredibly small, and this 
increase is most likely due to the significant increase in lactate concentration that occurs 
post-glycolysis when glucose is present in the media (producing mostly 
12
C-
1
H lactate 
with 1% abundance of the 
13
C labeled material).  Natural abundance control samples 
should in theory be able to confirm this. However, the peaks that arise from the unlabeled 
samples I collected have extremely poor signal to noise, which prevented accurate 
integration and therefore confirmation of my suspicions.  It is also possible that the 
difference in lactate is a result of complete glutaminolysis.  In some cell lines, significant 
amounts of [
13
C]lactate have been produced by glutaminolysis of [
13
C]glutamine 
(DeBerardinis et al., 2007).  This is a result of flux through malic enzyme (EC 1.1.1.39 
and EC 1.1.1.40), which degrades malate from the TCA cycle to pyruvate, which then 
can be converted to lactate by lactate dehydrogenase (EC 1.1.1.27).  If an increase in 
[
13
C]lactate production is really the reason for the increase in the peak at the [
13
C]lactate 
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resonance, this could easily be distinguished from an overall increase in unlabeled lactate 
production from glycolysis using mass spectrometry to identify any isotopologues. 
The significantly higher levels of [
13
C]aspartate under the glucose-deficient condition 
may be the result of increased aspartate aminotransferase activity needed to shuttle units 
of carbon from glutamate into the TCA cycle in order to maintain viability (Figure 3.3). 
Aspartate aminotransferase is one of multiple proteins that can catalyze the 
transamination from glutamate to oxaloacetate to generate α-ketoglutarate and aspartate, 
allowing generation of TCA cycle intermediates via glutaminolysis.  This reaction 
involves the transfer of the amino group from glutamate to [
13
C]oxaloacetate (from entry 
of the [
13
C5]glutamine carbon backbone into the TCA cycle), forming [
13
C]aspartate.  
When glucose is not present, glutaminolysis is the easiest way to replenish TCA 
metabolites and much more critical when units of acetyl-coA and pyruvate are not readily 
being produced.  In addition, [
13
C]uracil is synthesized from [
13
C]aspartate (Figure 3.4) , 
so it is likely that the decreased levels of [
13
C]aspartate when both glucose and glutamine 
are available is a result of increased aspartate metabolism to make nucleic acids and 
potentially other necessary metabolites.   
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Figure 3.3 Routes of glutamine and glucose entry into the TCA cycle.  Metabolites that were detected by 
NMR to be [
13
C]-labeled as a result of incubation with either 4 mM [
13
C5]glutamine or 25 mM [
13
C6] 
glucose for 12 hours are shown in red.  LDH=lactate dehydrogenase, ME=malic enzyme, PC=pyruvate 
carboxylase, PDH=pyruvate dehydrogenase, cADC=cis-aconitic decarboxylase, AST=aspartate 
aminotransferase, ALAT=alanine aminotransferase. 
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Figure 3.4 Biosynthetic pathway of [
13
C]UMP from [
13
C4]aspartate derived from [
13
C5]glutamine. 
 
3.3  Metabolites Identified in Extracts From VM-M3 Cells Incubated With 
[
13
C6]Glucose 
In order to assess glucose metabolism in VM-M3 cells, cells were incubated with 25 mM 
[
13
C6]glucose and 4 mM unlabeled glutamine or 25 mM [
13
C6]glucose alone for 12 h to 
parallel the glutamine experiments.  As with the glutamine experiments, the overall 
metabolite pool detected was the same between the two conditions (Figure 3.5).  When 
both glucose and glutamine were present, [
13
C6]glucose labeled significantly higher 
levels of [
13
C]AnP/InP on the ribose moiety, [
13
C]glutamate, [
13
C]glutathione and 
[
13
C]alanine.  There was no consistent trend in changes in intracellular [
13
C]ITA, 
[
13
C]glucose, or [
13
C]lactate levels, which may be largely due to the substantial errors 
between measurements of some of these metabolites (Figure 3.6). 
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Figure 3.5  Sample 1D-gHSQC spectrum of ethanol cell extracts from 10
7
 VM-M3 cells incubated for 12 h 
with 25 mM [
13
C6]glucose and 4 mM glutamine.  Not all peaks were identified, and some identified peaks 
could not be accurately integrated (i.e. aspartate). Spectra were obtained on a Varian 600 MHz VNMRS 
equipped with a triple resonance probe with nt=6400. 
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Figure 3.6 Relative levels of [
13
C]-labeled metabolites in VM-M3 ethanol extracts after 12 h incubation 
with 25 mM [
13
C6]glucose and 4 mM unlabeled glutamine (purple) or 25 mM [
13
C6]glucose (black/grey).  
Each color consists of 2 discrete data sets (indicated by shading) made up of three replicates each. 
It is not surprising that the VM-M3 cells are able to devote more of their energy to 
synthesize ribose from glucose via the pentose phosphate pathway when they have the 
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additional resource of glutamine present.  However, the increases in [
13
C]glutamate and 
the glutamate moiety of [
13
C]glutathione when glutamine is present are intriguing.  This 
labeling most likely results from the transamination of [
13C]α-ketoglutarate (not detected 
in my extracts because its steady state intracellular concentration is fairly low) from the 
TCA cycle, as the glutamate position primarily labeled is what we would expect from the 
entry of [
13
C2]acetyl-CoA into the TCA cycle via the pyruvate dehydrogenase complex.  
We know from the glutamine data that there is a significant amount of glutamate in the 
cells being synthesized via glutamine metabolism.  Why then are these cells still 
producing glutamate from glucose as well as glutamine?  The answer is not immediately 
clear based on the data I currently have available.  Since the VM-M3 cell line is derived 
from a brain tumor, glutamate may be a metabolite of particular importance.  There is 
evidence that malignant gliomas that secrete glutamate gain a growth advantage as a 
result of an excitotoxic mechanism, which could explain why these cells are making so 
much of it (Takano et al., 2001).  It is also a macrophage derived cell line, and 
glutathione production is a requirement for effective macrophage activation and therefore 
a critical metabolite which requires a significant supply of glutamate as a precursor 
(Buchmiller-Rouiller et al., 1995).  
The significantly increased [
13
C]alanine levels when both [
13
C6]glucose and glutamine 
are present may be a result of increased alanine aminotransferase activity to convert 
glutamate to α-ketoglutarate by transaminating [13C]pyruvate (resulting from glycolysis) 
to [
13
C]alanine.  Alanine aminotransferase is commonly found in brain tissue, and in 
addition to aspartate aminotransferase may be a major aminotransferase required for 
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glutamate entry into the TCA cycle in VM-M3 cells.  The dynamics between aspartate 
aminotransferase and alanine aminotransferase may depend on the relative levels of 
pyruvate and oxaloacetate, but more experiments must be done in order to confirm this.  
In particular, it would be useful to incubate 4 mM L-(α-15N)glutamine with and without 
25 mM unlabeled glucose to compare the levels of [
15
N]alanine and [
15
N]aspartate using 
15
N-NMR or ideally LC-MS.  This could potentially confirm that when glucose is present 
and there is a greater supply of pyruvate in the cells, alanine aminotransferase is the 
preferred transminase for the conversion of glutamate to α-ketoglutarate.  
3.4  Metabolites Identified in Tissue Culture Media from VM-M3 Cells Incubated 
with [
13
C5]Glutamine 
To analyze the metabolites being secreted by the VM-M3 cells as a result of 
[
13
C5]glutamine metabolism, 2 mL (20% of the total volume) of tissue culture media after 
the 12 hour incubation with and without unlabeled glucose was collected and lyophilized 
before resuspension and pH adjustment in 500 μL D2O with 4 μM [
13
C]formate standard.  
Spectral overlap was a serious problem with the media samples, so all gHSQC spectra 
had to be acquired in two dimensions (for an example, see Figure 3.7).  Even with 
normalization to protein concentration, there was much less consistency in the media 
samples than in the extracts (not surprising since a difference in numbers of cells will 
influence levels of what is secreted), so I am merely presenting the [
13
C]-labeled 
metabolites I found to be labeled in the media (Figure 3.8).  The overall profile of [
13
C]-
labeled metabolites was similar under both conditions, with the exception of 
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[
13
C]aspartate, which was only detected in the media from cells that were incubated with 
[
13
C5]glutamine.  This is consistent with the data from the extracts, which show a much 
higher concentration of [
13
C]aspartate  when glucose is not present.  If the cells are 
rapidly making significant quantities of aspartate as a product of the aspartate 
aminotransferase reaction, they may need to export it in order to keep the intracellular 
concentration from becoming too high. 
Two interesting labeled metabolites being secreted by the VM-M3 are citrate and 
asparagine.  Neither of these can be detected by NMR in the cell extracts, which should 
be much more concentrated in metabolites than the small fraction of media used for these 
experiments.  Asparagine can be synthesized from aspartate via asparagine synthetase 
(while simultaneously converting glutamine to glutamate) so it‟s no mystery how 
asparagine is getting labeled.  Why it is getting exported rather than accumulating in the 
cell is unclear, and why it is consistently exported into the media while its precursor 
aspartate is only exported in the absence of glucose is not clear.  Asparagine is an analog 
of glutamine and has been shown to inhibit glutamine uptake in rat brain mitochondria 
(Robert et al., 1999), so it may be advantageous for the VM-M3s to export any excess 
asparagine in order to maximize glutamine metabolism.   
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Figure 3.7 Representative 
1
H-
13
C 2D-gHSQC spectrum of tissue culture media from VM-M3 cells 
incubated for 12 hours with 4 mM [
13
C5]glutamine.  Peaks resulting from [
13
C] labeling have been 
identified with their respective metabolite; peaks visible that appear to be natural abundance have not been 
identified in this figure.  Multiple regions of the spectrum show significant crowding that would add 
significant error to integration.  Asterisks represent artifacts from the glutamine signal.  nt=128, ni=128.   
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Table 3.1 [
13
C]-Labeled Metabolites Present in Tissue Culture Media after 12 h 
Incubation with 4 mM [
13
C]Glutamine or 4 mM [
13
C]Glutamine and 25 mM Unlabeled 
Glucose 
Metabolite 
1
H-
13
C (ppm) Conditions Seen 
Glutamine (3.78, 57.03), (2.45, 33.65), (2.14, 28.97) Component of Media 
Glutamate (3.78, 57.03), (2.35, 35.73), (2.06, 30.01) Both 
Succinate (2.40, 37.03) Both 
Aspartate (2.81/2.78/2.70/2.67, 39.21), (3.90,54.81) Glutamine only 
Asparagine (2.96/2.94/2.89/2.85, 37.55), (4.00,54.18) Both 
Itaconate (3.15, 44.76), (5.85/5.37, 124.46) Both 
Pyruglutamate (4.18, 61.16), (2.41, 32.87), (2.50, 28.08), 
(2.02,28.08) 
Both 
Lactate (4.12, 71.24), (1.33, 22.80) Both 
Alanine (1.48, 18.86) Both 
Glucose (5.24,94.42), (4.66,98.11), 
(3.91/3.89/3.85/3.83, 65.53), (3.73/3.77, 
63.27), (3.84,74.18), (3.71, 75.48), (3.54, 
73.92), (3.41, 72.36), (3.25, 77.04), (3.49, 
78.34) 
Component of Media 
Citrate (2.70/2.68/2.54/2.51, 47.77) Both  
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The presence of high levels of citrate in the media rather than in the cell is also somewhat 
strange.  The cells are actively exporting citrate, but for what reason, and is it 
advantageous or a result of a malfunction?  If the VM-M3 cells have deregulated citrate 
export, this would ultimately result in depletion of TCA metabolites as well as a 
necessary precursor for lipid synthesis.  It has been noted that cytoplasmic citrate at high 
concentrations can negatively regulate glycolysis by allosteric inhibition of 
phosphofructokinase (Kemp and Foe, 1983; Usenik and Legisa, 2010).  Since tumor cells 
rely so heavily on glycolysis for energy, it may be beneficial for the cell to export any 
unnecessary citrate in order to minimize this inhibition.  While transporters responsible 
for the uptake of extracellular citrate have been studied, relatively little is known about 
the export of cytosolic citrate.  Prostate cells (both cancerous and normal) have been 
shown to express a K
+
 dependent citrate transporter that specifically transports trivalent 
citrate outward, however there has been little structural characterization of this 
unidentified transporter (Mycielska and Djamgoz, 2004; Mycielska et al., 2005).  It is 
possible that the expression of such a transporter in VM-M3 cells is responsible for this 
citrate efflux.  There is evidence that deregulation of monocarboxylate transport is related 
to the metastatic capability of tumor cells (Coady et al., 2004; Miyauchi et al., 2004), and 
since the VM-M3s are reportedly highly metastatic it is not unreasonable to postulate that 
increased citrate export could potentially be related to metastatic capability as well.   
The release of citrate by the VM-M3 cell line may also be a result of its glial origin.  
Other brain cells such as neurons and astrocytes have been found to not accumulate 
citrate, and astrocytes actively release citrate (Sonnewald et al., 1991; Westergaard et al., 
100 
1994).  It has subsequently been proven that citrate can modulate N-methyl D-aspartate 
receptors by chelating free divalent cations, resulting in increased neurotransmitter 
release (Westergaard et al., 1995).  It would be particularly interesting to compare the 
levels of citrate released by „normal‟ microglial cells and the VM-M3s; if the VM-M3s 
show significantly increased citrate efflux, it is possible that this, in combination with 
glutamate release, is part of an excitoxic mechanism for tumor growth. 
Initially, I was very surprised to see [
13
C]pyroglutamate in the media.  Pyroglutamate is a 
component of the -glutamyl cycle involved in glutathione synthesis, and since the cells 
are clearly making significant amounts of glutathione it seemed strange that they would 
be exporting a precursor.  However, it is important to note that pyroglutamate is a 
degradation product of glutamine in solution that occurs spontaneously over time and 
under cell culture conditions.  This has been observed in the culture media in controlled 
incubation of medium alone, so it is difficult to accurately determine if the pyroglutamine 
detected in the tissue culture media is actively being secreted by the cells in addition to 
forming spontaneously from glutamine.  The pyroglutamate resonances appeared about 
the same in the two different media conditions, so it is likely that the presence of 
pyroglutamate in this case is an artifact of glutamine degradation. 
3.5 Discussion 
While these data are incomplete, they do give a snapshot into the complimentary roles of 
glutamine and glucose as fuels in the VM-M3 tumor cell line.  Glutaminolysis is clearly 
active in these cells, as we see ample evidence of 
13
C-labeling in glutamate and TCA 
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cycle metabolites.  Glycolysis is also active, and glucose is ultimately able to enter the 
TCA cycle as acetyl-coA and pyruvate as indicated by the ITA labeling data (see Chapter 
3) and the presence of labeled glutamate.  It appears that glutamate and glutathione are 
critical metabolites in these cells, since they are simultaneously being synthesized from 
both glucose and glutamine.  It is curious that the cell would divert so much α-
ketoglutarate from the TCA cycle to metabolize as glutamate when glutamate is readily 
available via glutaminolysis.  Glutamate may be needed in quantities that cannot be 
obtained by glutaminolysis alone, or there may be a detour from the TCA cycle that 
results in the removal of TCA metabolites via the amination of α-ketoglutarate.  It is also 
possible that the cells maintain two pools of glutamate – one synthesized from glutamine 
and one from glucose – but to determine this I would require specifically labeled 
glutamine and glucose and mass spectrometry to determine if the labels were on the same 
molecules.   
 
 
 
 
 
 
 
102 
 
 
 
 
 
 
Chapter 4: 
Itaconic Acid is a Mammalian Metabolite  
Induced during Macrophage Activation 
  
103 
4.1 Introduction 
Small-molecule effectors of cells are often overlooked.  A case in point is itaconic acid 
(ITA), or methylenesuccinic acid, a metabolite made and secreted by the fungal organism 
Aspergillus terreus (Bonnarme et al., 1995; Bentley and Thiessen, 1955).  The 
biosynthesis of this dicarboxylic acid has been of interest because it can be used as a 
starting material for chemical synthesis of polymers (Yu et al., 2011; Okabe et al., 2009). 
More recently, ITA has been identified in a limited number of cases of metabolomic 
analysis of mammalian tissue specimens (Shin et al., 2011; Kvitvang et al., 2011; Wibom 
et al., 2010).  In those few cases, whether it was synthesized by mammalian cells or 
endogenous flora, or arose merely as an adventitious contaminant, was unknown.  
Despite the overall lack of study of ITA as a mammalian metabolite, there is evidence 
that ITA can be catabolized by both guinea pig and rat liver mitochondria (Adler et al., 
1957; Wang et al., 1961). 
4.2 Observation in Macrophage and Macrophage-Derived Cells and Tissue Culture 
Media 
The VM-M3 murine tumor cell line is derived from a spontaneously arising brain tumor 
in a VM mouse (Huysenstruyt et al., 2008).
 
 This cell line, reported to be metastatic, is 
similar in morphology to the well-characterized RAW 264.7 murine macrophage cell 
line, and both share properties of macrophages including gene expression and phagocytic 
capability (Huysenstruyt et al., 2010; Raschke et al., 1978).
 
 In the course of an NMR-
based metabolomics study of the differential metabolism of glucose and glutamine, we 
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detected ITA in 1D-gHSQC NMR experiments (obtained on a Varian 600 MHz VNMRS 
equipped with a triple-resonance probe) with methanol/water (80:20) extracts of VM-M3 
cells that had been incubated with [
13
C5]-glutamine or [
13
C6]glucose. [
13
C5]Glutamine 
resulted in detection of proton resonances at 3.15 ppm characteristic of the ITA signal for 
the -
13
CH2-moiety; [
13
C6]glucose incubation gave rise to resonances consistent with 
labeled -
13
CH2- and =
13
CH2 (at 5.37 and 5.85 ppm) groups (Table 4.1) (Cui et al., 2008). 
 
Table 4.1 Experimental 
1
H and 
13
C chemical shifts of ITA referenced to sodium formate 
in D2O, pH 7.4. 
Metabolite  δH (ppm)  δC (ppm) 
sodium formate 8.45 173.90 
ITA, -CH2- 3.15 44.76 
ITA, =CH2 5.85, 5.37 124.46 
 
 
 
 
 
105 
 
 
Figure 4.1 (A) 2D-gHSQC spectrum of methanol extracts of VM-M3 cells (8x10
6
 cells) incubated with 25 
mM [
13
C6]glucose for 12 h. Inset: structure of itaconate. Slices from 2D-gHSQC spectra diagnostic for ITA 
are shown for extracts of RAW 264.7 cells (10
7
 cells) that were (B) unstimulated or (C) stimulated with 10 
ng/mL LPS for 24 h, and extracts from murine macrophages (8x10
6
 cells) that were (D) unstimulated or (E) 
stimulated by priming with 150 U/mL IFN-γ for 6 h followed by 24 h incubation with 10 ng/mL LPS prior 
to incubation with 25mM [
13
C6]glucose for 12 h. For spectra A-C, nt = 128 and ni = 128.  For spectra D and 
E, nt = 256 and ni = 128. 
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The 
13
C-labeled ITA was present at sufficiently high levels that it could easily be 
identified using 2D-gHSQC (Figure 4.1.A) and 2D-gHSQCTOCSY experiments. The 
1
H 
resonances arising from itaconate were also confirmed by doping cell extracts with an 
itaconate standard. 
13
C-labeled ITA could also be identified in cell extracts using LC-MS 
(Figure 4.2)  Using the size of the VM-M3 cells and cell count used for the extracts, and 
quantifying the amount of ITA in the extracts using MS methods, we estimate the 
intracellular concentration of this compound to be 1.33 ± 0.16 mM (see Materials and 
Methods).  
13
C-Labeled ITA was also detected by 1D-gHSQC in an extract of the culture medium in 
which cells were incubated with [
13
C6]glucose for 12 h. In order to detect the ITA, the 
large amount of [
13
C6]glucose was removed from the resolubilized extract with Strata-X-
A solid-phase extraction cartridges.  Thus, this molecule appears to be secreted by the 
cells.  ITA may be a metabolite associated with a wide variety of tumors, or it could 
occur in a unique subset. We therefore investigated ITA synthesis in the macrophage-like 
RAW 264.7 cell line and the unrelated MCF-7 breast cancer cell line. Although 
1
H NMR 
has been used to profile the RAW 264.7 metabolome (Stuckey et al., 2005; Santini et al., 
2004), the relatively low concentration of ITA would make it difficult to detect in the 
absence of 
13
C-labeling and selective analysis of protons coupled to 
13
C. gHSQC spectra 
of extracts from unstimulated RAW 264.7 cells incubated with [
13
C6]glucose exhibited a 
detectable amount of ITA (Figure 4.1.B), while extracts from the MCF-7 cell line 
incubated with the labeled glucose did not contain NMR-detectable levels of ITA.  
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Figure 4.2 (A) Representative chromatographic traces for the detection of itaconic acid. (1) Standard of 
citraconic acid (5 µg/mL), a structural isomer of itaconic acid, has a retention time of 13.2 min and detected 
mass is 129.0196 (error of 2.3 ppm) compared to the theoretical mass of 129.0193, in negative ion mode. 
(2) Standard of itaconic acid (5 µg/mL), has a retention time of 12.70 min and detected mass of 129.0195 
(1.5 ppm error). (3) Itaconic acid detected in the cellular extract of VM-M3 cell line, with a detected mass 
of 129.0195 (1.5 ppm error).  (B) Sample mass spectrum of ITA (12.70 min peak) in extracts from VM-M3 
cells incubated for 12h with [
13
C6]glucose. 
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Moreover, analysis of several unrelated cell types (Escherichia coli strain NCM3722, 
Clostridium acetobutylicum strain ATCC 824, Saccharomyces cerevisiae strain CEN-PK, 
cultured human foreskin fibroblasts, or pancreatic tumor tissue) by LC-MS failed to 
reveal detectable levels of ITA. It is noteworthy that stimulation of RAW 264.7 cells with 
lipopolysaccharide (LPS) resulted ina greater than 10-fold increase in levels of detectable 
13
C-ITA  (Figure 4.1.C); ITA was also detected in the tissue culture media of the RAW 
264.7 cells as well as VM-M3 cells (Figure 4.3).  Thus, ITA synthesis is not a generic 
characteristic of all tumor cell lines, and might instead be indicative of those of 
macrophage lineage.   
 
 
Figure 4.3 1D-gHSQC spectra of culture media from (A) RAW 264.7 cell cultures stimulated with 10 
ng/mL LPS and (B) VM-M3 cell cultures that were incubated with [U-13C]glucose for 12 h and then 
treated to isolate weak acids including ITA (*). 6400 transients were collected for each spectrum. 
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To test the possibility that ITA synthesis is a characteristic of macrophages, we analyzed 
unstimulated mouse peritoneal macrophages and activated macrophages following ex 
vivo stimulation with IFN-γ and LPS that were then incubated with [13C6]glucose. While 
very low levels of ITA could be detected in the unstimulated cell extracts (Figure 4.1.D), 
a dramatic increase was observed in the activated cells (Figure 4.1.E). This is consistent 
with the findings of Shin et al. (2011), who detected ITA in the lungs of mice infected 
with Mycobacterium tuberculosis, the primary site of inflammation and macrophage 
response to infection, but not other organs. As with the VM-M3 cells, ITA was also 
detected in the culture medium, but only in cells that had been stimulated with LPS.  
Therefore, production of ITA may represent a previously unrecognized facet of the 
macrophage-mediated immune response.  
4.3 Determination of the Mammalian Biosynthetic Pathway of ITA 
Multiple pathways have been proposed for the biosynthesis of ITA (Figures 4.4 and 4.5)  
(Bonnarme et al., 1995; Shimi et al., 1962; Jakubowska and Metodiewa, 1974). To 
distinguish among these, we used isotope tracers. The low concentration of ITA in the 
13
C-labeled extracts made direct 
13
C detection by NMR impractical. Therefore, we used 
LC-MS measurements (Lu et al., 2010) of ITA and its potential precursors, including 
acetyl CoA, pyruvate, citrate, and aconitate, after incubating cells with [
13
C6]glucose or 
[
13
C5]glutamine (Figure 4.4). If the biosynthesis of ITA in mammalian cells occurs 
through the same pathway as in Aspergillus (decarboxylation of cis-aconitate followed by 
a 1,3-allylic rearrangement catalyzed by cisaconitic decarboxylase, Figure 4.4.A) 
110 
(Bonnarmet et al., 1995; Bentley and Thiessen, 1957; Ranzi et al., 1981), then incubation 
of the cells with [
13
C5]glutamine should yield [
13
C4]ITA as the primary isotopologue from 
the first turn of the TCA cycle. This results from glutamine hydrolysis to glutamate 
followed by transamination and production of α-ketoglutarate, which then enters the TCA 
cycle. This would ultimately result in [
13
C4]cis-aconitate that is site-specifically 
decarboxylated to [
13
C4]ITA (Figure 4.4.B). [
13
C4]ITA is indeed the major isotopologue 
of itaconic acid present under these conditions (Figure 4.6). This pathway is further 
supported by the fact that we see vastly more 
13
C-label at the -CH2- position than the 
=CH2 position by 1D-gHSQC NMR. Incubation of cells with [
13
C6]glucose, with the 
same biosynthetic scheme, should generate [
13
C1]ITA resulting from the [
13
C2]acetyl 
CoA that enters the TCA cycle and is converted to cis-aconitate, with one of the labeled 
carbons site-specifically lost during the cis-aconitate decarboxylase reaction (Figure 
4.4.C).  
This 
13
C flux through pyruvate dehydrogenase (PDH) does indeed result in the major 
isotopologues observed by MS, although there is also appreciable flux through pyruvate 
carboxylase (PC) (Merle et al., 2002; Riazi et al., 2009).  PC generates [
13
C3]oxaloacetate 
that will ultimately result in the [
13
C4]ITA isotopologue (Figure 4.4.D).  
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Figure 4.4 ITA labeling schemes and isotopologues distribution in ITA, aconitate and citrate for the first 
turn of the TCA cycle in VM-M3 cells incubated for 12 h with [
13
C6]glucose. ITA labeling scheme from 
[
13
C5]glutamine ((A,)) and
 
[
13
C6]glucose (B and C) if the cADC pathway is active. [
13
C6]glucose enters 
glycolysis and results in 
13
C3-pyruvate, which can enter the TCA cycle as 
13
C2-acetyl CoA through solely 
PDH, or as 
13
C3-oxaloacetate resulting from PC flux. Isotopologues of ITA synthesized by this pathway 
should be predominantely 
13
C1 (PDH flux only, (B,)) or 
13
C4 (both PC and PDH flux, (C,)). (D) 
Comparison of isotopologues of ITA, citric acid and aconitate in VM-M3 cells after incubation with 
[
13
C6]glucose: isotopologues resulting from PDH flux (grey bars), or PC/PDH flux (hatched bars). 
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By comparing the percentage of total isotopologues of ITA resulting from PDH and 
PDH+PC flux ([
13
C1] and [
13
C4], respectively) to the percentage of total isotopologues of 
anticipated precursors citrate and aconitate from both PDH and PDH+PC fluxes ([
13
C2] 
and [
13
C5], respectively), we see that the three metabolites show comparable percentages 
from each flux. The isotope labeling data we have obtained (Figure 4.4.D) are thus fully 
consistent with a biosynthetic pathway in mammalian cells whereby ITA is synthesized 
via the specific decarboxylation of cis-aconitate from the TCA cycle. The NMR data, 
which show significantly higher 
13
C-labeling at the =CH2 resonances but still an 
appreciable amount of label at the -CH2- resonance in the 1D-gHSQC spectrum, further 
support this pathway. This route requires the presence of a mammalian homologue of 
fungal cis-aconitic decarboxylase (cADC) (Dwiarti et al., 2002; Kanamasa et al., 2008). 
 
4.4 Exclusion of Other Proposed Pathways 
Other pathways of ITA synthesis have been proposed, each of which would give rise to a 
distinct 
13
C-labeling pattern (Figure 4.5). Beyond the pathway described in the main text, 
which agrees with all of our collected data, the first inconsistent pathway (Figure 4.5.A) 
involves the successive condensation of three acetyl-CoA molecules to form propane-
1,2,3-tricarboxylate, which is then converted to cis-aconitate and finally decarboxylated 
to form ITA (Shimi et al., 1962). If this were the active pathway, we would expect to see 
predominately [
13
C5]ITA when the VM-M3 cells were incubated with [
13
C6]glucose. 
However [
13
C1]ITA is the predominant isotopologue observed. Additionally, this 
113 
pathway would not result in substantial [
13
C4]ITA from incubation with [
13
C5]glutamine, 
as occurs in cells. The pathway shown in Figure 4.5.B describes the synthesis of ITA via 
dehydration of citramalate (Jakubowska and Metodiewa, 1974), but this mechanism 
would not result in a significant percentage of [
13
C4]ITA after incubation with 
[
13
C5]glutamine since under these conditions, pyruvate is not labeled to any appreciable 
extent and only approximately 10% of the acetyl CoA is 
13
C2 (Figure 4.7). Both acetyl 
CoA ([
13
C2] from the acetate moiety and [
13
C7] from label both in the acetate and the 
ribose) and pyruvate are highly labeled by [
13
C6]glucose, and therefore we would expect 
to see mostly [
13
C5]ITA rather than [
13
C1]. We also have direct enzymatic evidence that 
crude cell lysates can synthesize ITA from cis-aconitate, which is consistent with 
itaconate synthesis from cis-aconitate, rather than from citramalate.   
Pathway 4.5.C is a variant of pathway 4.5.A, except that one acetyl CoA molecule 
condenses with succinate from the TCA cycle. Since succinate is a symmetric molecule, 
its condensation with acetyl CoA labeled from [
13
C6]glucose would result in propane-
1,2,3-tricarboxylate labeled with [
13
C2] at either the 1 or 3 position carboxylate group. 
After conversion to cis-aconitate, decarboxylation would occur and result in a 1:1 mix of 
[
13
C1] and [
13
C2]ITA, which is not what is observed in the MS analysis. When cells are 
incubated with [
13
C5]glutamine, we see primarily [
13
C4]succinate with limited formation 
of [
13
C2]acetyl CoA. This should result in a roughly 1:1 mix of [
13
C4] and [
13
C3] ITA, and 
instead we see vastly more [
13
C4]ITA (Figure 4.6). Thus, none of these alternative 
pathways are consistent with the distribution of 
13
C-labeling we see from either 
[
13
C6]glucose or [
13
C5]glutamine. 
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Pathway 4.5.D is a possible contributor to ITA biosynthesis from glutamine, and involves 
a reversal of the TCA cycle between α-ketoglutarate and citrate. This pathway has been 
observed in several mammalian cell types including brown adipose cells and rat liver 
(Yoo et al., 2008; Des Rosiers et al., 1995) and would also result in [
13
C4]ITA from 
[
13
C5]glutamine. While this pathway might be a minor contributor, if it were the major 
source of glutamine incorporation into ITA, we would expect to see equivalent labeling 
of both –CH2– and =CH2 positions in the 1D-gHSQC NMR spectrum, and significant 
amounts of [
13
C5]citrate in these extracts.  However, we see a comparatively small 
percentage of [
13
C5]citrate in extracts that were incubated with [
13
C5]glutamine, and in 
the 1D-gHSQC NMR spectra we see significantly more labeling at the –CH2– position as 
compared to the =CH2 resonance, which supports our hypothesis. The small amount of 
[
13
C5]citrate present indicates that this pathway is potentially active; however, it is not the 
major route of synthesis of citrate, aconitate, or ITA.    
 
Figure 4.5 Other possible ITA biosynthetic pathways and expected labeling patterns. 
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Figure 4.6 Percentages of isotopomers used to determine the ITA biosynthetic mechanism. For pyruvate 
(A), acetyl CoA (B), succinate (C) and itaconate (D), the percentages of unlabeled metabolite are shown in 
black. The labeled isotopologues include: 
13
C1 (green), 
13
C2/
13
C7 (blue), 
13
C3 (yellow), 
13
C4 (red), 
13
C5 
(grey) and 
13
C6/
13
C8/
13
C9 (purple). 
 
4.5 Crude Cell Lysates Display cis-Aconitic Decarboxylase Activity 
The decarboxylation reaction catalyzed by cADC is unique among carboxy-lyases.  
cADC is the only carboxy-lyase in the ExPASy ENZYME database that catalyzes a 
decarboxylation resulting in both the reduction of a β-γ unsaturation and the formation of 
a methylidene group α to the decarboxylation.  There are no identifiable mammalian 
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sequence homologues of the Aspergillus cADC protein in the NCBI gene database and 
no structures of the fungal protein to suggest key motifs that could aid in identifying any 
structural homologues. Hence, we used crude cell extracts to assess in vitro synthesis of 
ITA. Because the RAW 264.7 cells generated a large amount of ITA when stimulated 
with LPS, we used cell extracts of these to assess in vitro synthesis of ITA. Crude RAW 
264.7 cell lysates, prepared by Dounce homogenization in a hypotonic buffer, were 
incubated with 4 mM cis-aconitate for 3 h at 37°C. Metabolites were extracted, 
lyophilized, and examined by 
1
H NMR. There was a 40-fold increase in the intensity of 
the ITA 
1
H resonances compared to control extracts (Figure 4.7), made either without the 
addition of cis-aconitate or using a boiled cell extract to inactivate any enzyme(s). VM-
M3 lysates also generated significant amounts of ITA from cis-aconitate (Figure 4.8). 
Thus, macrophage-derived cells possess a highly unusual enzymatic activity previously 
observed only in a few fungi.  
4.6 Attempts at Characterization of the Subcellular Localization of cADC Activity 
In order to determine the subcellular localization of the mammalian cADC protein, a 
range of subcellular fractionation techniques were employed.  Initially, RAW 264.7 crude 
lysates were Dounce homogenized and then subjected to differential centrifugation at 
800xg followed by 14,000xg to remove the nuclei/unbroken cells and mitochondria, 
respectively.  When the cADC activities in the cytosolic, nuclear and mitochondrial 
fractions were compared, the activity was overwhelmingly found in the nuclear pellet.  
However, trypan blue staining indicated that the plasma membranes were still largely 
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attached to the nuclei, so large protein complexes and perhaps some organelles as well as 
membrane proteins could be trapped in the nuclear fraction.  When nuclei were isolated 
using the detergent NP-40 that solubilizes the plasma membrane but not the nuclear 
membrane, the activity was no longer found in the nuclear pellet but in the 
cytosolic/membrane/organelle fraction.  This indicates that the mammalian cADC 
initially was not in the nucleus but just trapped in the nuclear pellet. 
 
Figure 4.7 cis-aconitate decarboxylase (cADC) activity in RAW 264.7 crude cell lysates. Comparison of 
1
H spectra (600 MHz) of stimulated RAW 264.7 crude extracts incubated at 37
o
C in the presence (A) or 
absence (B) of 4 mM cis-aconitate for 3 h. The resonance at 5.67 ppm is residual cis-aconitate (c-A). 
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Figure 4.8 cis-aconitic decarboxylase (cADC) activity in VM-M3 crude cell lysates. Comparison of 
1
H 
spectra (600 MHz) of VM-M3 crude extracts incubated at 37
o
C in the absence or presence of 4 mM cis-
aconitate for 3 h. In (A) is shown the incubation using crude lysate with cis-aconitate; in (B) is shown a 
control extract without the addition of cis-aconitate. A large increase in the intensity of the itaconate peaks 
at 5.85 and 5.37 ppm (indicated by *) is observed. Residual cis-aconitate (c-A) is responsible for the 
resonance at 5.67 ppm. 
 
Since cADC activity is associated with the TCA cycle, it seemed highly possible that 
cADC was localized to the mitochondria.  Mitochondria were purified using the 
Qproteome Mitochondrial Isolation Kit, which first lyses the cells using a proprietary 
detergent in order to collect cytosolic proteins.  The lysed cells were then vigorously 
passed through a needle until >80% of nuclei were free from visibly attached membranes 
using a light microscope.  Nuclei were then separated using differential centrifugation, 
followed by pelleting of mitochondria leaving only a solution of membrane proteins.  
119 
Activity in all four fractions was assayed, but there were small amounts of activity 
present in each fraction making the results inconclusive.  The subcellular localization of 
cADC in mammalian cells has not at this point been conclusively identified. 
4.7 Treatment of Crude Lysates with Iodoacetamide Does Not Attenuate cADC 
Activity 
To determine whether mammalian cADC has an active site cysteine residue, crude 
lysates of 3x10
6
 RAW 264.7 cells were incubated for 30 minutes at room temperatures 
with concentrations of the cysteine reactive iodoacetamide alkyne probe N-(hex-5-ynyl)-
2-iodoacetamide (Weerapana et al., 2010) of up to 500 μM prior to incubation with cis-
aconitate.  However, even at the highest concentration tested, the decrease in cADC 
activity was less than 10% and could be attributed to experimental error.  The 
mammalian cADC protein therefore does not appear to have a cysteine residue that is 
critical for its activity. 
4.8 Discussion 
Although ITA can be used to form synthetic polymers, that is unlikely to be its biological 
function. What is the purpose of the synthesis and excretion of this novel metabolite? 
ITA has been shown to be a potent inhibitor of isocitrate lyase (McFadden and Purohit, 
1977; Williams et al., 1971), an enzyme of the glyoxylate cycle found in bacteria, so its 
secretion could be part of an antibacterial response. However, ITA has also been shown 
to inhibit phosphofructokinase
 
(Sakai et al., 2004) and, thus, could potentially be 
involved in regulation of metabolism. It is also possible that ITA acts as a signaling 
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molecule involved in recruitment or regulation of other cells. That ITA levels in cells and 
culture supernatant significantly increase in response to IFN-γ and LPS points to a 
potential role in macrophage activation and/or macrophage effector responses. 
Macrophages are currently known to secrete over 100 substances of various molecular 
weights that are involved in inflammatory cell activation, proliferation, and effector cell 
migration (Laskin and Pendino, 1995). Interestingly, RAW 264.7 conditioned medium 
has been shown to induce migration and metastasis in colon cancer cells, due at least 
partially to secretion of chemokines (Green et al., 2008). That the ITA metabolite was 
first noticed in a metastatic tumor cell line hints that it may also have a role in tumor 
biology.  Observation of this novel metabolite opens up an array of future studies to 
determine its physiological function, including in the mammalian immune system and in 
cancer. 
 
Much of this work has previously been published (Strelko et al., 2011). 
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Chapter 5: 
Investigation into the Binding of Phospholipid  
Ligands to the Akt1 Pleckstrin Homology Domain   
122 
5.1 Introduction  
The PI3K-Akt signaling pathway is frequently upregulated in a number of cancers 
(Hennessey et al., 2005; Vivanco and Sawyers, 2002).  Constitutive activation of this 
pathway results in prevention of apoptosis and increased proliferation of tumor cells 
(Datta et al., 1997; Cardone et al., 1998).  Akt, the Ser/Thr kinase central to this pathway, 
is activated in response to the binding of PI(3,4)P2 or PI(3,4,5)P3 to its Class III PH 
domain and is translocated from the cytosol to the plasma membrane, where it can be 
phosphorylated at Thr308 and Ser 473 (Frech et al., 1997; James et al., 1996; Downward, 
1998; Bellacosa et al., 1998).  Attempts at characterizing the binding of PIPs have 
involved crystallization of the Akt1 PH domain with and without inositol 1,3,4,5-
tetrakisphosphate (IP4) , a soluble PI(3,4,5)P3 headgroup analogue (Thomas et al., 2002).  
That study indicated that IP4, and analogously PI(3,4,5)P3, bind to a cationic binding 
pocket at the open end of the PH domain β-barrel (Figure 5.1); furthermore, this binding 
induces a conformational change (Thomas et al., 2002).  A number of basic residues in 
this lipid binding site stabilize the negatively charged phosphate groups including Arg86, 
which forms hydrogen bonds with the 4-phosphate, Lys14 and Asn52 which interact with 
both the 3- and 4-phosphates and Arg23, which makes contact with the 1- and 3- 
phosphates (Thomas et al., 2002). 
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Figure 5.1 Crystal structure (PDB 1UNQ) of the Akt1 PH domain with IP4 bound.  Amino acids in the 
cationic binding pocket that make contacts with the IP4 phosphate groups (orange and red) are highlighted 
in blue.  Cysteine residues (Cys 60 and 77) are shown in pink. 
 
Phosphatidylinositol analogs, or PIAs, are molecules designed to bind competitively to 
the Akt PH domain and prevent membrane translocation and subsequent activation (Gills 
and Dennis, 2004; Cheng et al., 2005).  D-3-deoxy diC8PI is a novel PIA that was found 
to be cytotoxic in the U937 human lymphoma line by the Chiles and Roberts laboratories 
(Wang et al., 2008).  This original study showed that D-3-deoxy diC8PI decreased 
phosphorylation at Akt1 (Ser473) and of the transcription factor eIF4e (Ser209) 
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compared to cells treated with the inactive analog L-3-deoxy diC8PI.  It was suggested 
that D-3-deoxy diC8PI mediated its cytotoxicity by targeting Akt1 in vitro, whether by 
binding to the PH domain or via some other mechanism (Wang et al., 2008).  
Interestingly, phosphorylation at Thr308 of Akt1 was unaltered between treatment with 
the inactive analogue and D-3-deoxy diC8PI; this hinted that perhaps the classical PIA 
mechanism was not responsible for cytotoxicity in these cells.  However, these data are 
far from adequate to unequivocally prove this hypothesis.  The set of immunoblots 
presented in that work is missing a control of U937 cells without any treatment, and 
eIF4e is not a direct target of Akt so it is not a very good measure of Akt pathway 
activation.   
To determine the mechanism by which D-3-deoxy diC8PI kills cells, it was first important 
to test the hypothesis that it can bind to the Akt1 PH domain which in turn prevents 
membrane translocation and activation.  The ability of the PH domain to bind D-3-deoxy 
diC8PI is critical to this theory, and therefore I sought to establish a biophysical method 
by which I could measure phospholipid binding to this protein.  A number of techniques 
have been used to monitor the binding of phosphatidylinositols and suspected small 
molecule inhibitors of the PH domain including surface plasmon resonance (Meuillet et 
al., 2010; Moses et al., 2009), incubation of agarose-like PIPs with the PH domain 
followed by SDS/PAGE and immunoblotting (Hu et al., 2005), competitive ELISAs 
(Mahadevan et al., 2008) and intrinsic fluorescence (Frech et al., 1997; Landgraf et al., 
2008).   
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In this chapter I present a new method to examine the binding of PIPs and PIAs to the 
Akt PH domain: high resolution field-cycling 
31
P NMR spectrometry.  This technique is 
rooted in NMR relaxation theory, and explores the dynamics of 
31
P atoms of 
phospholipids in response to protein binding.  Changes in these dynamics can be 
enhanced by modifying cysteines on the protein with one or more spin labels near the 
anticipated binding site.  A spin label will differentially relax ligands depending on how 
closely they bind, and this information can be used to calculate the approximate location 
of the ligand binding site.  This is particularly useful for identifying novel lipid binding 
sites on a protein.  Using this method, I was able to monitor the binding of the compound 
of interest, D-3-deoxy diC8PI, and a number of other small molecules of biological 
interest, to the Akt1 PH domain.  While D-3-deoxy diC8PI can bind to the PH domain, its 
inactive analogue L-3,  5-dideoxy diC8PI can also bind in the same site, which is distinct 
from the site occupied by the natural ligand diC8PI(3,4,5)P3.  It is also apparent that the 
binding of the PH domain to highly anionic soluble ligands such as IP6 causes protein 
aggregation, which may have physiological relevance.  While this method has its 
drawbacks, the use of high-resolution field-cycling 
31
P has eliminated the mechanism that 
D-3-deoxy diC8PI exerts its cytotoxic effects by binding to the Akt1 PH domain in place 
of a PIP3 molecule and preventing membrane translocation.   
5.2 Expression and Modification of the Akt1 PH Domain. 
Early fluorescence studies were performed using a PH domain protein overexpressed 
from a PH-GST construct obtained from Dr. Boguslaw Stec, The Burnham Institute.  
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This PH-GST fusion protein was purified using GST-binding resin prior to thrombin 
cleavage and a final purification step through an anion-exchange column (see Chapter 2).  
However, the PH-GST plasmid was a gift without any sequence or vector information.  In 
order to work with a clone with complete sequence information, I re-cloned the PH 
domain (residues 1-131) from human Akt1 cDNA into the pET28(a) vector, and 
overexpressed it to make an N-terminal HIS6-PH fusion protein.  This was purified by 
metal affinity and anion exchange chromatographies (see Chapter 2).  The CD spectrum 
of the recombinant PH domain indicates that it is well folded (Figure 5.2).   
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Figure 5.2 CD spectrum of 0.13 mg/mL recombinant Akt1 HIS6-PH Domain in 11.76 mM phosphate 
buffer at 25°C.  Number of scans = 6.  The spectrum indicates that the protein is well-folded and largely β-
sheet in character. 
 
For high resolution 
31
P NMR experiments, the cysteines (Cys 60 and 77) of the PH 
domain were modified with the spin label reagent S-(2,2,5,5-tetramethyl-2,5-dihydro-1H-
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pyrrol-3-yl)methyl methanesulfonothioate (MTSL).  Briefly, the cysteines were fully 
reduced with DTT, then allowed to react with a ten-fold excess of MTSL at room 
temperature (Figure 5.3).  Excess MTSL was removed using a spin column.  The 
sulfhydryl groups of these cysteines are located 6.7 Å apart from one another, and 
between between 9.8 – 16.4 Å (Cys77) and 15.9 – 22.1 Å (Cys60) from the phosphate 
groups of IP4 bound to the PH domain in the crystal structure 1UNQ (Figure 5.1).  By 
modifying these cysteines with MTSL, which has an unpaired electron, the relaxation rate 
of any 
31
P atoms bound nearby will be greatly increased.  
 
Figure 5.3 Reaction of the spin-label reagent MTSL with the sulfhydryl groups of cysteine residues. 
 
5.3 Intrinsic Fluorescence Spectroscopy 
I first attempted to monitor the binding of the PH domain using intrinsic tryptophan 
fluorescence, as there is precedent in the literature (Landgraf et al., 2008).  It was very 
strange that Landgraf chose to use λexcitation=284 nm and λemission=322 nm, because for 
intrinsic tryptophan fluorescence, tryptophan fluorescence is usually monitored at λemission 
= 340-350 nm.  It was also curious that they were monitoring an increase in Trp 
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fluorescence, where when I tried to reproduce their work, I found that titration of ligands 
or their vehicles resulted in quenching of the Trp emission peak (~ 345 nm).   
 
Figure 5.4 Sample titration of 0.5 µM Akt1 PH domain with IP6.  When λexcitation=284 nm, an emission 
maximum is visible at 345 nm.  Titration with 100 mM IP6 , as well as titration with 25 mM Hepes binding 
buffer or ethanol, causes a decrease in this emission peak.  No shoulder is visible at 322 nm. 
 
When contacted about their choice of wavelength, the authors of this study reported that 
they did in fact see quenching of the large Trp peak at around 345 nm (personal 
communication, Prof. Joseph Falke, University of Colorado).  However, they specifically 
chose λemission=322 because emission at this wavelength was unaffected by the addition of 
buffer as a control and the main peak showed quenching even with the addition of only 
buffer.  They believe that a Trp that is significantly blue shifted during the binding of IP6 
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(their weakly binding ligand) causes this increase in fluorescence at 322 nm, and that 
they needed to use this wavelength because salts in their buffer were causing non-specific 
effects on the Trp emission which was causing the quenching at higher wavelengths.  I, 
however, never observed an increase at this wavelength when titrating any ligand.  It is 
likely that any fluorescence changes observed at 322 nm by Landgraf is due to an 
apparent increase in the Raman band of water rather than lipid binding.  Pure water and 
water-based solutions that are excited with light exhibit a peak in the fluorescence 
spectrum resulting from nonelastic light scattering (Lawaetz and Stedmon, 2009).  This 
peak is known as the Raman band, and varies with the wavelength of light used for 
excitation.  For excitation at a wavelength of 284 nm, a water Raman scattering band 
should be observed at roughly 320 nm (Lawaetz and Stedmon, 2009), which is consistent 
with the shoulder observed at 322 nm by the Falke group. 
While I used the same experimental conditions as Landgraf and colleagues, I was unable 
to get reproducible data.  I tested primarily the effects of IP6 in attempt to reproduce the 
data presented in the literature, but also titrated other molecules of interest including the 
alkylphospholipids perifosine and miltefosine and the natural ligand diC8PI(3,4,5)P3 and 
was unable to get consistent results.  I even had difficulty reproducing photobleaching 
and vehicle controls between experiments.  I experimented using different pH values, 
buffers, reducing agents and metal chelators but nothing was successful.  An example of 
the inconsistency between replicates is shown in Figure 5.5 for miltefosine titrated into a 
solution containing the PH domain. The variation in initial fluorescence intensity as well 
as ligand concentration dependence varied making any estimate of a Kd problematic.    
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Figure 5.5 Changes in intrinsic fluorescence emission of the Akt1 PH domain due to titration with 10 mM 
miltefosine at 345 nm.  Closed circles indicate titration in the presence of EDTA, while the open circles and 
squares represent two replicates of titration in the presence of 0.5 mM Mg
2+
.  Titration was performed in 25 
mM Hepes pH=7.4, 140 mM KCl, 15 mM NaCl.  Note the significant variation in initial fluorescence 
intensity and in the slope of the curve between runs.  λexcitation=284 nm. 
 
I eventually noticed that the quenching of fluorescence at higher wavelengths seemed to 
increase depending on whether or not I agitated the sample in between scans.  To test this 
theory, I performed an experiment where I alternated between leaving the sample cuvette 
untouched and vigorously inverting it between measurements (Figure 5.6).  These data 
make it very clear that agitation induces apparent quenching of Trp fluorescence in the 
Akt1 PH domain, which makes intrinsic fluorescence a very poor method to measure 
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lipid binding to this particular protein.  It is likely that this decrease in Trp fluorescence is 
a result of self-quenching due to aggregation of the PH domain, either from increased 
protein-protein contact during the agitation itself or incorporation of oxygen into the 
sample during the agitation.  However, such behavior could also represent protein 
unfolding at the air/H2O interface (although no changes in the CD spectrum were 
observed between samples that were not agitated and those that were vigorously mixed).  
These changes would provide a more plausible explanation to the decrease in 
fluorescence in response to vehicle addition observed by the Falke group, in contrast to 
their proposal of non-specific salt effects.   
 
Figure 5.6 Vigorously inverting the sample containing the Akt1 PH domain (closed circles) prior to 
intrinsic tryptophan fluorescence measurement at 345 nm results in quenching of the signal as compared to 
no sample manipulation (open circles).   
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Ultimately, the result of my fluorescence studies was that I could not use intrinsic 
fluorescence to measure binding of the recombinant PH domain to different amphiphiles. 
Another technique was needed to compare the binding of different ligands to the Akt PH 
domain 
5.4 Assessment of Lipid Binding By High-Resolution Field Cycling 
31
P NMR 
Spectrometry – Phosphorylated Inositols 
Given the difficulties with using intrinsic fluorescence to measure the binding of 
phospholipids to the PH domain, we opted to use high resolution field-cycling 
31
P NMR.  
As a positive control, we looked at the field-cycling profiles for a natural ligand of the 
PH domain (diC8PI(3,4,5)P3), as well as its soluble headgroup IP4, and IP6 which has 
been shown to bind weakly to the PH domain by fluorescence spectroscopy (Landgraf et 
al., 2008).  The short dioctanoyl acyl chains of diC8PI(3,4,5)P3 will cause this ligand to 
form small micelles at the millimolar concentrations necessary for field cycling NMR.  
Figure 5.7 shows the field dependence profile for diC8PI(3,4,5)P3.  A clear increase in the 
spin lattice relaxation rate R1 due to binding to the spin labeled PH domain is observed 
for the phosphodiester resonance, and to a lesser extent for the phosphomonoesters.  
These changes in rate are significantly increased when compared to the rates obtained 
from incubation of diC8PI(3,4,5)P3 and the unlabeled Akt1 PH domain.  
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Figure 5.7 Variation of R1, the spin-lattice relaxation rate, with magnetic field for 
31
P in diC8PI(3,4,5)P3.  
The sample was 3 mM diC8PI(3,4,5)P3 with 0.6 mg/ml (34.2 M) Akt1-PH-SL in 20 mM Hepes pH 7.4, 
125 mM NaCl, 1 mM EDTA with 30% D2O.  
 
In Figure 5.7, phosphomonoester resonances a, b, and c correspond to P(5), P(4), and 
P(3), respectively; PDE is the phosphodiester group. In the absence of spin-labeled 
protein R1 is constant for each resonance below 0.5T (0.3 s
-1
 for the phosphomonoesters 
and 0.4 s
-1
 for the PDE). The arrows provide a visual estimate of RP-e(0) for each of the 
resonances.  Phosphorus resonance identities are based on the work of Lu and Chen, 
1997. The key parameters obtained from this plot include RP-e(0), the relaxation rate 
extrapolated to low field and P-e, the correlation time for that dispersion. Values for each 
of the phosphorus resonances are shown in Table 5.1. 
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Table 5.1 Parameters Extracted from High Resolution Field-Cycling 
31
P NMR Data for 
diC8PI(3,4,5)P3 and IP6  
Ligand (mM) P-e (ns) RP-e(0) (s
-1
) P-e/RP-e(0) x10
8
 r/rPDE 
a 
diC8PI(3,4,5)P3 (2):     
     P-3   130 0.48±0.05 27 1.22 
     P-4  130±49 0.32±0.06 40 1.30 
     P-5  130 0.71±0.13 18 1.14 
     PDE 134±41 1.62±0.26 8.3 1.00 
     
IP6 + EDTA (5) :     
     P-1/P-3 217±52 0.21±0.02 59 1.39 
     P-2 133±60 0.23±0.04 132 1.58 
     P-4/P-6 206±45 0.17±0.01 123 1.57 
     P-5 314±156 0.24±0.06 105 1.53 
     
IP6 + Mg
2+ 
(5) :     
     P-a (P-2) 318±153 0.21±0.04 154 1.63 
     P-b (other P) 108±35 0.18±0.02 61 1.39 
     P-c (1,3?) 204±81 0.24±0.04 85 1.47 
a
 The relative distances for the different 
31
P are compared to the r that represents the PDE of 
diC8PI(3,4,5)P3. 
 
The ratio of P-e/RP-e(0) for each phosphorus nucleus in diC8PI(3,4,5)P3 yields some 
intriguing information (Table 5.1).  According to the crystal structure of the PH domain 
in complex with IP4, the 
31
P participating in the phosphodiester bond (the 1-phosphate) is 
located farther away from both the spin labels then the 3, 4 and 5 phosphate groups.  
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However according to our data, the phosphodiester phosphorus binds significantly closer 
to the spin label(s) than the phosphomonoesters.  This indicates that the alkyl chains play 
a significant role in the binding of natural ligands to the cationic binding site.  The 
importance of the alkyl chains in PIP3 binding is further evident in the data obtained from 
the field dependence of 3.7 mM IP4, the soluble headgroup (Figure 5.8).  There is no 
appreciable increase in R1 in any of the phosphorus nuclei in IP4, in stark contrast to 
diC8PI(3,4,5)P3.  It is likely that the presence of micelles is required to stabilize the 
phosphatidylinositol – PH domain complex. 
 
Figure 5.8 Field dependence of 
31
P R1 for the three resonances of IP4 (3.4 mM) in the presence of 0.6 
mg/ml Akt-PH-SL. 
IP6 is not a headgroup analog, but has been reported to bind weakly to the cationic 
binding site of the PH domain.  The field-dependency of IP6 bound to the spin-labeled PH 
domain (Figure 5.9) does indeed indicate a very slight increase in R1 in all of the 
136 
phosphate resonances.  This increase is much smaller than that seen with the natural 
ligand diC8PI(3,4,5)P3.  The average correlation time for the IP6- PH domain complex, 
218±74 ns, is much larger than would be expected for a soluble small molecule binding 
to a small protein like the PH domain.  This indicates that IP6 binding causes aggregation 
of the PH domain.  
 
Figure 5.9 Field dependence of 
31
P R1 for the four resonances of IP6 (3 mM) in the presence of 0.6 mg/ml 
Akt-PH-SL. The inset shows the change in R1 due to the spin-label as a function of field. 
 
Because Mg
2+ 
is often included in the buffers for binding experiments with the PH 
domain, we repeated this experiment with MgCl2 instead of the EDTA typically used.  
Mg
2+
 alters the IP6 chemical shifts and causes overlap of two of the four resonances, 
which made them difficult to definitively identify.  Despite these changes, the calculated 
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RP-e(0) values are similar with and without Mg
2+
 and the τP-e values are similar despite the 
significant errors (Table 5.1).  The average P-e/RP-e(0) ratio, which is related to the 
distance between the 
31
P nuclei and the spin labels (r
-6
) , is consistent with or without 
Mg
2+
.   
Additionally, the ratio of P-e/RP-e(0) of IP6 is much larger compared to that of 
diC8PI(3,4,5)P3 (Table 5.1).  There are multiple possible explanations for this, but based 
on the evidence from the IP4 experiments, it is likely that the orientation of soluble head 
groups (like IP4 and IP6) in the cationic binding pocket is different from that of the 
phospholipids like diC8PI(3,4,5)P3.   However, it is also possible that IP6 induced 
aggregation is short lived (less than 100 ns), which would decrease the relaxation effects 
from the spin label at the low fields.  Another interaction that might reduce the 
31
P 
relaxation in these aggregates, is that a PH domain that is bound to IP6 may complex and 
aggregate a number of other PH domains that may not be bound to IP6.  In this scenario, 
the actual concentration of protein with IP6 would be far less than initially calculated, 
which would explain the lesser increase in relaxation rates.  At this point, it is difficult to 
determine which mechanism(s) are responsible for the dissimilarities between P-e/RP-e(0), 
although IP6 is so highly negatively charged that it is unlikely to bind anywhere other 
than the cationic binding pocket which makes other mechanisms more likely. 
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5.5 Binding of Cytotoxic Alkylphospholipids 
The alkylphospholipids miltefosine (hexadecylphosphocholine) and perifosine 
(octadecyl-(1,1-dimethyl-4-piperidylio) phosphate) are cytotoxic to a number of tumor 
cell lines (Kondapenka et al., 2003; Ruiter et al., 2003).  There is evidence that these 
phospholipids exert their effects by inhibiting Akt activation, potentially by binding to 
the PH domain (Gills and Dennis, 2009).  To determine whether this was a plausible 
mechanism, field cycling was used to explore whether these drugs are capable of binding 
to the PH domain, and if they occupy the same binding site as the natural ligand 
diC8PI(3,4,5)P3.   
 
Figure 5.10 Structures of potential Akt1 PH domain ligands. 
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The field dependence profile of miltefosine showed a small increase in relaxation rates at 
all fields when 5 mM miltefosine was incubated with 0.6 mg/mL unlabeled PH domain as 
compared to by itself (3 mM) (Figure 5.11).  There was no significant change in the 
correlation time (20±7 ns for the lipid alone and 21±3 ns when the protein is added), 
which is consistent with relaxation of the 
31
P nucleus by the side chains of the protein by 
a dipolar mechanism (Table 5.2).  Additional evidence that miltefosine is binding to the 
protein is also visible in the shift of the dispersion above 4T to lower fields in the 
presence of protein – this is due to a retardation of fast (<100 ps) motions of miltefosine 
by the PH domain.  The field dependence profile of miltefosine and the unlabeled PH 
domain serves as useful control for the samples involving spin-labeled PH domain. 
 
Figure 5.11 Comparison of the field dependence of 
31
P R1 for miltefosine (5 mM) in the presence of 0.6 
mg/ml unlabeled Akt-PH (open circles) and for miltefosine (3 mM) alone (closed triangles). 
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When miltefosine is incubated with spin-labeled PH domain, there is a much more 
significant increase in R1 at low fields than with the unlabeled protein (Figure 5.12).  The 
unlabeled PH domain / miltefosine control can be subtracted from this field dependence 
profile, allowing us to evaluate purely the effects of the spin label on 
31
P relaxation in 
miltefosine.  It is clear that miltefosine is binding in a very different site than the natural 
ligand diC8PI(3,4,5)P3 as the P-e/RP-e(0) ratio is much smaller for the phosphodiester 
resonance in miltefosine than in diC8PI(3,4,5)P3.  This indicates that miltefosine is 
binding much closer to a spin label than diC8PI(3,4,5)P3.   
 
Figure 5.12  (A) Field dependence of miltefosine (5 mM) 
31
P R1 in the presence of unlabeled (open circles) 
or spin-labeled (closed circles) Akt1-PH (0.6 mg/ml).  (B) Contribution to 
31
P R1 due to the spin-labels on 
the PH domain. 
 
To confirm this, we analyzed the field dependence of miltefosine in the presence of both 
IP6 and the spin-labeled PH domain.  The extracted P-e and RP-e(0) for miltefosine were 
not changed by the addition of IP6, which indicates that IP6 does not compete for binding 
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to the miltefosine site.  However, the IP6 field dependence profile was very much affected 
by co-incubation with miltefosine (Figure 5.13); on its own, the spin-labeled PH domain 
causes a small but reproducible increase in R1 at low fields, but in the presence of 
miltefosine, there is essentially no visible increase in R1.  The much smaller correlation 
time for the miltefosine / spin-labeled PH domain complex indicates that the protein is 
not aggregating (at least to the same extent) under these conditions. It is likely that this 
decrease in P-e from that of IP6 / spin-labeled PH complex makes it difficult to observe 
any effect on R1 at lower fields.  
 
Figure 5.13 Effect of spin-labeled 0.6 mg/mL PH domain on the field dependence profile of 5 mM IP6 in 
the presence of 5 mM miltefosine. 
 
Perifosine is an alkylphospholipid that has been shown to be toxic to tumor cells and is 
currently in clinical trials.  The alkyl chains in this compound are longer than miltefosine 
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or diC8PI(3,4,5)P3, so it is likely that it forms significantly larger micelles.  The field 
dependence profiles for 5 mM perifosine and 0.6 mg/mL unlabeled or spin-labeled PH 
domain follow similar trends to what was observed for miltefosine.  The spin labeled 
protein results in a much larger increase in R1 in perifosine compared to miltefosine, and 
the correlation time is also longer, which is likely because of the larger micelle size 
(Figure 5.14, Table 5.2).  There also appear to be two distinct dispersions at high and low 
fields, which can be fit with a correlation time in the 10‟s of nanoseconds and one in the 
ns range. 
 
Figure 5.14 (A) Field dependence for the perifosine (5 mM) phosphodiester in the presence of 0.6 mg/ml 
Akt1-PH-SL (closed circle) compared to the control where the protein is not spin labeled (- - - ). (B) 
Increase in R1 due to the spin-labeled protein with the fit using a single correlation time for the 
31
P-e 
complex and a high field constant CSA contribution. (C) Increase in R1 due to the spin-labeled protein with 
the fit using two correlation times, in the ns region and the other 10‟s of ns. 
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The ratio of P-e/RP-e(0) for the perifosine 
31
P (between 1.5 and 2 x10
-8
) is about a factor 
of two larger than for miltefosine (~ 0.9 x 10
-8
) which implies a slightly different binding 
location or different dynamics between the two alkylphospholipids.  The P-e of perifosine 
is slightly longer (Table 5.2). If the complexes between each alkylphospholipid and the 
PH domain have about the same lifetime and it is shorter or comparable to the P-e of 
perifosine, we may be underestimating the proximity of the 
31
P since some of the effect 
of the spin-label on the 
31
P will have decayed away during the experiment for the larger 
complex.  If instead the different ratios of P-e/RP-e(0) are truly an indicator of different 
distances from the spin label, than the perifosine 
31
P binds 10% further from the spin-
labels than the miltefosine 
31
P.  Perifosine and miltefosine head groups are slightly 
different, and if the protein is primarily anchored to the protein by the alkyl chains this 
might occur. Although this cannot be conclusively be determined from this data, it is 
clear that these alkylphospholipids can bind to the PH domain and bind in a very different 
way than the natural ligand diC8PI(3,4,5)P3. 
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Table 5.2 Parameters Extracted from High Resolution Field-Cycling 
31
P NMR Data for 
Alkylphospholipids and Phosphatidylinositol Analogs 
Ligand (mM) P-e (ns) RP-e(0) (s
-1
) P-e/RP-e(0) x10
8
 
miltefosine (5) 13.1±1.4 1.42±0.06 0.92 
miltefosine (5) + IP6 (5) 12.4±2.5 1.32±0.12 0.94 
    
perifosine (3) 
     single  
     two :   slow  
                  fast  
 
67±25 
75±21 
1.9±0.6 
 
4.26±0.63 
3.86±0.45 
1.14±0.45 
 
1.56 
1.95 
 
    
diC7PC (5) 
     single  
     two :   slow  
                  fast  
 
 
72±13 
88±12 
5.2±3.6 
 
0.82±0.08 
0.71±0.05 
0.11±0.05 
 
8.7 
12.3 
4.9 
D-3-deoxy diC8PI (3) 38±3 6.16±0.23 0.62 
L-3,5-dideoxy diC8PI (2) 29±5 4.62±0.66 0.62 
    
diC8PI(3,4,5)P3 (3.7) 134±41 1.62±0.26 8.3 
 
 
In order to determine if the putative alkylphospholipid binding site is generic for 
amphiphiles, we examined the effect of the spin-labeled PH domain on the field 
dependence profile of diheptanoylphosphatidylcholine (diC7PC).  There is a relatively 
small but clear effect of the spin labeled PH domain on R1 compared to the unlabeled 
protein (Figure 5.15).  Fitting this field dependence curve, similar to that of perifosine, 
can be done with either one or two P-e parameters (the latter improving the fit) – but 
from the ratio of P-e/RP-e(0) it is clear that diC7PC binds more like diC8PI(3,4,5)P3 than 
the alkylphospholipids (Table 5.2).  While it is possible that diC7PC could bind to the 
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putative generic amphiphilic site occupied by the alkylphospholipids, it is certainly not 
saturating that site as P-e/RP-e(0) is much larger than for the alkylphospholipids with the 
observed RP-e(0).  It is also possible that while diC7PC can occupy this site, the lifetime of 
this protein-lipid complex is sufficiently shorter that we lose some of the relaxation effect 
of the spin-label. This would cause us to underestimate the effectiveness of the spin label 
in our calculation of P-e/RP-e(0). 
 
Figure 5.15 (A) Field dependence for the diC7PC (5 mM) phosphodiester in the presence of 0.6 mg/ml 
Akt1-PH-SL (closed circles) compared to the control where the protein is not spin labeled (open circles). 
(B) Increase in R1 due to the spin-labeled protein with the fit using a single correlation time for the 
31
P-e 
complex and a high field constant CSA contribution. (C) Increase in R1 due to the spin-labeled protein with 
the fit using two correlation times, in the ns region and the other 10‟s of ns. 
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5.6 Binding of Phosphatidylinositol Analogs 
Prior work has shown that D-3-deoxy diC8PI is cytotoxic to the U937 human lymphoma 
cell line, while the structurally similar L-3,5-dideoxy diC8PI is not cytotoxic at 
concentrations below its CMC (Wang et al., 2008).  At concentrations above the CMC, 
micellar L-3,5-dideoxy diC8PI will non-specifically perturb the cell membrane (and 
potentially solubilize it) and make it leaky.  Both of these compounds were designed to 
mimic the natural PIP ligands that bind to the Akt PH domain, and inhibit the activation 
of Akt.  L-3,5-dideoxy diC8PI was selected as the inactive analogue for this study 
because it has a similar affinity for PTEN as D-3-deoxy diC8PI.  Thus far, our results 
indicate that there are at least two discrete binding sites on the Akt1 PH domain.  If the 
cytotoxicity of D-3-deoxy diC8PI is indeed related to its ability to bind to this protein, we 
should see a difference in the binding between D-3-deoxy-diC8PI and the inactive 
analogue L-3,5-deoxy-diC8PI using field-cycling 
31
P NMR.   
The micelles formed by these two lipids are smaller than those formed by diC7PC and the 
alkylphospholipids, which is indicated by the relative lack of increase in R1 at low fields 
in the individual field dependence profiles of each compound.  When the profile of each 
PIA with the spin-labeled Akt1 PH domain is compared, both D-3-deoxy diC8PI and L-
3,5-dideoxy diC8PI profiles are very similar and the extracted ratios of P-e/RP-e(0) are 
identical and quite small (Figure 5.16).  This strongly indicates that the cytotoxic 
compound and its inactive analogue both bind to the same site on the spin labeled PH 
domain, and that this site is comparatively close to one or both of the spin labels.  The 
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magnitude of P-e/RP-e(0) of the PIAs is not identical to miltefosine or perifosine; 
however, if the difference in concentration between D-3-deoxy diC8PI (3 mM) and 
miltefosine (5 mM) are taken into consideration, the ratio of P-e/RP-e(0) for these two 
compounds should be 3/5.  This is very close to the observed values
 
Figure 5.16 (A) Field dependence of 
31
P R1 for 3 mM of D-3-deoxy diC8PI (closed circle) or L-3,5-
dideoxy diC8PI (open circles) in the presence of 0.6 mg/ml Akt1-PH-SL compared to the control for either 
short-chain PI alone (x). (B) Field dependence of R1 due to spin-labeled protein. Note the two PIAs have 
the same profiles, implying they are binding to the same site. Yet D-3-deoxy diC8PI is cytotoxic while L-
3,5-dideoxy diC8PI is not. 
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Therefore D-3-deoxy diC8PI, L-3,5-dideoxy diC8PI and the alkylphospholipids bind to a 
different site on the PH domain than the natural ligand diC8PI(3,4,5)P3. Assuming that 
the soluble headgroups (IP6 and I(1,3,4,5)P4) bind to the PIP3 site, they are not saturating 
it at the ligand and protein concentrations and buffer conditions used in these 
experiments. 
5.6 Discussion 
We have successfully used high resolution field-cycling 
31
P NMR spectrometry to 
characterize the binding of the spin-labeled Akt1-PH domain to its natural ligand, as well 
as cytotoxic phospholipids that could potentially bind to this protein as part of their 
mechanism of cytotoxicity.  We have determined that the acyl chains of the natural ligand 
diC8PI(3,4,5)P3 play a significant role in binding, and that the headgroup of this ligand 
may be oriented differently than suggested by the crystal structure of the Akt1 PH 
domain with the soluble headgroup analog IP4 bound (PDB 1UNQ).  Our data also show 
that IP6, which has been used as a weak binding ligand to the PH domain (Landgraf et al., 
2008) causes aggregation of this protein as evidenced by an uncharacteristically large 
correlation time of the IP6- SL-PH domain complex.  It is possible that aggregation of the 
protein has a physiological role in vivo. However, this behavior was only observed with 
IP6 as a ligand.  No binding of IP4, the soluble headgroup of diC8PI(3,4,5)P3 was 
observed – this may be because without the acyl chains, the lifetime of the headgroup – 
spin labeled PH domain complex is extremely short or the headgroup simply cannot bind 
on its own in the absence of acyl chains. 
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D-3-deoxy diC8PI and its inactive analogue L-3,5-dideoxy diC8PI can both bind to the 
PH domain in the same site, which is distinct from the cationic binding pocket occupied 
by the natural ligand.  This strongly argues against the classical mechanism of PIA 
cytotoxicity for D-3-deoxy diC8PI, wherein it exerts its effects by competitively binding 
to the Akt PH domain and preventing the binding of the natural ligand and subsequent 
translocation and activation.  The lifetime of each spin-labeled PH domain / lipid 
complex must be reasonably long or we could not detect enhancement of R1 at low fields  
However due to the high concentrations of ligand necessary to acquire an NMR signal, 
we cannot extract any additional information about binding constants.  It is possible that 
D-3-deoxy diC8PI and L-3,5-dideoxy diC8PI do not bind to the PH domain with exactly 
the same affinity; however even under such circumstances, it is still unlikely that the 
ability of D-3-deoxy diC8PI to bind to this protein is responsible for its cytotoxicity.  
Therefore a more thorough, cell-based investigation of the effects of D-3-deoxy diC8PI 
will be required in order to establish its actual mechanism of cytotoxicity in mammalian 
cells.   
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Chapter 6: 
Investigation into the Mechanism of Cytotoxicity of  
D-3-deoxy diC8PI in the MCF-7 Tumor Cell Line 
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6.1 Introduction 
In Chapter 5, I discussed the prior study of the Roberts and Chiles laboratories to 
determine the mechanism of action of D-3-deoxy diC8PI in cells (Wang et al., 2008).  
Using biophysical methods, I have presented evidence that D-3-deoxy diC8PI does not 
exert its effects by the expected mechanism of binding to the PH domain and preventing 
translocation and activation of Akt1.  In light of this information, a new hypothesis for 
the D-3-deoxy diC8PI mechanism of action was needed.  I embarked on a “directed 
fishing expedition” and analyzed phosphorylation patterns of proteins involved in cell 
growth, proliferation, and apoptosis in the hope of discovering signaling pathways that 
were altered upon D-3-deoxy diC8PI treatment.  I chose to do these experiments in MCF-
7 cells rather than the U937 cell line that was used in preliminary studies (Wang et al., 
2008), as I was also interested in using imaging to obtain additional proof that D-3-deoxy 
diC8PI does not prevent Akt translocation to the plasma membrane.  The MCF-7 cells are 
excellent for imaging because they are adherent, and have a reasonably large cytoplasm 
to nucleus ratio which makes it easy to see localization at the plasma membrane.   
In the course of these experiments, a number of proteins were identified that might play a 
role in the cytotoxicity of D-3-deoxy diC8PI.  The cAMP-regulatory element binding 
protein (CREB) is one such protein.  This transcription factor can be activated by 
phosphorylation at Ser133 by a number of kinases and signaling cascades including 
p38MAPK, PKA, Akt and MAPK1/2 (for review see Sakamoto and Frank, 2009).  
Phosphorylation at Ser133 promotes the interaction of CREB with its coactivator protein 
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CREB binding protein (Mayr et al., 2001).  CREB then regulates the expression of a 
number of genes involved in cell survival and proliferation including the genes for cyclin 
D1, Bcl-2, and MAP kinase kinase (Sakamoto and Frank, 2009; Boulon et al., 2002).   
p38MAPK, another potential target of D-3-deoxy diC8PI, is a kinase that can be activated 
in response to cellular stress, inflammatory cytokines and growth factors (Hui et al., 
2007; Raingeaud et al., 1995; Neve et al., 2002).  p38MAPK can be phosphorylated by 
mitogen-activated protein kinase kinases (MAPKKs) and phosphorylates a number of 
downstream targets including MAPK-APK2, CREB and cyclin D1 (Cuenda and 
Rousseau, 2007; Zarubin and Han, 2005; Thoms et al., 2007).  Since p38MAPK is 
involved in cell cycle regulation it is generally considered to be a tumor suppressor; 
however, it has also been shown to mediate drug induced cell death (Cuenda and 
Rousseau, 2007; Deacon et al., 2003).  In immune cells, activation of p38MAPK by an 
inflammatory stimulus mediates critical functions including adhesion, degranulation and 
the oxidative burst (Herlaar and Brown, 1999). 
D-type cyclins are key regulators of cell cycle progression and are unique because their 
expression is induced by signals from extracellular mitogens, linking cell cycle regulation 
to the exogenous environment (Weinberg, 1995).  They are expressed through the G1 
phase of the cell cycle (Ho and Dowdy, 2002).  In the absence of such signals, the D-type 
cyclins are degraded by the 26S proteasome which prevents the cell from progressing 
from early G1 phase into late G1 and ultimately S phase (Cheng et al., 1998; Alao, 1997).  
However in many breast cancers, the D-class cyclins are overexpressed, particularly 
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cyclins D1 and D3 (Zhang et al., 2011).  This promotes unrestricted progression through 
the cell cycle and tumorigenesis.  There is significant redundancy between cyclins D1 
and D3, as well as between D-type cyclins and cyclin E, which is expressed later in G1 
phase (Zhang et al., 2011; Yu et al., 2011; Geng et al., 1999).  
In this chapter, I explore the alterations to levels and phosphorylation states of these 
proteins in response to treatment with D-3-deoxy diC8PI in the hope that they will 
provide insight into the mechanism of cytotoxicity of this compound.  In some cases, I 
have compared the effects of D-3-deoxy diC8PI to those of perifosine, a cytotoxic 
alkylphospholipid that may act similarly (although its own mechanism of action is poorly 
understood) (Liu et al., 2012; Fei et al., 2010).  These results highlight alterations in the 
p38MAPK pathway and D-type cyclin expression in response to D-3-deoxy diC8PI 
treatment, and their role in its mechanism of cytotoxicity. 
6.2 D-3-deoxy diC8PI is Cytotoxic to MCF-7 Breast Cancer Cells and Induces 
Apoptosis 
D-3-deoxy diC8PI was initially incubated with MCF-7 cells for 24 h at concentrations 
from 0 to 400 µM.  However, the compound did not appear to be causing cell death as 
assayed by the Alamar blue method.  Consequently, the same experiments were 
performed in serum free media.  Without serum, D-3-deoxy diC8PI was much more 
potent.  By plotting relative viability with respect to D-3-deoxy diC8PI concentration and 
fitting the curve, an IC50= 78.6 ± 10.5 µM was obtained (Figure 6.1.A).  Therefore, all 
further experiments with D-3-deoxy diC8PI were performed without serum.  Lysates from 
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MCF-7 cells cultured with 100 µM D-3-deoxy diC8PI were probed for PARP cleavage 
(after 6.5 h of incubation) and caspase 9 cleavage (after 3.5 h of incubation) using 
western blots (Figure 6.1.B).  The cleavage of these two proteins indicates that D-3-
deoxy diC8PI treatment induces apoptosis in MCF-7 cells.   
Viability curves for two alkylphospholipids, miltefosine and perifosine, were also 
obtained under these conditions in the MCF-7 cell line (Figure 6.2).  From these curves, 
an IC50= 13.9 ± 1.7 µM was obtained for miltefosine and IC50= 16.3 ± 0.1 µM for 
perifosine.   
 
Figure 6.1. (A) Viability curve of MCF-7 cells treated with D-3-deoxy diC8PI for 24 h in MEM without 
serum.  (B) D-3-deoxy diC8PI induces apoptosis in MCF-7 cells as evidenced by PARP cleavage after 6.5 h 
and caspase 9 cleavage after 3.5 h. 
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Figure 6.2  Viability of MCF-7 cells incubated with miltefosine (A) or perifosine (B) for 24 h in MEM in 
the absence of serum. 
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6.3 Fluorescence Imaging Studies of Akt1-GFP 
D-3-deoxy diC8PI was designed as a more soluble phosphatidylinositol analog, a class of 
compounds that are thought to act by binding to the Akt PH domain (Wang et al., 2008).  
Evidence of this mechanism of PIA action has been presented in the past by showing that 
treatment with PIAs inhibits the translocation of fluorescently tagged Akt to the plasma 
membrane in cells (Hennessy et al., 2007; Watton and Downward, 1999).  To determine 
whether D-3-deoxy diC8PI inhibits the translocation of Akt in response to stimuli, I 
cloned mouse Akt1 cDNA into an enhanced GFP vector and transfected the construct 
into MCF-7 cells (see Chapter 2).  After 16 h of serum starvation, a clear translocation of 
cytosolic Akt1-GFP to the plasma membrane was visible 2 min after stimulation with 100 
ng/mL heregulin β1 (HRG β1) (Figure 6.3).   
 
Figure 6.3 Translocation of Akt1-GFP from the cytoplasm in serum starved cells (A) to the plasma 
membrane after 2 min of stimulation with 100 ng/mL HRG β1 (B).   
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However, problems arose when attempting to image transfected cells that had been 
treated with D-3-deoxy diC8PI or perifosine, which had previously been shown to block 
Akt translocation (Hennessey et al., 2007).  Treatment with either compound, in addition 
to the serum starvation and transfection procedure, caused the cells to detach after 2-4 h.  
The very few cells that were successfully transfected and remained attached to the 
coverglass made it difficult to determine whether or not the behavior of a single imaged 
cell was characteristic of the whole population. A promising result showed excellent 
translocation of Akt1-GFP in response to HRG β1 stimulation after 2 h of treatment with 
200 µM D-3-deoxy diC8PI, while 32 µM perifosine prevented translocation.  However, 
the dearth of cells still adherent after this treatment made it impossible to reproduce this 
result.   
Coating the coverslips with poly L-lysine increased the adherence of the cells during 
treatment; however, the translocation response of Akt1-GFP on cells attached to the 
coated coverslips was significantly decreased and almost eliminated in comparison to 
uncoated coverslips.  This may be a result of poly L-lysine binding to cell surface 
receptors and activating signaling pathways, which counteracts the serum starvation and 
makes the translocation event less obvious.  While there is not abundant evidence that 
this can occur, there is some precedent as other plating matrices like collagen have been 
shown to activate the PI3K-Akt pathway in a cell type dependent manner (Boisvert-
Adamo and Aplin, 2006).   
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I was unable to find an incubation period and proportional concentrations at which 
translocation was inhibited by perifosine but unimpeded by D-3-deoxy diC8PI treatment, 
which would have supported my theory that D-3-deoxy diC8PI does not act by binding to 
the Akt PH domain and inhibiting translocation.  However, the initial viability studies 
and all subsequent experiments were performed in the absence of serum.  Without serum, 
Akt is rapidly dephosphorylated and the PI3K-Akt pathway is inactive (Figure 6.5).  The 
fact that D-3-deoxy diC8PI induces apoptosis when the PI3K-Akt pathway is inactive 
requires an alternate mechanism of cytotoxicity, even without conclusive fluorescence 
data for translocation. 
6.4 Exploration of Signaling Pathways 
In order to identify an alternative mechanism of cytotoxicity of D-3-deoxy diC8PI, I 
probed for changes in phosphorylation of proteins involved in cell growth and survival.  
In preliminary experiments, MCF-7 cells were treated with 100 µM D-3-deoxy diC8PI or 
16 µM perifosine for 3 h 10 min followed by 20 min stimulation with 100 ng/mL HRG 
β1.  Although the mechanism of action of perifosine in MCF-7 cells was not specifically 
under investigation, its effect on signaling pathways was also explored in these early 
experiments to determine whether or not perifosine and D-3-deoxy diC8PI act by the 
same mechanism.  After treatment with either compound and in response to stimulation, 
changes were identified in a number of key signaling pathways.  Akt phosphorylation at 
Ser473 was severely impaired by D-3-deoxy diC8PI and perifosine (Figure 6.4).  D-3-
deoxy diC8PI also decreased the phosphorylation of p70S6K at Thr389 and Akt Thr308 
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(to a much lesser extent than Ser473); data for these phosphorylation sites was not 
collected for perifosine.  Conversely, there were also proteins that showed an increase in 
phosphorylation in D-3-deoxy diC8PI and perifosine treated stimulated cells.  CREB 
showed a clear increase in phosphorylation at Ser133 as did p38MAPK at Thr180/Tyr182 
when compared to control stimulated cells.  D-3-deoxy diC8PI treatment also slightly 
increased p-p42/44 MAPK at Thr202/Tyr204 compared to control cells. 
 
Figure 6.4 Identification of altered phosphorylation patterns in HRG β1 stimulated MCF-7 cells.  Cells 
were incubated with PBS (control), 100 µM D-3-deoxy diC8PI (D-3-deoxy) or 16 µM perifosine for 3 h 10 
min prior to stimulation by 100 ng/mL HRG β1 for 20 min.  Perifosine extracts were not probed for all 
phosphorylated proteins. 
 
However, signaling pathways that are activated or deactivated in response to a stimulus 
after treatment with D-3-deoxy diC8PI or perifosine are not necessarily involved in the 
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mechanism of action.  The viability assays are performed under completely serum free 
conditions – therefore, it is possible that certain pathways are inhibited by treatment, but 
the lack of serum already renders that pathway inactive.  For example, it is clear that 
pretreatment with either D-3-deoxy diC8PI or perifosine inhibits the phosphorylation of 
Akt at Ser473 in response to HRG β1.  However, after 3.5 h serum starvation, there is no 
detectable phosphorylation of Akt in control cells at this site which is required for Akt 
activity (Figure 6.5).  Since Akt is already dephosphorylated by the nature of serum 
starvation, the ability of D-3-deoxy diC8PI and perifosine to inhibit its phosphorylation in 
response to stimulation is not, under these conditions, the mechanism of cytotoxicity, 
although it could contribute to cytotoxicity in the presence of serum. 
 
Figure 6.5 Serum-starvation of MCF-7 cells for 3.5 h eliminates phosphorylation of Akt at Ser473.   Cells 
were incubated with PBS (Control), 100 µM D-3-deoxy diC8PI (D-3-deoxy), or 16 µM perifosine for 3.5 h 
without serum (lanes 1-3).  For lane 4, cells were incubated with PBS without serum for 3 h 10 min and 
stimulated with 100 ng/mL HRG β1 for 20 min. 
 
It was therefore critical to determine alterations in pathways that were occurring in the 
absence of any stimulus.  All of the phosphorylation sites that were decreased in response 
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to D-3-deoxy diC8PI (Akt Ser473, p70S6K and Thr389, and p42/44 MAPK at 
Thr202/Tyr204) are not detectably phosphorylated in MCF-7 cells after 3.5 h of serum 
starvation, so these decreases are unrelated to the mechanism of cytotoxicity.  The 
increase in phosphorylation of p42/44 MAPK at Thr202/Tyr204 by D-3-deoxy diC8PI 
also was not detected without a stimulus.  However, the increases in CREB 
phosphorylation at Ser133 and p38MAPK at Thr180/Tyr183 by D-3-deoxy diC8PI and 
perifosine were still visible even in the absence of stimulus and warranted further 
investigation (Figure 6.6).   
 
Figure 6.6 Changes of phosphorylation patterns in serum starved MCF-7 cells.  Cells were incubated with 
PBS (Control), 100 µM D-3-deoxy diC8PI (D-3-deoxy) or 16 µM perifosine without serum for 3.5 h. 
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6.5 D-3-deoxy diC8PI Induces CREB Hyperphosphorylation by Activation of 
p38MAPK 
Phosphorylation of CREB at Ser133 can occur downstream of a number of different 
signaling pathways, including p38MAPK.  D-3-deoxy diC8PI treatment induces 
phosphorylation of p38MAPK at Thr180/Tyr182, and activation at this site is required for 
p38MAPK activity.  That both D-3-deoxy diC8PI and perifosine activate p38MAPK was 
confirmed by the increase in phosphorylation of MAPKAPK-2 at Thr222, a direct 
substrate of p38MAPK (Figure 6.6).  To determine whether activation of this pathway 
was the source of CREB hyperphosphorylation at Ser133, the p38MAPK inhibitor 
SB203580 was utilized.  Pre-incubation of cells with 10 µM SB203580 prior to treatment 
with D-3-deoxy diC8PI almost completely eliminated the increase in phosphorylation of 
CREB at Ser133 (Figure 6.7).  This is conclusive evidence the hyperphosphorylation of 
CREB induced by D-3-deoxy diC8PI occurs as a result of activation of the p38MAPK 
pathway.   
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Figure 6.7 Inhibition of p38MAPK eliminates CREB hyperphosphorylation but not PARP cleavage 
induced by D-3-deoxy diC8PI.  Cells were pretreated with DMSO (lanes 1 and 2) or 10 µM SB203580 
(lanes 3 and 4, structure shown) in serum free media for 1 h prior to treatment with 100 µL D-3-deoxy 
diC8PI or PBS for 3.5 h (pCREB) or 6.5 h (PARP). 
 
Although this pathway is activated by D-3-deoxy diC8PI, it does not necessarily 
contribute to its cytotoxicity.  Pretreatment with SB203580 does block CREB 
hyperphosphorylation at Ser133; however it does not eliminate the PARP cleavage 
induced by D-3-deoxy diC8PI after 6.5 h of treatment (Figure 6.7).  In addition, 
pretreatment with 10 µM SB203580 for 6 h slightly increases the efficacy of D-3-deoxy 
diC8PI (Figure 6.8).  Therefore the activation of the p38MAPK pathway does not 
contribute to the apoptosis induced by D-3-deoxy diC8PI, and may be purely 
compensatory.  In an attempt to further define the role of CREB activation, CREB was 
knocked down with siRNA prior to treatment with various concentrations of D-3-deoxy 
diC8PI.  However, CREB knockdown did not significantly increase or decrease the 
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efficacy of D-3-deoxy diC8PI (Figure 6.9).  While the overall trend seems to indicate that 
CREB knockdown mitigates the effects of D-3-deoxy diC8PI, the errors are too large for 
these results to be statistically significant.  Particularly critical is the large error in the 
untreated CREB knockdown, which is used in the calculation of relative viability for all 
other CREB knockdown data points.   It is also important to note that D-3-deoxy diC8PI 
does not decrease levels of CREB but merely prevents its phosphorylation.  Since non-
phospho-CREB can still play a physiological role in the cell, this experiment does not 
mimic the effects of D-3-deoxy diC8PI with complete accuracy. 
 
Figure 6.8 Inhibition of p38MAPK increases the efficacy of D-3-deoxy diC8PI.  Cells were treated with 
DMSO (solid grey) or 10 µM SB203580 (hatched) in serum free media for 6 h prior to 24 h incubation with 
various concentrations of D-3-deoxy diC8PI. 
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Figure 6.9 (A) siRNA knockdown of CREB does not statistically significantly affect the efficacy of D-3-
deoxy diC8PI in MCF-7 cells.  After 48 h transfection with control (solid grey) or CREB (hatched) siRNA, 
cells were incubated with D-3-deoxy diC8PI for 24 h. (B) Western blot showing efficiency of CREB 
knockdown after 48 and 72 h. 
6.6 D-3-deoxy diC8PI Lowers Levels of Cyclins D1 and D3  
Since there is evidence that phospho-CREB can negatively regulate the transcription of 
cyclin D1 (Boulon et al., 2002), I examined whether treatment with D-3-deoxy diC8PI 
had any effect on cyclins D1 and D3.  The levels of both cyclin D1 and cyclin D3 were 
dramatically reduced in cells treated with D-3-deoxy diC8PI compared to the control cells 
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(Figure 6.10).  Phosphorylation of the retinoblastoma protein (pRb) on Ser780 and 
Ser807/811 was also decreased by D-3-deoxy diC8PI – these sites are phosphorylated by 
D-type cyclin – CDK 4/6 complexes (Lundberg and Weinberg, 1998).  However, the 
decrease in cyclin D1 levels cannot be restored by pretreatment with SB203580 and is 
therefore independent of the p38MAPK pathway.  SB203580 pretreatment does appear to 
partially restore the levels of cyclin D3 and phosphorylation of pRb at Ser780.  
Phosphorylation at this site is regulated by both cyclin D3 and cyclin D1 – CDK4/6 
complexes, as opposed to the Ser807/811 site which is not associated with cyclin D3 
(Paternot et al., 2006) The third D-type cyclin, cyclin D2, was not detected by western 
blot and has previously been shown to be absent in the MCF-7 cell line (Evron et al., 
2001). 
 
Figure 6.10 Regulation of levels of cyclins D1 and D3 by D-3-deoxy diC8PI.  Cells were pretreated with 
DMSO (lanes 1 and 2) or 10 µM SB203580 (lanes 3 and 4) for 1 h prior to incubation with PBS (lanes 1 
and 3) or 100 µM D-3-deoxy diC8PI for 3.5 h. 
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It is well accepted that GSK-3β can facilitate the degradation of cyclin D1 by 
phosphorylating it on Thr386 and targeting it for the proteasome (Guo et al., 2005; Alao, 
2007), and these decreases in levels could potentially be due to increased proteasomal 
degradation.  To determine if D-3-deoxy diC8PI decreases cyclin D1 levels via increased 
GSK-3β activity, MCF-7 cells were pretreated with the GSK-3β inhibitors 10 mM LiCl 
or 10 µM SB216763 before incubation with 100 µM D-3-deoxy diC8PI for 3.5 h.  Neither 
inhibitor could prevent the decrease in cyclin D1 levels in response to D-3-deoxy diC8PI.  
Although GSK-3β does not appear to be involved, it was possible that the decrease in 
these cyclins is still the result of increased proteasomal degradation.  However, 
pretreatment of cells with 26S proteasome inhibitor MG132 does not fully restore the 
levels of cyclin D1 or cyclin D3 in D-3-deoxy diC8PI treated cells compared to control 
cells pretreated with MG132.  In addition, a cycloheximide chase experiment did not 
show a conclusive decrease in half-life of either cyclin D1 or cyclin D3.  These results 
strongly suggest that D-3-deoxy diC8PI does not decrease the levels of these cyclins by 
enhancing proteasomal degradation, but instead are regulating them at the transcriptional 
level.  
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Figure 6.11 (A) Inhibition of GSK-3β with LiCl or SB216763 (structures shown) does not prevent the loss 
of cyclin D1 by D-3-deoxy diC8PI.  (B) Pretreatment with MG132 (structure shown) does not fully prevent 
the loss of cyclin D1 or cyclin D3 induced by D-3-deoxy diC8PI.  (C) A cycloheximide chase experiment 
shows that D-3-deoxy diC8PI does not noticeably reduce the half-life of cyclin D1 or cyclin D3.  For (A), 
MCF-7 cells were pretreated with 10 mM LiCl or 10 µM SB216763 for 1 h prior to treatment with 100 µM 
D-3-deoxy diC8PI for 3.5 h.  For (B) cells were incubated with 10 µM MG132 for 30 min prior to treatment 
with 3.5 h 100 µM D-3-deoxy diC8PI.  For (C), cells were incubated with PBS or 100 µM D-3-deoxy 
diC8PI for 1 h prior to treatment with 20 µg/mL cycloheximide (CHX). 
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6.7 siRNA Knockdown of Cyclin D1 Inhibits Proliferation 
Since cyclin D1 and cyclin D3 are important regulators of the cell cycle, it was possible 
that their loss was part of the mechanism of cytotoxicity of D-3-deoxy diC8PI.  Using 
siRNA, cyclin D1 and/or cyclin D3 was knocked down, but no increase in PARP 
cleavage was observed which indicated that apoptosis was not occuring.  However, an 
Alamar blue proliferation assay shows that the growth of cells with cyclin D1 or cyclin 
D1/D3 knockdowns were reduced compared to cells transfected with control siRNA or 
cyclin D3 alone (Figure 6.12).  Incidentally, knockdown of cyclin D3 resulted in higher 
levels of cyclin D1 compared to control cells.  This compensation with cyclin D1 may 
explain why knockdown of cyclin D3 alone is insufficient to inhibit proliferation. 
 
Figure 6.12. (A) Successful siRNA knockdown of cyclin D1 and/or cyclin D3 48 h post transfection does 
not increase PARP cleavage compared to cells transfected with control siRNA.  (B) siRNA knockdown of 
cyclin D1, but not cyclin D3, significantly inhibits the proliferation of MCF-7 cells. 
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6.8 D-3-deoxy diC8PI Induces Cell Cycle Arrest 
D-3-deoxy diC8PI significantly decreases the levels of both cyclin D1 and cyclin D3 
which are critical regulators of cell cycle progression.  Since siRNA knockdown of cyclin 
D1 inhibits proliferation in these cells, it was likely that part of the D-3-deoxy diC8PI 
mechanism of action involved cell cycle arrest.  To confirm this, MCF-7 cells were 
pulsed with 10 µM BRDU for 8 h following treatment with 13 µM D-3-deoxy diC8PI for 
24 h.  Staining with an anti-BRDU antibody and flow cytometric analysis confirm that at 
sub-lethal concentrations, D-3-deoxy diC8PI inhibits BRDU incorporation into DNA and 
therefore causes cell-cycle arrest (Figure 6.13). 
 
Figure 6.13 D-3-deoxy diC8PI inhibits BRDU incorporation.  MCF-7 cells were incubated with PBS 
(control) or 13 µM D-3-deoxy diC8PI for 24 h in MEM without serum, prior to the addition of 10 µM 
BRDU for 8 h.  
 
 
171 
6.9 Discussion 
While I may not have completely elucidated the mechanism of D-3-deoxy diC8PI 
cytotoxicity in MCF-7 cells, I have at the very least been able to characterize some 
changes that it causes in signaling pathways and cell cycle regulation.  Initial 
fluorescence translocation studies did not yield conclusive data.  However, the data 
obtained from high resolution 
31
P field-cycling NMR as well as the omission of serum 
from these experiments definitively prove that that D-3-deoxy diC8PI does not act 
primarily by inhibition of Akt translocation and activation.  The same is true for the 
cytotoxic alkylphospholipids miltefosine and perifosine.  D-3-deoxy diC8PI and 
perifosine both clearly can affect Akt phosphorylation in the presence of a stimulus such 
as HRG β1.  However, this is not the primary mechanism of either compound, since they 
are cytotoxic in the absence of such a stimulus under conditions where Akt is already 
dephosphorylated.  Deactivation of the PI3K-Akt pathway may therefore be a secondary 
mechanism of toxicity, and is most likely not occurring because of inhibition of Akt 
translocation but by some other mechanism.  This could potentially involve disruption of 
lipid rafts required for effective PIP3 signaling, or inhibition of an upstream kinase for 
Akt phosphorylation such as PDK1 or the mTOR-rictor complex.  Regardless, it is not 
the primary mechanism of action in MCF-7 cells under the conditions used for these 
experiments.  
Both D-3-deoxy diC8PI and perifosine activate the p38MAPK pathway in MCF-7 cells.  
The activation of this pathway and the resulting CREB hyperphosphorylation appears to 
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be compensatory, which is not unusual since this pathway is primarily activated in 
response to cellular stress (Cuenda and Rousseau, 2007).  Inhibition of this pathway can 
partially restore cyclin D3 levels, but this is not enough to prevent D-3-deoxy diC8PI 
induced apoptosis.  Activation of p38MAPK may be a generic response to stress in MCF-
7 cells.  The fact that both D-3-deoxy diC8PI and perifosine treatment induces activation 
of this pathway does not necessarily mean that they achieve cytotoxicity by the same 
mechanism.  However, this evidence coupled with similar changes in phosphorylation 
state of Akt in response to HRG β1 stimulation suggests that these two compounds may 
act in a similar manner.  This is counterintuitive as their structures are very different, and 
clearly the mechanism of D-3-deoxy diC8PI is very specific as only the D- enantiomer is 
cytotoxic and the L- is not (Wang et al., 2008).  In addition, perifosine treatment has been 
reported to decrease the levels of total Akt along with its phosphorylation (Fu et al., 
2009), and this was not detected as a response to D-3-deoxy diC8PI treatment in these 
experiments.  Like D-3-deoxy diC8PI, perifosine has been shown to decrease levels of 
cyclin D1 expression; however, this was attributed to an increase in proteasomal 
degradation (Fu et al., 2009; Liu et al., 2012), which is not consistent with the evidence 
obtained for D-3-deoxy diC8PI treatment in these experiments.  A more definitive 
mechanism of cytotoxicity for one or both of these small molecules is required in order to 
determine whether they act by the same mechanism, as opposed to different mechanisms 
that generate similar phenotypes. 
The loss of cyclins D1 and D3 as a result of treatment with D-3-deoxy diC8PI may be 
particularly relevant to the mechanism of cytotoxicity, as the MCF-7 cells are an 
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epithelial breast cancer cell line.  While siRNA knockdown of cyclin D1 and/or cyclin 
D3 was not enough to induce apoptosis, the loss of cyclin D1 did significantly inhibit 
proliferation of MCF-7 cells.  The loss of D-class cyclins results in failure to progress 
through G1 phase, which is supported by the inhibition of BRDU incorporation after 
treatment with D-3-deoxy diC8PI.  However, modulation of other cyclins, particularly 
cyclin E, may contribute to the actual induction of apoptosis.  The redundancy of the 
cyclins is well established by reports in the literature (Yu et al., 2001; Geng et al., 1999).  
Direct evidence of this is presented in Figure 6.12, in which siRNA knockdown of cyclin 
D3 clearly increases the levels of cyclin D1 which compensates for the loss of cyclin D3.  
For this reason, it is possible that these siRNA knockdowns result in increased levels of 
cyclins which I have not identified as being modulated by D-3-deoxy diC8PI.  These 
experiments most likely do not describe the full D-3-deoxy diC8PI induced cyclin 
phenotype, and a decrease in levels of related cyclins may be required in order to commit 
the MCF-7 cells to apoptosis.   
My studies suggest that D-3-deoxy diC8PI appears to regulate the expression of these 
cyclins at the transcriptional level.  A more detailed investigation into this mechanism of 
transcriptional regulation will provide critical information about how D-3-deoxy diC8PI 
regulates the cyclins and other proteins that may be involved in the induction of 
apoptosis.  However, my results clearly indicate that D-3-deoxy diC8PI causes cell cycle 
arrest in these MCF-7 cells, which precedes the cell‟s apoptotic fate. 
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Chapter 7: 
Overall Summary and Future Directions  
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7.1 Overall Summary 
In conclusion, I have studied 2 novel small molecules and their relationship to tumor cell 
biology.  The first, ITA, is a found not only in macrophage derived tumor cell lines, but 
primary macrophages.  This metabolite was identified in the course of an NMR-based 
metabolomics study to analyze the differential metabolism of [
13
C5]glutamine and 
[
13
C6]glucose in the VM-M3 tumor cell line. It is biosynthesized via the decarboxylation 
of cis-aconitate from the TCA cycle by a novel mammalian enzyme, cis-aconitic 
decarboxylase.  ITA production and secretion is increased upon macrophage stimulation, 
and the physiological relevance of this metabolite is as of yet unknown.  ITA production 
is a previously unidentified characteristic of the mammalian immune response.  
The second small molecule, D-3-deoxy diC8PI, is not an endogeneous metabolite but a 
synthetic compound cytotoxic to the U937 and MCF-7 tumor cell lines.  Using high 
resolution 
31
P field-cycling NMR spectroscopy, the suspected mechanism of cytotoxicity 
in which D-3-deoxy diC8PI competitively binds to the Akt1 PH domain and prevents its 
translocation to the plasma membrane was eliminated.  Signaling pathway analysis in the 
MCF-7 breast cancer cell line revealed the D-3-deoxy diC8PI induced CREB 
hyperphosphorylation through the p38MAPK pathway.  This pathway is not related to the 
mechanism of cytotoxicity.  D-3-deoxy diC8PI induces cell cycle arrest in this cell line, 
most likely through the decrease in levels of cyclin D1.   
I have made significant strides towards elucidating the mechanism of cytotoxicity of D-3-
deoxy diC8PI as well as characterizing ITA as a mammalian metabolite and exploring the 
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dual roles of glucose and glutamine metabolism in cancer cells.  Yet, there are still a 
number of unanswered questions that would benefit from further investigation. 
7.2 Itaconic Acid is a Mammalian Metabolite Induced during Macrophage 
Activation – Future Directions 
There is a tremendous amount that is still unknown about the mammalian cADC enzyme.  
We plan on overexpressing and purifying the Asperigillus cADC gene and attempting to 
solve the crystal structure.  While proteins from different organisms don‟t always show 
significant primary sequence similarity, they often do have structural similarity and this 
may aid us in identification of mammalian cADC from the mouse genome when primary 
sequence blasting was unhelpful.  Our collaborators are interested in pursuing gene 
microarray analyses, and looking for differences between stimulated and unstimulated 
RAW 264.7 cells to try to identify the cADC gene.   
Since the physiological relevance of ITA as a mammalian metabolite is unknown, we 
would like to try to determine if it is involved in regulation of metabolism or extracellular 
signaling to other immune cells.  We therefore intend to do activity assays of several 
TCA cycle enzymes with and without ITA to see if it modulates the activity of any 
critical metabolic enzymes.  We also hope to collaborate and determine whether the 
addition of ITA to culture medium stimulated migration or differentiation in unactivated 
macrophages and other immune cells.  In addition, it would be interesting to examine 
other immune cells (such as primary B- and T-cells) to determine if ITA production is 
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specific to macrophages or is produced by other immune cells in different states of 
differentiation or activation. 
7.3 Glucose and Glutamine Metabolism in the VM-M3 Tumor Cell Line – Future 
Directions 
This data presents some interesting trends that bear further investigation.  However, 
NMR limits the amount of information we can obtain from these extract and media 
samples.  It would be advantageous to do the same experiments, but using LC-MS to 
obtain data on the distribution of isotopologues of each metabolite as well as to obtain 
labeling information for a greater number of metabolites. This methodology has much 
better sensitivity and would be particularly critical when using specific isotope labeled 
glucose or glutamine.  The LC-MS would also provide a much more accurate method of 
quantitation (if extracts were doped with standards), which is necessary in order to make 
more comparisons between glutamine and glucose metabolism. Such data would be 
critical to designing further experiments. 
7.4 Investigation into the Binding of Phospholipid Ligands to the Akt1 Pleckstrin 
Homology Domain 
The field dependence data for the cytotoxic alkylphospholipids, D-3-deoxy diC8PI and L-
3,5-dideoxy diC8PI yield information about a previously unidentified binding site on the 
Akt1 PH domain.  This site is not generic for all amphiphiles, as diC7PC does not appear 
to bind there.  However, the exact location of this site has yet to be identified.  To 
maximize our chances of observing the effects of the spin-labels on the relaxation rates of 
178 
our test compounds, we chose to label both cysteines naturally found in the PH domain.  
However, since both are labeled, it makes it difficult to pin down the exact location of 
this new binding site as one or both of the spin labels could be responsible for the 
enhancement in R1.  This ambiguity makes it impossible to accurately calculate r, the 
distance from the unpaired electron of the spin label to a given phosphorus nucleus, from 
P-e/RP-e(0).  To definitively calculate r, we will need to mutate one of the cysteine 
residues using site-directed mutagenesis so that only one unpaired electron will be 
contributing to the dipolar relaxation mechanism.  Once we can more accurately calculate 
r, we can search for a positively charged binding site in a radius around the single labeled 
cysteine.  We can further narrow down the location of this site by mutating both cysteines 
individually, and determining r for each spin label. 
7.5 Investigation into the Mechanism of Cytotoxicity of D-3-deoxy diC8PI in the 
MCF-7 Tumor Cell Line 
The current studies have identified a number of changes in signaling pathways and 
protein levels that occur as a result of treatment with D-3-deoxy diC8PI in MCF-7 cells.  
However, these changes have not yielded the exact mechanism of cytotoxicity.  Since 
these results suggest that D-3-deoxy diC8PI regulates the levels of cyclins D1 and D3 at 
the transcriptional level, it would be helpful to perform quantitative RT-PCR experiments 
to assess changes in cyclin D1 and cyclin D3 mRNA in response to D-3-deoxy diC8PI 
treatment.  It would also be interesting to probe for changes in mRNA using a microarray 
of genes involved in cell survival and cell cycle regulation in order to get a better idea of 
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the breadth of effects on translation by D-3-deoxy diC8PI, as it may also decrease the 
levels of mRNA for other critical proteins that are currently not identified as targets.  
Obtaining information about a larger pool of genes that have their translation affected by 
D-3-deoxy diC8PI will help narrow the field of transcription factors and signaling 
pathways that D-3-deoxy diC8PI is modulating that result in decreased protein 
expression.  Ideally, more L-3-deoxy diC8PI would be synthesized and used as an 
inactive analogue in these experiments in order to eliminate non-specific effects. 
It is imperative to determine whether D-3-deoxy diC8PI affects the levels of cyclin E, 
which has been shown to compensate for the loss of other cyclins.  If levels cyclins E, D1 
and D3 are all significantly decreased by D-3-deoxy diC8PI, it is possible that this is 
responsible for the induction of apoptosis.  This hypothesis could then easily be tested by 
simultaneous siRNA knockdown of all three cyclins.  If this proves to be insufficient to 
cause cytotoxicity, combinations of any newly identified proteins from the mRNA 
microarray could be knocked down to attempt to identify the combination necessary for 
an apoptotic phenotype. 
If none of these experiments are successful, it may be useful to employ metabolomics as 
a strategy to solve this mechanism of cytotoxicity.  Monitoring changes in intracellular 
and extracellular metabolite concentrations may provide a new perspective on how D-3-
deoxy diC8PI treatment affects metabolic pathways, which is not easily obtained by 
analyzing protein levels and phosphorylation states.  Due to the miniscule amount of D-3-
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deoxy diC8PI available, however, these experiments would require the sensitivity of LC-
MS rather than NMR-based metabolomics. 
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